





Central Council for Research in Unani Medicine

Ministry of Ayush, Government of India

AMUAL PEPURT 2022-2023



Central Council for Research in Unani Medicine

Ministry of Ayush, Government of India



Published by

CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE

Ministry of Ayush, Government of India 61–65, Institutional Area, Janakpuri, New Delhi – 110 058 Telephone: +91-11-28521981, 28525982 E-mail: unanimedicine@gmail.com Website: https://ccrum.res.in

Printed at
Hi-Tech Graphics
F-28/3, Okhla Industrial Area, Phase-II, New Delhi-110 020





CONTENTS

٦.	. OVERVIEW	5
	1.1. Objectives of the Council 1.2. Programme-wise Achievements	5 5
_	-	
2.	. MANAGEMENT	9
	2.1. Governing Body	9
	2.2. Executive Committee	9
	2.3. Standing Finance Committee	10
	2.4. Scientific Advisory Committee 2.4.1. Research Sub-Committees	10 11
	2.5. Institutional Ethics Committee	11
	2.6. Organisational Set-Up	16
	2.7. Budget (Actual Expenditure)	22
3.	. TECHNICAL REPORT	24
	3.1. Intramural Research	24
	3.1.1. Centre-wise Activities	24
	3.1.2. Programme-wise Activities	28
	3.1.2.1. Survey and Cultivation of Medicinal Plants Programme	28
	3.1.2.2. Drug Standardization Research Programme	30
	3.1.2.3. Clinical Research Programme	33
	Preclinical Studies	33
	Clinical Studies	35
	Randomised Controlled Trials	38
	Validation of Unani Pharmacopoeial Drugs	39
	Validation of Regimen Therapies	52
	Validation of Fundamentals	54
	Research-oriented Healthcare	56
	3.1.2.4. Literary Research Programme	57
	3.2. Studies under IMR Policy	58
	3.3. Collaborative Research	60
	3.4. Publications	62
	3.4.1. Books, Monographs, Reports, etc.	62
	3.4.2. Journals / Periodicals 3.4.3. Research Papers	63 63
	3.5. Extension of Healthcare Services	70
	3.5.1. School Health Programme	70 70
	3.5.2. Unani Medical Centres in Allopathic Hospitals	71
	3.5.3. Health Melas / Camps	71
	3.5.4. Activities under Gender Component Plan for Women	71
	3.5.5. Activities in the North-Eastern Region	72
	3.5.6. Ayush Wellness Centre - President Estate	72





	3.5.7. Mobile Healthcare Programme under Scheduled Caste Sub-Plan	72
	3.5.8. Mobile Healthcare Programme under Tribal Sub Plan	73
	3.6. Linking Education with Research	73
1.	INFORMATION, EDUCATION & COMMUNICATION	74
	4.1. Library Services	74
	4.2. Organization of Conferences, Seminars, Workshops, etc.	74
	4.2.1. Unani Day and International Conference on Unani Medicine	74
	4.2.2. National Conference on Regimenal Therapy	75
	4.2.3. Awareness Programme on NABL Accreditation for Ayush Scientists	76
	4.2.4. National Seminar on Public Health & Wellness	76
	4.2.5. National Seminar on Post-Covid-19 Complications	77
	4.2.6. Workshop-cum-Hands-on Training in Unani Pharmacy	77
	4.2.7. Workshop on Understanding NABH/NABL Accreditation	78
	4.2.8. NABL Exposure Training Programme	78
	4.2.9. Union Ayush Minister Inaugurates RRIUM, Silchar	78
	4.2.10. NABL Exposure Training Programme	79
	4.2.11. Workshop on Statistical Analysis in Excel	80
	4.2.12. National Workshop on <i>ʿIlāj biʾl-Tadbīr</i>	80
	4.2.13. Seminar on IPR and Public Health	80
	4.2.14. Seminar on Intellectual Property Rights	81
	 4.2.15. Ayush Minister Inaugurates Unani and Homoeopathy Research Buildir Mumbai 	ng at Navi 81
	4.2.16. Refresher Training Program for Community Health Officers (CHOs)	82
	4.2.17. Lecture on Application of Artificial Intelligence in Unani Medicine	82
	4.2.18. Sensitization Program on Ayush Information Hub	83
	4.2.19. Lecture on Early Detection and Prevention of Diabetes Mellitus	83
	4.2.20. Lecture on Drug Standardization	83
	4.3. Participation in Arogya Fairs/ Expos	83
	4.4. Participation in Promotion of Official Language	85
	4.5. Appointments	86
	4.6. Promotions	86
	4.7. Retirements	87
	4.8. Deaths	88
5.	FINANCIAL STATEMENT	89
	5.1. Audit Report	89
	5.2. Audited Statement of Accounts	93
	5.3. Notes on Accounts	166



1. OVERVIEW

1.1. Objectives of the Council

The Central Council for Research in Unani Medicine (CCRUM) is an autonomous organization under the Ministry of Ayush, Government of India. It was established on March 30, 1978 under the Societies Registration Act, 1860 and started functioning from January 10, 1979. The main objectives of the CCRUM are as follows:

- Formulation of aims and patterns of research on scientific lines in Unani Medicine
- To undertake research or any other programmes in Unani Medicine
- Prosecution of and assistance in research and propagation of knowledge and experimental measures generally in connection with the causation, mode of spread and prevention of diseases
- To initiate, aid, develop and coordinate scientific research on different aspects, fundamental and applied, of Unani Medicine, and to promote and assist institutions of research for the study of diseases, their prevention, causation and remedy
- To finance enquiries and researches for the furtherance of the objectives of the council
- To exchange information with other institutions, associations and societies interested in the objectives similar to those of the council, especially in the observation and study of diseases in the East in general, and in India in particular
- To prepare, print, publish and exhibit any papers, posters, pamphlets, periodicals and books for furtherance of the objectives of the council and to contribute to such literature

1.2. Programme-wise Achievements

The year 2022–2023 marked a significant turnaround following two challenging years dominated by the global COVID-19 pandemic. Despite the adversities, the CCRUM demonstrated satisfactory progress in its diverse research endeavours.

Throughout this reporting period, the CCRUM excelled in its core research domains, namely the Survey and Cultivation of Medicinal Plants, Drug Standardization Research, Clinical Research, and Literary Research. These fundamental areas formed the backbone of the organization's pursuit of advancements in Unani Medicine. Additionally, the council extended its reach into supplementary domains such as information, education, and communication. The CCRUM also continued the expansion of healthcare services facilitated by a well-established network of 23 centres across the country. These centres played a pivotal role in disseminating Unani healthcare, effectively reaching diverse communities, and contributing to the overall well-being of the population.

Under the **Survey and Cultivation of Medicinal Plants Programme**, ethnopharmacological surveys were conducted in different forest divisions/areas. As a result of these surveys, 1,831 botanical specimens were collected and 742 plant species identified. Later, herbarium sheets of 1,463 specimens including new and previous collections containing their basic details were prepared and 660 index cards were updated. A total of 521 herbarium sheets were digitized as well. The survey teams collected 3,787 saplings of important medicinal species for plantation and 233 kg of raw drugs. The surveyors recorded 145 folk medicinal claims from the tribal inhabitants and other rural folks of the study areas. Experimental and large-scale cultivation of some important medicinal species was also undertaken which



yielded 234 kg of raw drugs. A total of 485 common species of medicinal plants used in Unani Medicine were maintained in the nurseries of the CCRUM centres.

Under the **Drug Standardization Research Programme**, SOPs for manufacture of 28 Unani formulations and their pharmacopoeial standards were developed. Besides, pharmacopoeial standards for 17 single drugs were developed. The drug testing laboratory at the RRIUM, Chennai analysed 16 ASU drug samples received from different organizations. In an effort to revisit the existing Unani Pharmacopoeia of India (UPI), monographs of 45 Unani single drugs from UPI, part-I, vol. I were revised as per the new format provided by the Pharmacopoeia Commission of Indian Medicine and Homoeopathy (PCIM&H). Besides, phyto-constituents were isolated from four Unani single drugs at the Chemical Research Unit located at Aligarh Muslim University, Aligarh and RRIUM, Srinagar.

Under the **Clinical Research Programme**, preclinical safety evaluation studies, clinical studies on validation of safety and efficacy of classical/pharmacopoeial formulations, regimen therapies and fundamentals of Unani Medicine continued. Besides, research under intramural research (IMR) policy and collaborative research also continued.

Preclinical safety and pharmacological studies were undertaken on 06 Unani drugs and 06 more drugs were allotted to RRIUM, Srinagar and NRIUMSD, Hyderabad for similar studies.

In clinical research, five randomised controlled trials (RCTs) were conducted. Besides, 51 studies for clinical validation of Unani pharmacopoeial formulations in different diseases were conducted, 17 studies were initiated, and 20 new studies were allotted. Various regimen therapy procedures were performed on 13,288 patients of different diseases. Hijāma bilā-Sharṭ (dry cupping) was performed on 4,961 patients, Hijāma bi'l-Sharṭ (wet cupping) on 1,607, Hijāma bi'l-Nār (fire cupping) on 714, Hijāma Muzliqa (moving cupping) on 2,701, Hammām al-Bukhār (steam bath) on 407, Dalk Mu'tadil (moderate massage) on 1,506, Hammām Yābis (sauna) on 37, Naṭūl (fomentation) on 31, Inkibāb (vaporization) on 1,452, Munḍij-Mushil therapy on 160, Ta'līq (leeching) on 87, Takmīd (fomentation) on 789, Faṣd (venesection) on 05, and other therapies ('Amal-i-Kayy or cauterization, cleaning & dressing, and mechanical massage) on 84 patients.

Under the validation of fundamentals of Unani Medicine, 07 genetic studies were completed and 09 were initiated. Clinical assessment of *Mizāj* (temperament) of 163 patients was done and susceptibility of acquiring diseases in relation to the temperament of the patients was studied.

Four different projects were undertaken and three projects initiated under the IMR policy at various institutes of the CCRUM.

The CCRUM also undertakes research in collaboration with other prestigious institutes. During the reporting period, 14 collaborative studies continued/were initiated at different collaborating institutions.

The **Literary Research Programme** made significant strides undertaking translation of pivotal Unani texts including *Kitāb al-Masāʾil fiʾl-Ṭibb liʾl-Mutaʿallimīn, Kitāb al-Abniya ʿan Ḥaqāʾiq al-Adviya', 'Man lā yaḥḍuruhu al-Ṭabīb', 'Khulāṣa al-Tajārib', 'Kitāb al-Ahviya waʾl-Miyāh waʾl-Buldān'*, French and Spanish translation of 'Unani Medicine: The Science of Health & Healing - An Overview'. Simultaneously, work progressed on monographs focusing on 'Ḥammām' as a component of regimenal therapy and 'Amrāḍ-i-Tanaffus' in Unani Medicine. The CCRUM successfully completed work on the WHO's project regarding international terminologies of Unani Medicine, culminating in the publication of the document

titled 'WHO International Standard Terminologies on Unani Medicine'. Moreover, extensive efforts were made, including term collection, identification, data preparation, translation, and multiple releases of 'India AYUSH Extensions' under the Systematized Nomenclature for Medicine—Clinical Terminology (SNOMED-CT) Extension for Unani Medicine project. The CCRUM continued updating NUMC Version 1.0, developing 322 addendum codes for integration into NAMASTE Portal and AHMIS. Besides, retrieving/compiling NUMC data from NAMASTE-P was also carried out.

With a view to disseminating the research findings, 88 research papers were published in national and international scientific journals. During the reporting period, 11 books were also brought out. Besides, publication of quarterly English journal Hippocratic Journal of Unani Medicine, quarterly Urdu journal *Jahan-i Tib*, quarterly bulletin CCRUM Newsletter, Annual Report, and publicity material continued.

Research-oriented healthcare services continued at GOPDs and special OPDs of clinical centres of the CCRUM. During the reporting period, a total of 6,66,025 beneficiaries comprising 5,37,355 in GOPDs, 41,598 in Geriatric OPDs, 12,744 in RCH / MCH OPDs, 26,551 in NCD OPDs and 47,777 in OPDs for Post-trial Treatment Access (PTA) were treated at different centres. In-Patient Department (IPD) services continued at seven peripheral institutes of the council and a total of 6,521 beneficiaries were treated.

Under the **Mobile Clinical Research Programme**, 16 rural pockets/urban slums covering over 2.02 lakh population were adopted and a total of 23,230 patients were treated with Unani pharmacopoeial formulations in 687 mobile visits made to these pockets during the reporting period. Under the **School Health Programme**, a total of 576 school children were covered and their health check-up was conducted. Of them, 481 children suffering from different ailments were treated in 13 visits made to their schools.

The **Unani Medical Centres** functioning under the scheme of co-location of Ayush centres in Dr. Ram Manohar Lohia Hospital, Deen Dayal Upadhyay Hospital and VMMC & Safdarjung Hospital, New Delhi treated 26,811; 29,206 and 14,373 patients, respectively. Besides, 19 health camps were organized on different occasions and 5,114 patients were treated in these camps.

At **Ayush Wellness Clinic** established in President Estate, 3,645 patients were treated in Unani OPD and 1,646 in Regimenal Therapy Section.

Under the **Gender Component Plan for Women**, 3,44,576 female patients were treated in different OPDs. Clinical studies on the diseases specific to women, such as *Sayalān al-Raḥim* (leucorrhoea), *Iḥtibās al-Ṭamth* (amenorrhoea) and *Kathrat al-Ṭamth* (menorrhagia) also continued.

Under the **Activities in North Eastern Region**, 18,990 patients were treated for their common and chronic ailments at RRIUM, Silchar, and CRU, Imphal.

Under the Special Component Plan – Scheduled Caste Sub-Plan (SCSP) and Tribal Sub-Plan (TSP), 14,15,822 total population including 8,68,233 SC population were covered under SCSP, whereas 86,590 total population including 61,253 ST population were covered under TSP. A total of 63,192 and 16,433 individuals benefited from SCSP and TSP, respectively.

The academic activities under the **postgraduate programme** in Unani Medicine successfully continued. A total of 29 new scholars in addition to continuing MD (Unani)



students were actively engaged in academic, research and training activities at NRIUMSD, Hyderabad, and RRIUM, Srinagar.

During the period under report, the CCRUM celebrated Unani Day and organized International Conference on 'Unani Medicine for Public Health' at Vigyan Bhawan, New Delhi during February 10–11, 2023. The conference aimed to discuss the value of using Unani Medicine to treat non-communicable illnesses and other chronic conditions while also enabling public health experts to work together, think outside the box, and influence the direction of public health with Unani Medicine. Apart from this, the CCRUM organized more than 20 conferences, seminars, workshops and other such events.

The CCRUM participated in 36 Arogya fairs/expos and similar events to propagate Unani Medicine and highlight its activities and achievements.

The council continued the promotion of the Official Language and organized Hindi Pakhwada at the headquarters and different centres. Quarterly workshops on Hindi language were also organized. The CCRUM attained success in official language review of its headquarters and four of its institutes conducted by the third sub-committee of the Committee of Parliament on Official Language.

In essence, the year 2022–2023 emerged as a period of achievement for the CCRUM, showcasing resilience and commitment to advancing research, education, and healthcare services in the field of Unani Medicine. We hope that the CCRUM work even more efficiently in the coming years for the fulfilment of its aims and objectives in the area of research and development in Unani Medicine.

New Delhi December 04, 2023 **Dr. N. Zaheer Ahmed**Director General

2. MANAGEMENT

The management of the affairs of the CCRUM is entrusted to the Governing Body (GB), the Executive Committee (EC) and the Standing Finance Committee (SFC). The research activities are conducted with the recommendations of the Scientific Advisory Committee and ethical clearance of the Institutional Ethics Committee (IEC).

2.1. Governing Body

The constitution of the GB of the CCRUM at the end of the reporting period was as given below:

President

Minister Incharge, Ministry of Ayush

Vice-President-L

Minister of State, Ministry of Ayush

Vice-President-II

Secretary, Ministry of Ayush

Official Members

- Financial Advisor, Ministry of Ayush
- Special Secretary / Additional Secretary / Joint Secretary (dealing with CCRUM), Ministry of Ayush
- · Adviser (Unani), Ministry of Ayush
- Director, National Institute of Unani Medicine, Bengaluru

Non-Official Members

- Prof. Aftab Ahmad, Jamia Hamdard, New Delhi
- Prof. Mohammad Idris, Ayurvedic & Unani Tibbia College, New Delhi
- Prof. S. J. B. Bokhari, Government Nizamia Tibbi College, Hyderabad
- Prof. Irfan Ahmad, Unani Medical College, Prayagraj, Uttar Pradesh
- Dr. Mohd. Zafar Hasan, Private Practitioner, Bhopal
- Prof. Sunil Kohli, Hamdard Institute of Medical Sciences & Research, New Delhi
- Dr. Swaran Jeet Singh Flora, Former Director, National Institute of Pharmaceutical Education and Research, Raebareli
- Dr. Rajeev Kumar Sharma, Former Director, Pharmacopoeial Laboratory for Indian Medicine. Ghaziabad
- Dr. Kommu Nagaiah, Indian Institute of Chemical Technology, Hyderabad

Member Secretary

Director General, CCRUM

2.2. Executive Committee

The constitution of the EC at the end of the reporting period was as given below:

Chairperson

Secretary, Ministry of Ayush, Government of India





Official Members

- Financial Advisor, Ministry of Ayush, Government of India
- Special Secretary/Additional Secretary/Joint Secretary (dealing with CCRUM), Ministry of Ayush, Government of India
- Adviser (Unani), Ministry of Ayush, Government of India
- Director, National Institute of Unani Medicine, Bengaluru

Non-Official Members

- Prof. Aftab Ahmad, Jamia Hamdard, New Delhi
- Prof. S. J. B. Bokhari, Government Nizamia Tibbi College, Hyderabad
- Prof. Irfan Ahmad, Unani Medical College, Prayagraj, Uttar Pradesh
- Dr. Swaran Jeet Singh Flora, Former Director, National Institute of Pharmaceutical Education and Research, Raebareli
- Dr. Kommu Nagaiah, Indian Institute of Chemical Technology, Hyderabad

Member Secretary

Director General, CCRUM

2.3. Standing Finance Committee

The composition of the SFC at the end of the reporting period was as follows:

• Special Secretary/Additional Secretary/Joint Secretary : Chairman

(dealing with CCRUM), Ministry of Ayush, Government of India

• Financial Advisor or his nominee not below the rank of Deputy : Member

Secretary, Integrated Finance Division, Ministry of Ayush, Government of India

Adviser (Unani), Ministry of Ayush, Government of India
 Member

Prof. Aftab Ahmad, Jamia Hamdard, New Delhi : Member
 Dr. Swaran Jeet Singh Flora, Former Director, National : Member

Institute of Pharmaceutical Education and Research, Raebareli

• Director General, CCRUM : Member-Secretary

2.4. Scientific Advisory Committee

The following was the composition of the SAC as on March 31, 2023:

Dr. Ram Vishvakarma, Director, CSIR-IIIM, Jammu
 : Chairperson

Dr. M. A. Waheed, Former Officiating Director, NRIUMSD, : Member

Hyderabad

Prof. Abdul Wadud, Director, NIUM, Bengaluru : Member

Prof. Imamuddin, Former Principal, Government Unani: Member

Medical College, Chennai

Prof. D. S. Arya, Department of Pharmacology, AIIMS, New : Member

Delhi

Prof. Sunil Kohli, Hamdard Institute of Medical Sciences & : Member

Research, New Delhi



• Dr. (Mrs.) Sunita Garg, Chief Scientist (Retd.), National : Member

Institute of Science Communication and Information Resources, CSIR, New Delhi

Member

Dr. Arun Kumar Sinha, Chief Scientist, Medicinal and Process
 Chemistry, CSIR-Central Drug Research Institute, Lucknow

Director General, CCRUM : Member Secretary

2.4.1. Research Sub-Committees

The SAC is assisted by five research sub-committees, namely Clinical Research Sub-committee, Drug Standardization Sub-committee, Literary Research Sub-committee, Survey and Cultivation of Medicinal Plants Sub-committee and Claim of Cure Sub-committee. However, there was no sub-committee in place during the reporting period.

2.5. Institutional Ethics Committee

It is mandatory that all the proposals on biomedical research involving human participants are approved by a duly constituted ethics committee to protect their welfare and rights. At the end of the reporting period, there were 14 Institutional Ethics Committees (IEC) functioning at various institutes/units of the CCRUM. These committees review and approve research proposals involving human participants. They also examine the compliance with regulatory requirements, applicable guidelines, and laws.

National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad

 Prof. M. U. R. Naidu, Former Dean, Faculty of Medicine, : Chairperson Nizam's Institute of Medical Sciences, Hyderabad

 Prof. Chennakesavulu Dara, ESIC Medical College & : Member Hospital, Hyderabad

 Prof. Md. Ahsan Farooqui, Government Nizamia Tibbi : Member College, Hyderabad

Shri Abdul Fatah Khan, Advocate, Hyderabad : Member
 Dr. Md Abdulwassey, Cardiovascular Health Officer (CVHO), : Member WHO Telangana.

 Shri Nasirulhaq, Former Administrative Officer, Telangana : Member Electrical Department

• Dr. Qamar Uddin, NRIUMSD, Hyderabad : Member Secretary

Central Research Institute of Unani Medicine (CRIUM), Lucknow

 Dr. Kauser Usman, Department of Medicine, King George's : Chairperson Medical University, Lucknow

 Dr. Tarique Mahmood Ansari, Faculty of Pharmacy, Integral : Member University, Lucknow

 Prof. Jamal Akhtar, Principal, State Takmil-ut-Tib College, & : Member Hospital, Lucknow

• Sh. I. H. Farooqui, Advocate, Formerly Assistant Solicitor : Member General of India, Lucknow

Sh. Vaish Mohammad, Bright Way Foundation, Lucknow : Member
 Prof. Shabbir Ahmad Nadwi, Former Head, Department of : Member Arabic, University of Lucknow



Sh. Abdul Jabbar, Khurram Nagar, Lucknow Member

Dr. Mahboobus Salam, Research Officer (Unani), CRIUM, : Member Secretary Lucknow

Regional Research Institute of Unani Medicine (RRIUM), Chennai

Hakim Sved Imamuddin Ahmed, Former Principal, : Chairperson

Government Unani Medical College, Chennai

Member Dr. P. Elango, Ramachandra Medical College & Research :

Institute, Chennai

Member Dr. R. Ilavarasan, Assistant Director Incharge, CSM Drug

Research Institute of Ayurveda, Chennai

Dr. V. Md. Habibullah, Head, Department of Jarahat, : Member

Government Unani Medical College, Chennai

Dr. Syed Hissar, Scientist C, ICMR-NIRT, Chennai Member

Member Dr. K. Amjath Khan, Advocate, Madras High Court, Chennai

Member Dr. C. Ponnuraja, Scientist D, NIRT, Chennai

Member Dr. S. Nagasubramanian, Chennai

Member Shri Abdul Samad, Institute of Management, The New

College, Chennai

Ms. R. Naseema Begum, Stenographer, RRIUM, Chennai Member

Alternate Member Dr. Noman Anwar, Research Officer (Unani), RRIUM, Chennai

Secretary

Dr. (Mrs.) T. Shahida Begum, Research Officer (Unani): Member Secretary

Scientist-IV, RRIUM, Chennai

Regional Research Institute of Unani Medicine (RRIUM), Srinagar

Prof. Zahoor Ahmad Wafai, Former Head, Department of : Chairperson

Clinical Pharmacology, Sher-i-Kashmir Institute of Medical Sciences Soura, Srinagar

Prof. S. M. Salim Khan, Head, Department of Community : Member

Medicine, Government Medical College, Srinagar

Dr. Showkat Hussain Yatoo, Administrator, Board of Ayush, Member

J&K

Dr. Ghulam Nabi Maknoo, Consultant (Cardiology), Noora : Member

Hospital, Srinagar

Member Shri Sajad Buchh, Advocate, Moominabad Court, Srinagar

Shri Mohammad Farooq Rathar, Srinagar Member

Dr. Irfat Ara, Research Officer (Unani) Scientist-IV, RRIUM, : Member Secretary

Srinagar

Regional Research Institute of Unani Medicine (RRIUM), Aligarh

Prof. K. M. Y. Amin, Department of Ilmul Advia, Aimal Khan : Chairperson

Tibbiya College, Aligarh Muslim University, Aligarh

Dr. Zameer Ahmed, Associate Professor, Aimal Khan Tibbiya Member

College, Aligarh Muslim University, Aligarh

Dr. Jamal Azmat, Assistant Professor, Ajmal Khan Tibbiya : Member

College, Aligarh Muslim University, Aligarh



• Dr. Arshi Khan, Professor, Department of Political Science, : Member

Aligarh Muslim University, Aligarh

Ms. Asma Farheen, Advocate, Aligarh
 : Member

Dr. Syed Sirajuddin Ajmali, Professor, Department of Urdu, : Member

Aligarh Muslim University, Aligarh

In-charge, RRIUM, Aligarh
 : Member Secretary

Regional Research Institute of Unani Medicine (RRIUM), New Delhi

Prof. Prem Kapoor, Department of Medicine, Hamdard : Chairperson

Institute of Medical Sciences & Research, New Delhi

Prof. Surender Singh, Department of Pharmacology, AIIMS, : Member

New Delhi

Dr. Poonam Saith, Consultant Gynecologist-Obstetrician, : Member

Kalkaji, New Delhi

• Dr. Md. Wasi Akhtar, Assistant Professor, Department of : Member

Moalajat, SUMER, Jamia Hamdard, New Delhi

Shri Mobashshir Sarwar, Advocate, Delhi High Court, New : Member

Delhi

Dr. M. Jamshed, Assistant Professor, School of Management : Member

and Business Studies, Jamia Hamdard, New Delhi

Dr. Priyanka Verma, Research Officer (Biochemistry),
 : Member Secretary

RRIUM, New Delhi

Regional Research Institute of Unani Medicine (RRIUM), Mumbai

Dr. Priya Venkatesh Patil, Professor & Head, Department of : Chairperson

Medicine, Grant Govt. Medical College & Sir J. J. Group of

Hospitals, Mumbai

Dr. Kamal Ahmad, Department of Ilmul Advia, Yunus Fazlani : Member

Unani Medical College, Kunjkheda, Maharashtra

Dr. Madhukar Gangaram Gaikwad, Department of Medicine, : Member

St. Georges Hospital, Mumbai

Adv. Ashna Maryam Sayed, High Court of Bombay Fort, : Member

Mumbai

• Dr. Balkrishna Vithal Bhosale, Department of Sociology, : Member

University of Mumbai, Mumbai

• Dr. Nikhat Shaikh, Research Officer (Unani), RRIUM, Mumbai : Alternate Member

Secretary

Dr. Humaira Bano, Research Officer (Unani) Scientist-IV, : Member Secretary

RRIUM, Mumbai

Regional Research Institute of Unani Medicine (RRIUM), Kolkata

Dr. Santanu Munshi, Professor & Head, Clinical & : Chairperson

Experimental Pharmacology, School of Tropical Medicine,

Kolkata

Prof. Md. Tajuddin, The Calcutta Unani Medical College & : Member

Hospital, Kolkata

Dr. Yogiraj Ray, Associate Professor, IPGMER, Kolkata : Member

Md. Imtiyaz, Secretary, Sankalp Today (NGO), Kolkata : Member

Member



Smt. Sima Perween, Advocate, Kolkata Member Shri Haider Ali, President, Howrah Health Awareness Mission, Member Kolkata Member Secretary In-charge, RRIUM, Kolkata Regional Research Institute of Unani Medicine (RRIUM), Patna Prof. Alauddin Ahmad, Former Vice-Chancellor, Jamia: Chairperson Hamdard, New Delhi Prof. Abdul Aziz, Nalanda Medical College, Patna Member Prof. Shahnawaz Akhtar, Government Tibbi College & Member Hospital, Patna Shri Nadim Akhtar, Advocate, Civil Court & Patna High Court, : Member Patna Dr. Haroon Rasheed, Programme Manager for Rural: Member Development, Government of Bihar Prof. Shakil Ahmad Qasmi, Formerly Head, Department of : Member Urdu, Oriental College, Patna Shri Mohammad Azam, Social Worker, Patna Member Member Secretary In-charge, RRIUM, Patna Regional Research Institute of Unani Medicine (RRIUM), Bhadrak Prof. Debashish Hota, Head, Department of Pharmacology, : Chairperson AIIMS, Bhubaneswar Dr. Dhirendra Kumar Roy, Medical Director, Institute of : Member Medical Sciences & SUM Hospital, Bhubaneswar Dr. Jhasaketan Mohanty, Former Sr. Medicine Specialist, : Member District Headquarters Hospital, Bhadrak Dr. Sayed Mozammil Ali, Medical Officer (Unani), Government : Member Unani Dispensary, Balasore Shri Shaikh Zulfigar Ali, Advocate, Bhadrak District Court, : Member Bhadrak Shri S. M. Farooque, Secretary, Fellowship (NGO), Bhadrak Member Member Shri Basant Kumar Nayak, Bhadrak Dr. Abdur Rasheed, Research Officer (Unani), RRIUM, : Member Secretary **Bhadrak** Regional Research Centre (RRC), Silchar Dr. Dolly Roy, Chairperson / Associate Professor of : Chairperson Pharmacology, Silchar Medical College and Hospital, Silchar Dr. Riturag Thakuria, Assistant Professor, Department of : Member Medicine, Silchar Medical College and Hospital, Silchar Dr. Wahiduzzaman, Former Deputy Director, RRIUM, Patna Member Shri Ramizur Rahman Barlaskar, Advocate, Silchar Bar Member Association, Silchar

Shri Lutfur Rahman Laskar, Secretary, Bank Sangha (NGO),



Neairgram, Cachar

Ikramuddin Mazumder. Assistant Member Maulana Teacher, Ghoniwala Hafizia Madarsa, Silchar Shri Saleh Ahmed Mazumder, Silchar Member Member Secretary In-charge, RRC, Silchar Clinical Research Unit (CRU), Meerut Dr. Surbhi Gupta, Head, Department of Pharmacology, Chairperson Subharti Medical College, Meerut Dr. Sabahatullah, Physician, Amroha Member Dr. Mohd Sakir, Muzaffarnagar Medical College & Hospital, Member Mansoorpur, Muzaffarnagar Dr. Mushtag Hussain, Allama Igbal Unani Medical College, Member Muzaffarnagar Mohd. Aslam, Advocate, Collectorate of Meerut Member Member Mohd. Akhlaq, Imam, Chhoti Masjid Sotiganj, Meerut Maulvi Tanveer Akhtar, Religious Teacher, Meerut Member Mohd. Parvaz, Social Worker, Meerut Member Member Shri Sarfaraz Ahmad, Social Worker, Meerut Member Secretary In-charge, CRU, Meerut Research Research Centre (RRC), Prayagraj Dr. (Prof.) Shiv Prakash, Head, Department of Community: Chairperson Medicine, Moti Lal Nehru Medical College, Prayagraj Prof. Irfan Ahmad, State Unani Medical College, Prayagraj Member Dr. Abhinav Agarwal, Assistant Professor, Moti Lal Nehru Member Medical College, Prayagraj Shri Vinay Singh, Advocate, High Court of Judicature, : Member Prayagraj Prof. Najeeb Hanzla Ammar, State Unani Medical College, : Member Prayagraj Member Mohd. Arif, Kareli, GTB Nagar In-charge, RRC, Prayagraj Member Secretary Clinical Research Unit (CRU), Burhanpur Chairperson Dr. Ranjendra Sighal, Director, Icon Hospital, Burhanpur Member Dr. Shaikh Imran, Assistant Professor (Moalajat), Saifia Hamidia Unani Tibbiya College, Burhanpur Dr. Mazhar Husain Ansari, Assistant Professor (Ilmul Advia), Member Saifia Hamidia Unani Tibbiya College, Burhanpur Maulana Shaikh Javed Qasmi, Burhanpur Member Shri Waseem Khan, Advocate, Burhanpur Member Shri Rizwan Abbas, Rotarian, Social Worker, Director Red Member Cross Society, Burhanpur Member Shri Mohammad Ismail Khan, Burhanpur Member Secretary In-charge, CRU, Burhanpur



2.6. Organisational Set-Up

The CCRUM is headquartered in New Delhi and has a network of 23 centres functioning in different parts of the country. These centres are as follows:

Centre	Number
National Research Institute of Unani Medicine for Skin Disorders	01
Central Research Institute of Unani Medicine	01
Regional Research Institute of Unani Medicine	09
Regional Research Centre	01
Clinical Research Unit	07
Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine	01
Drug Standardization Research Institute	01
Drug Standardization Research Unit	01
Chemical Research Unit (Grant-in-aid)	01

The CCRUM centres are based in different States. The following is the State-wise institutional network.

Andhra Pradesh

Clinical Research Unit (CRU), Kurnool

Assam

Regional Research Institute of Unani Medicine, Silchar

Bihar

Regional Research Institute of Unani Medicine (RRIUM), Patna

Delhi

- Regional Research Institute of Unani Medicine (RRIUM), New Delhi
- Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine (HAKILHRUM), New Delhi
- Drug Standardization Research Unit (DSRU), New Delhi
- Unani Medical Centre (Extension Centre of RRIUM, New Delhi), Dr. Ram Manohar Lohia Hospital, New Delhi
- Unani Speciality Centre (Extension Centre of RRIUM, New Delhi), Deen Dayal Upadhyay Hospital, New Delhi
- Unani Medical Centre (Extension Centre of RRIUM, New Delhi), VMMC & Safdarjung Hospital, New Delhi

Jammu & Kashmir

Regional Research Institute of Unani Medicine (RRIUM), Srinagar

Karnataka

Clinical Research Unit (CRU), Bengaluru

Kerala

 Clinical Research Unit (CRU), Edathala (Alwaye) with an extension centre at Pattiam, Kannur

Madhya Pradesh

- Clinical Research Unit (CRU), Bhopal
- Clinical Research Unit (CRU), Burhanpur





Maharashtra

• Regional Research Institute of Unani Medicine (RRIUM), Mumbai

Manipur

Clinical Research Unit (CRU), Imphal

Odisha

• Regional Research Institute of Unani Medicine (RRIUM), Bhadrak

Tamil Nadu

Regional Research Institute of Unani Medicine (RRIUM), Chennai

Telangana


 National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad


Uttar Pradesh

- Central Research Institute of Unani Medicine (CRIUM), Lucknow
- Regional Research Institute of Unani Medicine (RRIUM), Aligarh
- Drug Standardization Research Institute (DSRI), Ghaziabad
- Regional Research Centre (RRC), Prayagraj
- Clinical Research Unit (CRU), Meerut
- Chemical Research Unit (Grant-in-aid), Aligarh

West Bengal


Regional Research Institute of Unani Medicine (RRIUM), Kolkata













2.7. Budget (Actual Expenditure)

The centre-wise actual expenditure of the Council during 2022–23 was as follows:

S. No.	Name of State and Centre	Rupees in Thousand
1.	Andhra Pradesh	
	(i) CRU, Kurnool	3,373
2.	Assam (NER)	
	(i) RRIUM, Silchar	2,909
3.	Bihar	
	(i) RRIUM, Patna	30,484
4.	Jammu & Kashmir	
	(i) RRIUM, Srinagar	106,090
5.	Karnataka	
	(i) CRU, Bengaluru	2,821
6.	Kerala	
	(i) CRU, Alwaye	911
7.	Madhya Pradesh	
	(i) CRU, Burhanpur	2,828
	(ii) CRU, Bhopal	4,684
8.	Maharashtra	
	(i) RRIUM, Mumbai	40,124
9.	Manipur (NER)	
	(i) Clinical Research Unit, Imphal	201
10.	New Delhi	
	(i) HAKILHRUM, New Delhi	5,400
	(ii) RRIUM, New Delhi	90,313
	(iii) Headquarters, New Delhi	564,420
	(iv) DSRU, New Delhi	2,181
11.	Odisha	
	(i) RRIUM, Bhadrak	37,205
12.	Tamil Nadu	
	(i) RRIUM, Chennai	78,075
13.	Telangana	
	(i) NRIUMSD, Hyderabad	174,762
14.	Uttar Pradesh	

S. No.	Name of State and Centre	Rupees in Thousand
	(i) DSRI, Ghaziabad	4,347
	(ii) CRIUM, Lucknow	90,471
	(iii) RRC, Prayagraj	4,274
	(iv) RRIUM, Aligarh	61,106
	(v) CRU, Meerut	4,344
15.	West Bengal	
	(i) RRIUM, Kolkata / Howrah	3,825
16.	Other Charges	
	(i) AHMIS	116
	(ii) Contribution to NPS	28,478
	(iii) CGHS Contribution	2,511
	(iv) Pension Fund Transfer	325,379
	(v) IEC	20
	(vi) Swatchhta Action Plan	3,000
	(vii) Hindi Pakhwada	1,677
	(viii) Collaborative Research Projects	44,730
	(ix) Hindi Workshop	7,909
	(x) Arogya Mela	277
	(xi) Ethics Committee	161
	(xii) NPCDCS	99
	(xiii) Seminar/Workshop	2,409
	(vix) Capital Works	33,855
	(xv) Advance to Govt. Servants	3,148
	Grand Total S. No. 1 to 16	17,68,887



3. TECHNICAL REPORT

3.1. Intramural Research

3.1.1. Centre-wise Activities

CENTRE	ACTIVITIES
National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad	 Survey and Cultivation of Medicinal Plants Programme Drug Standardization Research Programme Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Pharmacological Research Programme Validation of Regimen Therapies Validation of Fundamentals Research-oriented Healthcare General Outpatient Department (GOPD) Programme In-patients Department (IPD) Programme Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Central Research Institute of Unani Medicine (CRIUM), Lucknow	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Validation of Regimen Therapies Research-oriented Healthcare General Outpatient Department (GOPD) Programme In-patients Department (IPD) Programme Mobile Clinical Research Programme Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Regional Research Institute of Unani Medicine (RRIUM), Chennai	 Survey and Cultivation of Medicinal Plants Programme Drug Standardization Research Programme Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Validation of Regimen Therapies Research-oriented Healthcare General Outpatient Department (GOPD) Programme In-patients Department (IPD) Programme Mobile Clinical Research Programme Mobile Healthcare Programme under Scheduled Caste Sub-Plan
Regional Research Institute of Unani Medicine (RRIUM), Bhadrak	 Survey and Cultivation of Medicinal Plants Programme Clinical Research Programme Validation of Unani Pharmacopoeial Drugs

CENTRE	ACTIVITIES		
CENTRE	ACTIVITIES		
	 Validation of Regimen Therapies Research-oriented Healthcare General Outpatient Department (GOPD) Programme In-patients Department (IPD) Programme Mobile Clinical Research Programme School Health Programme Mobile Healthcare Programme under Tribal Sub Plan 		
Regional Research Institute of Unani Medicine (RRIUM), Patna	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Validation of Regimen Therapies Research-oriented Healthcare General Outpatient Department (GOPD) Programme In-patients Department (IPD) Programme Mobile Clinical Research Programme School Health Programme Mobile Healthcare Programme under Scheduled Caste Sub-Plan 		
Regional Research Institute of Unani Medicine (RRIUM), Aligarh	 Survey and Cultivation of Medicinal Plants Programme Drug Standardization Research Programme Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Research-oriented Healthcare General Outpatient Department (GOPD) Programme In-patients Department (IPD) Programme Mobile Clinical Research Programme Mobile Healthcare Programme under Scheduled Caste Sub-Plan 		
Regional Research Institute of Unani Medicine (RRIUM), Mumbai	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Validation of Regimen Therapies Research-oriented Healthcare General Outpatient Department (GOPD) Programme In-patients Department (IPD) Programme Mobile Clinical Research Programme Mobile Healthcare Programme under Scheduled Caste Sub-Plan 		
Regional Research Institute of Unani Medicine (RRIUM), Srinagar	 Survey and Cultivation of Medicinal Plants Programme Drug Standardization Research Programme 		

CENTRE	ACTIVITIES	
	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Pharmacological Research Programme Validation of Regimen Therapies Research-oriented Healthcare General Outpatient Department (GOPD) Programme In-patients Department (IPD) Programme Mobile Clinical Research Programme School Health Programme Mobile Healthcare Programme under Tribal Sub Plan 	
Regional Research Institute of Unani Medicine (RRIUM), Kolkata	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Research-oriented Healthcare General Outpatient Department (GOPD) Programme Mobile Clinical Research Programme Mobile Healthcare Programme under Scheduled Caste Sub-Plan 	
Regional Research Institute of Unani Medicine (RRIUM), New Delhi	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Validation of Regimen Therapies Research-oriented Healthcare General Outpatient Department (GOPD)	
Regional Research Institute of Unani Medicine (RRIUM), Silchar	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Research-oriented Healthcare General Outpatient Department (GOPD) Programme 	
Regional Research Centre (RRC), Prayagraj	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Research-oriented Healthcare General Outpatient Department (GOPD) Programme Mobile Clinical Research Programme Mobile Healthcare Programme under Scheduled Caste Sub-Plan 	



CENTRE	ACTIVITIES		
Clinical Research Unit (CRU), Bengaluru	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Research-oriented Healthcare General Outpatient Department (GOPD) Programme Mobile Healthcare Programme under Scheduled Caste Sub-Plan 		
Clinical Research Unit (CRU), Meerut	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Research-oriented Healthcare General Outpatient Department (GOPD) Programme Mobile Healthcare Programme under Scheduled Caste Sub-Plan 		
Clinical Research Unit (CRU), Bhopal	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Research-oriented Healthcare General Outpatient Department (GOPD) Programme Mobile Healthcare Programme under Scheduled Caste Sub-Plan 		
Clinical Research Unit (CRU), Burhanpur	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Research-oriented Healthcare General Outpatient Department (GOPD) Programme Mobile Healthcare Programme under Tribal Sub Plan 		
Clinical Research Unit (CRU), Edathala	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Research-oriented Healthcare General Outpatient Department (GOPD) Programme 		
Clinical Research Unit (CRU), Kurnool	 Clinical Research Programme Validation of Unani Pharmacopoeial Drugs Research-oriented Healthcare General Outpatient Department (GOPD) Programme Mobile Healthcare Programme under Tribal Sub Plan 		
Clinical Research Unit (CRU), Imphal Drug Standardization Research	Research-oriented Healthcare General Outpatient Department (GOPD) Programme Drug Standardization Research Programme		
Unit (DSRU), New Delhi	Drug Standardization Research Programme		

CENTRE	ACTIVITIES		
Drug Standardization Research Institute (DSRI), Ghaziabad	Drug Standardization Research Programme		
Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine (HAKILHRUM), New Delhi	 Literary Research Programme Research-oriented Healthcare General Outpatient Department (GOPD) Programme 		
Chemical Research Unit (CRU) (Grant-in-aid), Aligarh	Chemical Investigation of Unani Medicinal Plants		

3.1.2. Programme-wise Activities

3.1.2.1. Survey and Cultivation of Medicinal Plants Programme

The CCRUM has a programme for extensive survey of medicinal plants in different parts of the country, primarily with a view to collect and identify medicinal plants and record basic data on ethno-pharmacological uses of plants from the tribal and other rural folks of the study area. The broad objectives of the programme are:

- To survey, collect and identify medicinal plants in different forest zones of the country;
- To study distribution, availability, ethno-pharmacological uses and threats of medicinal plants;
- To carry out experimental and field-scale cultivation of medicinal plants;
- To maintain a herbarium of medicinal plants and raw drugs for demonstration purposes;
- To maintain a demonstrable herb garden;
- To document folk knowledge on medicinal uses of plants;
- To collect samples of genuine drugs from the forests for pharmacopoeial standardization;
 and
- To develop nurseries of medicinal plants for demonstration purpose with a view to popularize them among masses.

This programme is carried out at the following research centres:

- National Research Institute of Unani Medicine for Skin Disorders, Hyderabad
- Regional Research Institute of Unani Medicine, Chennai
- Regional Research Institute of Unani Medicine, Srinagar
- Regional Research Institute of Unani Medicine, Bhadrak
- Regional Research Institute of Unani Medicine, Aligarh

Ethnopharmacological Survey

Under this programme, the CCRUM undertook ethno-pharmacological surveys in different forest divisions/areas during the period under report. These include Tiruchirappalli and Tiruvannamalai Forest Division, Tamil Nadu; Hyderabad Forest Divisions, Telangana; Krishna Forest Division and Tirupati Forest Division, Andhra Pradesh; Haldawani Forest Division, Uttrakhand; Sindh Valley Forest Division and Anantnag Forest Division, Union Territory of Jammu and Kashmir. As a result of the survey tours conducted, 1,831 botanical



specimens were collected by the surveyors. During the period under report, 742 plant species were identified.

Herbarium

The plant specimens collected from the study areas, including the previous collection, were mounted on herbarium sheets. During the reporting period, 1,463 such herbarium sheets were prepared and information pertaining to the botanical name, family, local name, Unani name (wherever available), date of collection, brief morphological features and medicinal / other uses of the plants were recorded on each herbarium sheet. Besides, 660 index cards were updated.

The survey team members collected 3,787 saplings of important medicinal species for plantation in the Herbal Garden and nursery attached to the institutes. The survey teams also collected 233 kg of raw drugs and sent them to the pharmacy section of NRIUMSD, Hyderabad for preparation of Unani formulations.

Digitization and Documentation of Herbarium Specimens

Under this activity, 521 herbarium sheets were digitized by the CCRUM research centres at Chennai and Hyderabad.

Folk Claims

The surveyors enquired from the local communities about traditional uses of plants after obtaining oral informed consent. The information was systematized taxonomically and efforts were made to develop a database for comparative analysis of the information recorded. As a result, 145 folk medicinal claims were recorded from the tribal inhabitants and other rural folks of the study areas. The CCRUM publishes the information in the form of books providing details comprising botanical name and family, synonym, local name, Unani name, habit and habitat, wild or cultivated, medicinal efficacy claimed and name of the tribe, locality, collection number, part(s) used, mode of application, and biodynamic notes.

Experimental and Field-Scale Cultivation of Medicinal Plants

Under this activity, the CCRUM cultivates some important medicinal plants used in Unani medicines. These include *Atrilāl* (*Ammi majus* L.), *Afsantīn* (*Artemisia absinthium* L.), *Bābchī* (*Psoralea corylifolia* L.), *Gulnār Fārsī* (*Punica granatum* L. abortive var.), *Gurmārbūti* (*Gymnema sylvestre* (Retz.) R. Br. ex Sm.), *Gul-i-Bābūna* (*Matricaria chamomilla* L.), *Suddāb* (*Ruta graveolens* L.), *Gilo* (*Tinospora cordifolia* (Willd.) Miers), *Janglī Piyāz* (*Drimia indica* (Roxb.) Jessop), *Nāgdawn* (*Artemisia nilagirica* (C.B.Clarke) Pamp), *Darmana Turkī* (*Artemisia maritima* L.), *Ajwāyin Khurāsāni* (*Hyoscyamus niger* L.) etc. As a result of the field-scale cultivation, 234 kg of raw drugs were obtained and supplied to the pharmacy section of NRIUMSD, Hyderabad from Aligarh, Chennai, and Srinagar for preparation of Unani formulations.

Herbal Garden and Nursery of Medicinal Plants

With a view to popularize medicinal plants among the masses, the CCRUM maintained about 485 plant species in its herbal garden at NRIUMSD, Hyderabad; and RRIUM, Aligarh, Chennai and Srinagar. Some of the important and interesting species grown under this activity include: $\bar{A}mla$ (*Phyllanthus emblica* L.), $An\bar{a}r$ (*Punica granatum* L.), Ashok (*Saraca asoca* (Roxb.) Willd.), $Atril\bar{a}l$ (*Ammi majus* L.), $Afsant\bar{l}n$ (*Artemisia absinthium* L.), $Ar\bar{u}s\bar{a}$ (*Justicia adhatoda* L.), Aspghol (*Plantago ovata* Forssk.), Asl al-Sus (*Glycyrrhiza glabra* L.),

Asrol (Rauvolfia serpentina (L.) Benth. ex Kurz.), Bed Mushk (Salix caprea L.), Bijāsar (Pterocarpus marsupium Roxb.), Belgirī (Aegle marmelos (L.) Correa.), Bābchī (Psoralea corylifolia L.), Banafshā (Viola odorata L.), Bhāngrā (Eclipta prostrata (L.) L.), Brinjāsif (Achillea millefolium L.), Fūfal (Areca catechu (L.f.) Willd.), Ga'uzabān (Borago officinalis L.), Ghīkawār (Aloe vera (L.) Burm.f.), Gulnār Fārsī (Punica granatum L. abortive var.), Gurmārbūtī (Gymnema sylvestre (Retz.) R. Br.ex Sm.), Ḥinā (Lawsonia inermis L.), Irsā (Iris ensata Thunb.), Jadwār (Delphinium denudatum Wall. ex Hook.f. & Thoms.), Keorā (Pandanus tectorious Soland. ex Parkinson.), Kājū (Anacardium occidentale L.), Khulanjān (Alpinia galanga Willd.), Konch (Mucuna pruriens L.), Mako (Solanum americanum Mill.), Marorphalī (Helicteres isora L.), Muqil (Commiphora mukul (Hook. ex Stocks) Engl.), Pālas (Butea monosperma (Lam.) Taub.), Qinnāb (Cannabis sativa L.), Qurţūm (Carthamus tinctorius L.), Qust (Saussurea costus (Falc.) Lipsch.) Rasan (Inula racemosa C.B. Clarke), Rivand Chīnī (Rheum emodi Wall. ex Meissn), Sadābahār (Catharanthus roseus (L.) G. Don), Şandal Surkh (Pterocarpus santalinus L.f.), Satāwar (Asparagus racemosus Willd.), Suddāb (Ruta graveolens L.), Raiḥān (Ocimum tenuiflorum L.), Tagar (Valeriana jatamansi Jones), Toke-Baluch (Ginkgo biloba L.), Turbud (Ipomoea turpethum R. Br.), 'Ūd al-Ṣalīb (Paeonia emodi Wallich ex Royle), Waj (Acorus calamus L.), Zīra Makkī (Verbascum thapsus L.), etc.

3.1.2.2. Drug Standardization Research Programme

The Drug Standardization Research Programme is mainly concerned with evolving pharmacopoeial standards for single and compound drugs of Unani Medicine included in various volumes of National Formulary of Unani Medicine (NFUM) and Essential Drugs List for their incorporation in Unani Pharmacopoeia of India (UPI). The work on compound formulations includes development of standard operating procedures (SOPs) for their manufacture followed by the development of their pharmacopoeial standards. Besides, standardization of investigational drugs for clinical trials at the CCRUM and estimation of heavy metals, microbial load, aflatoxins, and pesticidal residues in the drugs and chemical investigations of Unani medicinal plants are also carried out under this programme. The standardization work is carried out in accordance with the format approved by the Scientific Advisory Board, Pharmacopoeia Commission for Indian Medicine & Homoeopathy, Government of India through the following research centres:

- Drug Standardization Research Institute (DSRI), Ghaziabad
- National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad
- Regional Research Institute of Unani Medicine (RRIUM), Chennai
- · Regional Research Institute of Unani Medicine (RRIUM), Srinagar
- Regional Research Institute of Unani Medicine (RRIUM), Aligarh
- Drug Standardization Research Unit (DSRU), New Delhi

During the reporting period, the following works were carried out:

Development of SOPs for Method of Preparation of Unani Formulations and their Pharmacopoeial Standards

Under this programme, SOPs for the method of preparation and pharmacopoeial standards of the following 28 Unani formulations were developed:





S. N.	Formulation	S. N.	Formulation
1	lṭrīfal Ṣaghīr	15	Qurş Dhāt al-Janb
2	lṭrīfal Shāhitara	16	Maʻjūn Mochras
3	Jawārish Fanjnosh	17	Ḥabb Nishāt
4	Jawārish Kundur	18	Ḥabb Jawāhir
5	Jawārish Nār-i-Mushk	19	Ḥabb Sūranjān
6	Jawārish ʿUd Shīrīṇ	20	Ḥalwa Gazar
7	Jawārish Pūdīna	21	lṭrīfal Kishnīzī
8	Sanūn Mukhrij-i-Ruṭūbat	22	lṭrīfal Mulayyin
9	Ḥabb Buḥḥa al-Ṣawt Ḥād	23	Jawhar Munaqqā
10	Ḥabb Buḥḥa al-Ṣawt Muzmin	24	Jawhar Sīn
11	Pachlona	25	Jawārish Shāhī
12	Ḥabb Shabyār	26	Jawārish Qābiḍ
13	Ḥabb Hindī Muḥallil	27	Jawārish Zirishk
14	Ḥabb Ṣarʿ	28	Jawārish Shahryārān

Development of Pharmacopoeial Standards of Single Drugs

Under the programme, pharmacopoeial standards of the following 17 single drugs were developed:

Drug	Botanical / English Name	Part Studied	
Bāch	Acorus calamus L.	Rhizome	
Balū <u>t</u>	Quercus infectoria Olive	Gall	
Bachhnāk / Bīsh	Aconitum chasmanthum Stapf. Ex. Holmes.	Root tuber	
Bajardantī	Barleria prionitis L.	Whole plant	
Anannās	Ananas comosus (L) Merrill	Fruit	
Gul-i- <u>Dh</u> āwā	Woodfordia fruticosa Kurz.	Flower	
Tukhm-i-Gandanā	Asphodelus tenuifolius Cav.	Seed	
Arūsa	Adhatoda vasica Nees	Root bark	
Barg-i-Kasondī	Cassia occidentalis L.	Leaf	
Barg-i-Ḥinā	Lawsonia inermis L.	Leaf	
Fūfal	Areca catechu L.	Fruit	
Bālangu	Lallemantia royleana Benth.	Seed	
Barg-i-Kakronda	Blumea balsamifera (L.) DC.	Leaf	
Qurṭu m	Carthamus tinctorius L.	Seed	
Kachnār	Bauhinia variegata L.	Flower	
Anzarūt	Astragalus sarcocolla Dymock	Gum resin	
Ḥabb al-Ghār	Laurus nobilis L.	Fruit	
	Bāch Balūṭ Bachhnāk / Bīsh Bajardantī Anannās Gul-i-Dhāwā Tukhm-i-Gandanā Arūsa Barg-i-Kasondī Barg-i-Ḥinā Fūfal Bālangu Barg-i-Kakronda Qurṭum Kachnār Anzarūt	BāchAcorus calamus L.BalūṭQuercus infectoria OliveBachhnāk / BīshAconitum chasmanthum Stapf. Ex. Holmes.BajardantīBarleria prionitis L.AnannāsAnanas comosus (L) MerrillGul-i-DhāwāWoodfordia fruticosa Kurz.Tukhm-i-GandanāAsphodelus tenuifolius Cav.ArūsaAdhatoda vasica NeesBarg-i-KasondīCassia occidentalis L.Barg-i-ḤināLawsonia inermis L.FūfalAreca catechu L.BālanguLallemantia royleana Benth.Barg-i-KakrondaBlumea balsamifera (L.) DC.QurṭumCarthamus tinctorius L.KachnārBauhinia variegata L.AnzarūtAstragalus sarcocolla Dymock	



Analysis of DTL Samples

The drug testing laboratory (DTL) at the RRIUM, Chennai analysed the following 16 ASU drug samples received from different organizations:

S. N.	Sample	Source	Parameters Analysed	
1.	ʿAraq-i-Biranjāsif	NIUM, Bangaluru	Physiochemical parameters, HPTLC studies, preliminary phytochemical test, Heavy metal analysis, Microbial Load	
2.	Sample 1 [SH]	Queen May's College,	HPTLC	
3.	Sample 2 [SL]	Chennai		
4.	Code – A	St. Peter's University,	Antimicrobial activity	
5.	Code – B	Chennai		
6.	Code – C			
7.	Code – D			
8.	Code – E			
9.	Gond Babūl		Identification of <i>Kāfūr</i> ,	
10.	Kāfūr		Physicochemical parameters, Microbial contamination, Heavy metal analysis, Analytical tests, Pharmacognostic work, HPTLC	
11.	Joshānda Aftīmūn		Physicochemical parameters, Preliminary phytochemical test, HPTLC study	
12.	Ushaq Maḥlūl	NIUM, Bengaluru		
13.	Ḥabb Mubārak		Physicochemical parameters, Preliminary phytochemical test, HPTLC study	
14.	Ḥabb Hindī		Physicochemical parameters, Preliminary Phytochemical test, HPTLC study	
15.	HL (Rhizome) – Inji Mango	Queen Mary's College, Chennai	HPTLC study	
16.	Achyranthes aspera (Ethanolic extract)	Vel Tech High Tech Engineering College, Chennai	HPTLC study	

Revision of Unani Pharmacopoeia of India

In an effort to revisit the existing Unani Pharmacopoeia of India (UPI), monographs of 45 Unani single drugs from UPI, part-I, vol. I were revised as per the new format provided by the PCIM&H.

Isolation of Phytoconstituents from Unani Single Drugs

Four Unani single drugs were taken up for isolation of phytoconstituents at RRIUM, Srinagar and CRU, Aligarh. The details of isolated compounds are given below:

S. N.	Drug	Botanical/English Name	Part Studied	Phytoconstituents Isolated	Study Centre
1.	Ispand	Peganum harmala L.	Root	Harmine and Harmaline	RRIUM, Srinagar
2.	Sūranjān	Colchicum luteum Baker	Seed	Colchicines and β- lumicolchicine	RRIUM, Srinagar
3.	Harsinghāhr	Nycanthes arbor- tristis L.	Leaf	D-mannitol, β-sitosterol, Astragaline, Nicotiflorin	CRU, Aligarh
4.	Gul Nīlofer	Nymphaea alba L.	Flower	Palmitic acid, Linolenic acid	CRU, Aligarh

3.1.2.3. Clinical Research Programme

Preclinical Studies

Preclinical safety and efficacy studies on Unani formulations are conducted at the National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad and the Regional Research Institute of Unani Medicine (RRIUM), Srinagar. During the reporting period, preclinical safety evaluations were conducted for the following Unani formulations: Sharbat I'jāz, Sharbat 'Unnāb, Itrīfal Shāhitara, Sharbat Tūt Siyāh, Safūf Dama Haldī Wālā, and Qurş Aşfar. Besides the above studies, six more formulations were allotted for preclinical studies. Maʿjūn Muṣaffī Aʿzam, Safūf Makhānā, and Mufarriḥ Shaikh al-Raʿīs were allotted for acute and repeated dose 28-day oral toxicity studies, while Ḥabb Gul-i-Āk for acute and repeated dose 90-day oral toxicity study at the NRIUMSD, Hyderabad. Habb Khardal and La'uq Unșul were allotted for acute and repeated dose 28-day oral toxicity study at the RRIUM, Srinagar. The summaries of the studies conducted are as follows:

Preclinical Safety Evaluation of Sharbat I'jāz

Sharbat I jāz is a traditional Unani polyherbal formulation used for cough, catarrh, and coryza. Despite its widespread use, data regarding its safety and toxicity profile were lacking. The study assessed the acute and repeated dose oral toxicity of Sharbat I'jāz in Sprague Dawley (SD) rats.

An acute oral toxicity study was conducted, administering a single dose of 20 mL/kg body weight, in accordance with OECD-425 guidelines. Subsequently, a repeated dose oral toxicity study was performed using Sprague Dawley (SD) rats at dosage levels of 2, 4, and 10 mL/kg body weight for 28 days. These doses corresponded to approximately 1X, 2X, and 5X the therapeutic equivalent dose, respectively. Preliminary findings suggest a favourable safety profile, with no significant adverse effects observed. Additional assessment through



histopathological findings is pending, but initial results indicate that *Sharbat l'jāz* can be considered safe for its intended use.

Preclinical Safety Evaluation of Sharbat 'Unnāb

Sharbat 'Unnāb is a classical Unani polyherbal formulation used as an expectorant and sedative for cough. The study, following OECD-425 guidelines, assessed the acute and repeated dose oral toxicity of Sharbat 'Unnāb in SD rats. An acute oral toxicity study was conducted following OECD-425 guidelines with single dose of 20 mL/kg body weight. The repeated dose oral toxicity study was carried out using SD rats at dose levels of 2, 4, and 10 mL/kg body weight, which corresponded to approximately 1X, 2X, and 5X the therapeutic equivalent dose, respectively, for a duration of 28 days. Control animals received only water as a vehicle. No mortality or significant alterations were observed in body weight, feed intake, and physiological parameters. The study suggests that Sharbat 'Unnāb demonstrates a favourable safety profile.

Preclinical Safety Evaluation of Itrīfal Shāhitara

Iţrīfal Shāhitara is a traditional polyherbal compound Unani pharmacopoeial formulation for blood purification and laxative purposes. The study included acute and repeated dose (28-days) oral toxicity studies in SD rats.

An acute oral toxicity study was conducted at a limit dose of 2000 mg/kg bw, following the OECD-425 test guideline. The LD50 of *lţrīfal Shāhitara* was determined to be greater than 2000 mg/kg bw in female SD rats. Repeated dose 28-day oral toxicity study on *lţrīfal Shāhitara* was carried out in SD rats. The formulation was orally administered as an aqueous suspension at dose levels of 500, 1,000, and 1,500 mg/kg bw/day p.o. for 28 days, corresponding to approximately 1X, 2X, and 3X of the therapeutic equivalent dose, respectively. No toxicological signs or significant adverse effects were observed, indicating a favorable safety profile. Further conclusions await histopathological findings.

Preclinical Safety Evaluation of Sharbat Tūt Siyāh

Sharbat Tūt Siyāh is a traditional polyherbal compound Unani formulation with anti-inflammatory and demulcent properties. An acute oral toxicity study was conducted, administering a single dose of 20 mL/kg body weight, in accordance with OECD-425 guidelines. Animals were administered with single dose of formulation and observed for lethality and toxic signs & symptoms for 14 days post-treatment. As no lethality was observed following treatment with Sharbat Tūt Siyāh in 5 consecutive animals, dosing to further animals was stopped. All the five animals were sacrificed on day 15 and necropsy was performed. The study indicated no lethality or significant abnormalities and, therefore, oral LD50 of Sharbat Tūt Siyāh in the female SD rat was estimated to be greater than 20 mL/kg body weight. A repeated dose 28-day toxicity study was in progress.

Preclinical Safety Evaluation of Safūf Dama Haldī Wālā

An acute oral toxicity study adhering to OECD-425 guidelines was conducted in Wistar albino rats, with the drug orally administered at a dose of 5000 mg/kg body weight, equivalent to 4 times the extrapolated dose for rats. Physiological parameters, including body weight changes, water consumption, and feed consumption, were systematically monitored on a weekly basis. A subsequent subacute oral toxicity study of *Safūf Dama Haldī Wālā* followed OECD-407 guidelines, involving both male and female Wistar albino rats. The drug was orally administered at dose level of 2000 mg/kg body weight, corresponding to 2 times the extrapolated dose for

rats. Rats underwent close observation for behavioural and neurological changes for 4 hours at 30-minute intervals post-drug administration, and then twice daily for the duration of the experiment. Body weight changes, water consumption, and feed consumption were recorded on a weekly basis. On the 29th day of oral drug administration, rats were sacrificed after an overnight fast. Statistical analysis and data compilation were in progress.

Preclinical Safety Evaluation of Qurs Asfar

An acute oral toxicity study was conducted following OECD-425 guidelines in Wistar albino rats. The rats were administered Qurs Asfar orally at a dose of 2000 mg/kg body weight. Cage-side observations were conducted for behavioral and neurological changes for 24 hours after drug administration and twice daily thereafter until the end of the experiment. A sub-acute oral toxicity study of Qurs Asfar was conducted according to OECD-407 guidelines in both male and female Wistar albino rats. The rats were orally administered Qurs Asfar daily at the dose level of 1000 mg/kg body weight, equivalent to 5 times the extrapolated dose for rats. Observations and examinations did not reveal significant abnormalities. Histopathological studies and data compilation were in progress.

Clinical Studies

The Clinical Research Programme of the CCRUM deals with the methods of diagnosis and treatment of diseases and aims at critical appraisal of the theory of pathogenesis, symptomatology, clinical methods of diagnosis, principles and methods of treatment, and the drug and diet therapies peculiar to Unani Medicine. Under this programme, clinical studies on different diseases were undertaken with a view to develop safe and effective Unani treatments. Besides, clinical validation of the safety and efficacy of Unani pharmacopoeial formulations and validation of Unani pharmacopoeial fast-acting drugs in different diseases was conducted. The programme continued at the following centres:

- National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad
- Central Research Institute of Unani Medicine (CRIUM), Lucknow
- Regional Research Institute of Unani Medicine (RRIUM), Chennai
- Regional Research Institute of Unani Medicine (RRIUM), Bhadrak
- Regional Research Institute of Unani Medicine (RRIUM), Patna
- Regional Research Institute of Unani Medicine (RRIUM), Aligarh
- Regional Research Institute of Unani Medicine (RRIUM), Mumbai
- Regional Research Institute of Unani Medicine (RRIUM), Srinagar
- Regional Research Institute of Unani Medicine (RRIUM), Kolkata
- Regional Research Institute of Unani Medicine (RRIUM), New Delhi
- Regional Research Institute of Unani Medicine (RRIUM), Silchar
- Regional Research Centre (RRC), Prayagraj
- Clinical Research Unit (CRU), Bengaluru
- Clinical Research Unit (CRU), Meerut
- Clinical Research Unit (CRU), Bhopal
- Clinical Research Unit (CRU), Burhanpur
- Clinical Research Unit (CRU), Edathala
- Clinical Research Unit (CRU), Kurnool



CENTRE-WISE ALLOCATION OF DISEASES FOR CLINICAL STUDIES ON SAFETY AND EFFICACY OF UNANI DRUGS

Centre	Diseases
National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad	Haṣāt al-Kulya (nephrolithiasis), Kathrat al-Ṭamth (heavy menstrual bleeding), Dīq al-Nafas (bronchial asthma), Duf al-Mi'da (functional dyspepsia), Iḥtibās al-Ṭamth (amenorrhoea), Mālankhūliyā (mixed anxiety depressive disorder), Sū' al-Qinya (anaemia), Ḥummā (fever), Kathrat al-Bawl (overactive bladder), Amrāḍ-i-Jild (skin eruptions), Dhayābīṭus Sukkarī (diabetes mellitus) and Qūbā (dermatophytosis)
Central Research Institute of Unani Medicine (CRIUM), Lucknow	Sū' al-Qinya (anaemia), Sayalān al-Raḥim (leucorrhoea), D̄q al-Nafas (bronchial asthma), Du'f al- Dimāgh (cerebrasthenia), Ḥummā (fever), lḥtibās al-Ṭamth (amenorrhoea), Kathrat al-Ṭamth (heavy menstrual bleeding), Su' al-Haḍm (dyspepsia), Waja' al-Mafāṣil (rheumatoid arthritis), Du'f al-Mi'da (functional dyspepsia), Ḥaṣāt al-Kulya (nephrolithiasis) and Mālankhūliyā (mixed anxiety depressive disorder)
Regional Research Institute of Unani Medicine (RRIUM), Chennai	Ḥaṣāt al-Kulya (nephrolithiasis), Ḥummā (fever), Qūbā (dermatophytosis), Mālankhūliyā (mixed anxiety depressive disorder), Dīq al-Nafas (bronchial asthma), Duf al-Dimāgh (cerebrasthenia), Sahar (insomnia), Wajaʻ al-Mafāṣil (rheumatoid arthritis), Fālij (hemiplegia) and Sayalān al-Raḥim (leucorrhoea)
Regional Research Institute of Unani Medicine (RRIUM), Bhadrak	Buthūr al-Jild (skin eruptions), Wajaʻ al-Mafāṣil (rheumatoid arthritis), Surʻat al-Inzāl (premature ejaculation), Khafaqān (palpitation), Jarab (scabies), Dīq al-Nafas (bronchial asthma), Duʻf al-Miʻda (functional dyspepsia), Bahaq Abyaḍ / Aswad (pityriasis alba/nigra)
Regional Research Institute of Unani Medicine (RRIUM), Patna	Sū' al-Qinya (anaemia), Nazla Muzmin (chronic rhinosinusitis), Qūbā (dermatophytosis), Niqris (gout), Waja' al-Mafāṣil (rheumatoid arthritis), Du'f al-Mi'da (functional dyspepsia), Du'f al-Dimāgh (cerebrasthenia), Bawāsīr Dāmiya (bleeding piles) and Sahar (insomnia)
Regional Research Institute of Unani Medicine (RRIUM), Aligarh	Du'f al-Ishtihā' (anorexia), Dīq al-Nafas (bronchial asthma), Du'f al-Mi'da (functional dyspepsia), Ḥummā Ajāmiyya (malaria), Sayalān al-Raḥim (leucorrhoea), Du'f al-Dimāgh (cerebrasthenia), Qulā' (stomatitis), Nigris (gout), Ḥumūḍat al-Mi'da (hyperacidity), Jildī Qurūḥ (cutaneous ulcers), Waram al-Ḥanjara (laryngitis) and Sū' al-Haḍm (functional dyspepsia)
Regional Research Institute of Unani Medicine (RRIUM), Mumbai	Dīq al-Nafas (bronchial asthma) Ḥaṣāt al-Kulya (nephrolithiasis), Sū' al-Qinya (anaemia), lḥtibās al-Ṭamth (amenorrhoea), Niqris (gout), Qūbā (dermatophytosis), Khafaqān (palpitation), Mālankhūliyā (mixed anxiety

Centre	Diseases
	depressive disorder), <i>Sayalān al-Raḥim</i> (leucorrhoea), <i>Nisyān</i> (amnesia), <i>Salas al-Bawl</i> (stress urinary incontinence) and <i>Qurūḥ</i> (healing ulcers)
Regional Research Institute of Unani Medicine (RRIUM), Srinagar	Dīq al-Nafas (bronchial asthma), Du'f al-Mi'da (functional dyspepsia), Ḥummā (fever), Sayalān al-Raḥim (leucorrhoea), Mālankhūliya (mixed anxiety depressive disorder), Dhayābīṭus Sukkarī (diabetes mellitus), Daghṭ al-Dam Qawī (hypertension), Kathrat al-Ṭamth (heavy menstrual bleeding), Iḥtibās al-Ṭamth (amenorrhoea) and Niqris (gout)
Regional Research Institute of Unani Medicine (RRIUM), Kolkata	Nazla Muzmin (chronic rhinosinusitis), Du'f al-Ishtihā' (anorexia) and Sū' al-Qinya (anaemia)
Regional Research Institute of Unani Medicine (RRIUM), New Delhi	Sayalān al-Raḥīm (leucorrhoea), Buthūr al-Jild (skin eruptions), Kathrat al-Ṭamth (heavy menstrual bleeding), Sū' al-Qinya (anaemia), Khafaqān (palpitation), Sū' al-Haḍm (dyspepsia), Dhayābīṭus Sukkarī (diabetes mellitus), 'Irq al-Nasā (sciatica), Nisyān (amnesia) and Du'f al-A'ṣāb (neurasthenia)
Regional Research Institute of Unani Medicine (RRIUM), Silchar	Buthūr al-Jild (skin eruptions), Wajaʻ al-Asnān (toothache), Sū'al- Qinya (anaemia), Sahar (insomnia) and Bahaq Abyaḍ / Aswad (pityriasis alba/nigra)
Regional Research Centre (RRC), Prayagraj	Nazla Ḥārr (common cold), Niqris (gout), Sū' al-Qinya (anaemia), Waja' al-Mafāṣil (rheumatoid arthritis), Su'āl Yābis (dry cough), Sahar (insomnia) and Dīq al-Nafas (bronchial asthma)
Clinical Research Unit (CRU), Bengaluru	Nazla Ḥārr (common cold), Wajaʻ al-Asnān (toothache), Dhayābīṭus Sukkarī (diabetes mellitus), and Fālij (hemiplegia)
Clinical Research Unit (CRU), Meerut	 Du'f al-Ishtihā' (anorexia), Dīq al-Nafas (bronchial asthma), Nazla Muzmin (chronic rhinosinusitis), Sayalān al-Raḥim (leucorrhoea), Sū' al-Haḍm (dyspepsia), Su'āl Yābis (dry cough), Salas al-Bawl (stress urinary incontinence), Bawāsīr Dāmiya (bleeding piles) and Waram al-Ḥanjara (laryngitis)
Clinical Research Unit (CRU), Bhopal	Duf al-Ishtihā' (anorexia), Sayalān al-Raḥīm (leucorrhoea) and Mālankhūliya (mixed anxiety depressive disorder)
Clinical Research Unit (CRU), Burhanpur	Sur'at al-Inzāl (premature ejaculation), Nazla Ḥārr (common cold), $S\bar{u}$ ' al-Qinya (anaemia) and $S\bar{u}$ ' al-Haḍm (functional dyspepsia)
Clinical Research Unit (CRU), Kerala	Nazla (common cold), Sahar (insomnia) and Sur'at al- Inzāl (premature ejaculation)
Clinical Research Unit (CRU), Kurnool	<i>Du'f al-Ishtihā'</i> (anorexia), <i>Wajaʻ al-Asnān</i> (toothache), <i>Qulāʻ</i> (stomatitis) and <i>Amrāḍ-i-Jild</i> (skin eruptions)



Randomised Controlled Trials

The following studies under the randomised controlled trials were conducted / initiated during the reporting period:

A single blind, randomised, parallel group study to compare the efficacy and safety of coded Unani formulation K2019 with Ferrous sulphate in the patients of *Faqr al-Dam* (iron deficiency anaemia)

A randomised controlled clinical study of a coded Unani formulation K2019 with Ferrous sulphate was carried out in the patients of *Faqr al-Dam* (iron deficiency anaemia) at RRIUM, New Delhi. The patients were divided into two groups. The test group received UNIM K2019 in a dose of two tablets (500 g each), whereas the control group received ferrous sulphate one tablet (325 mg) once a day for 12 weeks. The test drug was found well-tolerated and no adverse effect was observed.

A single blind, randomised, parallel group study to compare the efficacy and safety of Unani formulation *Qurṣ-i-Mafāṣil* with Paracetamol in the patients of *Taḥajjur al-Mafāṣil* (osteoarthritis)

A randomised controlled clinical study of a Unani formulation *Qurṣ-i-Mafāṣil* with Paracetamol in the patients of *Taḥajjur al-Mafāṣil* (osteoarthritis) was carried out at CRIUM, Lucknow. The patients were divided into two groups. The test group received *Qurṣ-i-Mafāṣil* in a dose of two tablets (500 mg each) whereas the control group received Paracetamol one tablet (500 mg) once a day for eight weeks.

During the reporting period, 88 patients were registered in the study. Of them, 68 completed the study. Out of the completed cases, 31 were relieved, 29 partially relieved and eight were not relieved. There were 20 dropouts and no case was under study. The test drug was found well-tolerated and no adverse effect was observed.

A single blind, randomized, parallel group study to compare efficacy and safety of Unani formulation *Safūf-i-Dama Haldī Wālā* with Salbutamol in patients with *Dīq al-Nafas* (bronchial asthma)

A randomised controlled clinical study of a Unani formulation *Safūf-i-Dama Haldī wālā* with Salbutamol in the patients of *Dīq al-Nafas* (Bronchial Asthma) was carried out at NRIUMSD, Hyderabad. The patients were divided into two groups. The test group received *Safūf-i-Dama Haldi wālā* in powder form in a dose of 5 g once daily whereas the control group received Salbutamol 2 mg once a day for 51 days.

During the reporting period, two new patients were registered in the study and undergoing the trial.

A single blind, randomised, parallel group study to compare the efficacy and safety of coded Unani formulation UNIM-D 2000 with Metformin in the patients with *Dhayābīṭus Sukkarī Qism Thānī* (diabetes mellitus type II)

A randomised controlled clinical study of a coded Unani formulation UNIM-D 2000 with Metformin in the patients of *Dhayābīṭus Sukkarī Qism Thānī* (diabetes mellitus type II) was carried out at RRIUM, Aligarh. The patients were divided into two groups. The test group received UNIM-D 2000 (powder form) in a dose of 500 mg twice daily with water ½ hr before



meals, whereas the control group received Metformin one tablet (850 mg) twice a day for 12 weeks.

During the reporting period, 20 patients completed the study and four were under the trial. The test drug was found well-tolerated and no adverse effect was observed.

A single blind, randomised, parallel group study to compare the efficacy and safety of Unani formulation *Cap. Shaqīqa* with Divalproate in the patients of *Shaqīqa* (migraine)

A randomised controlled clinical study of a coded Unani formulation *Cap. Shaqīqa* with Divalproate in the patients of *Shaqīqa* (migraine) was carried out at RRIUM, Chennai. The patients were divided into two groups. The test group received *Cap. Shaqīqa* in the dose of two capsules (500 mg each) twice a day, whereas the control group received Divalproate 250 mg (body weight <30 kg) or 850 mg (body weight >80 kg) once a day for 12 weeks.

During the reporting period, 28 patients were registered in the study. Out of them, 20 cases completed the study. Of the completed cases, 17 were relieved, two partially relieved and one was not relieved. There were two dropouts and seven cases were under study. The test drug was found well-tolerated and no adverse effect was observed.

Validation of Unani Pharmacopoeial Drugs

Clinical validation of a Unani pharmacopoeial formulation *Khamīra Banafsha* in *Suʿāl Yābis* (dry cough)

A study on clinical validation of a Unani pharmacopoeial formulation *Khamīra Banafsha* was conducted in the patients of *Suʻāl Yābis* (dry cough) at NRIUMSD, Hyderabad; and RRIUMS, Aligarh and New Delhi. The study drug *Khamīra Banafsha* was given orally in the dose of 7 g twice daily for seven days.

During the reporting period, 293 patients completed the study. Of the completed cases, 135 (46.08%) were relieved, 118 (40.27%) partially relieved and 40 (13.65%) were not relieved. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Sanūn Mukhrij-i-Ruṭūbat* in *Litha Dāmiya* (bleeding gums)

A study on clinical validation of a Unani pharmacopoeial formulation *Sanūn Mukhrij-i-Ruṭūbat* was conducted in the patients of *Litha Dāmiya* (bleeding gums) at NRIUMSD, Hyderabad; RRIUM, Aligarh; and CRU, Kurnool. The study drug *Sanūn Mukhrij-i-Ruṭūbat* 1 g was applied locally on the gums twice a day for seven days.

During the reporting period, 156 patients completed the study. Out of the completed cases, 97 (62.18%) were relieved, 53 (33.97%) partially relieved and six (3.85%) were not relieved. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Safūf-i-Tīn* in *Zaḥīr* (dysentery)

A study on validation of a Unani pharmacopoeial formulation $Saf\bar{u}f$ -i- $T\bar{i}n$ in the patients of $Za\bar{h}\bar{i}r$ (dysentery) was carried out at RRIUM, Bhadrak; CRU, Kurnool; and RRC, Allahabad. The patients received $Saf\bar{u}f$ -i- $T\bar{i}n$ 7 g twice daily for six weeks.

During the reporting period, 160 patients completed the study. Out of the completed cases, 84 (52.5%) were relieved, 65 (40.63%) partially relieved and 11 (6.88%) were not relieved. The test drug was found well-tolerated and no adverse effect was observed.



Clinical validation of a Unani pharmacopoeial formulation Qurş Ḥābis in Kathrat al-Ṭamth (menorrhagia)

A study on validation of a Unani pharmacopoeial formulation *Qurṣ Ḥābis* in the patients of *Kathrat al-Ṭamth* (menorrhagia) was carried out at NRIUMSD, Hyderabad; and RRIUMs, Mumbai and Chennai. The patients received *Qurṣ Ḥābis* (250 mg) twice daily for nine days a month starting from the 1st day of the menstrual cycle for three consecutive months.

During the reporting period, 74 patients were studied, of which 31 completed the study. Out of the completed cases, 30 (97%) patients were relieved, and one (3%) showed no response. A total of 26 patients were under study and 17 dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *lţrīfal Zamānī* in *Nazla Muzmin* (chronic rhinosinusitis)

A study on validation of a Unani pharmacopoeial formulation *lṭrīfal Zamānī* in the patients of *Nazla Muzmin* (chronic rhinosinusitis) was carried out at RRIUMs, Aligarh, New Delhi and Kolkata; and CRU, Meerut. The patients received *lṭrīfal Zamānī* 7 g at bedtime for six weeks.

During the reporting period, 119 patients completed the study. Out of the completed cases, 100 (84.03%) patients were relieved, 18 (15.13%) were partially relieved whereas one (0.84%) showed no response. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb Mudirr* in the patients of *lḥtibās al-Ṭamth* (amenorrhoea)

A study on validation of a Unani pharmacopoeial formulation *Ḥabb Mudirr* was conducted in the patients of *lḥtibās al-Ṭamth* (amenorrhoea) at NRIUMSD, Hyderabad; CRIUM, Lucknow; and RRIUM, Mumbai. The study drug *Ḥabb Mudirr* was given in the dose of two pills (500 mg) thrice daily for 5 days each month for three consecutive months.

During the reporting period, 213 patients completed the study. Out of the completed cases, 121 (56.81%) patients were relieved and 54 (25.35%) partially relieved, whereas 38 (17.84%) showed no response. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation Sharbat-i-Khāksī in Hummā (fever)

A study on validation of a Unani pharmacopoeial formulation *Sharbat-i-Khāksī* in the patients of *Ḥummā* (fever) was carried out at CRIUM, Lucknow; and RRIUMs, Srinagar and Chennai. The patients received *Sharbat-i-Khāksī* 15 ml four times a day.

During the reporting period, 30 patients completed the study. Out of the completed cases, 17 (56.67%) were relieved, 12 (40%) were partially relieved, whereas one (3.3%) patient showed no response. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb Muṣaffī-i-Khūn* in *Buthūr al-Jild* (skin eruptions)

A study on validation of a Unani pharmacopoeial formulation *Ḥabb Muṣaffī-i-Khūn* in the patients of *Buthūr al-Jild* (skin eruptions) was carried out at RRIUMs, New Delhi and

Bhadrak; and RRC, Silchar. The patients received *Ḥabb Muṣaffī-i-Khūn* one pill (250 mg) twice daily for two weeks.

During the reporting period, 127 patients completed the study. Out of the completed cases, 30 (23.62%) were relieved, 69 (54.33%) partially relieved and 28 (22.04%) were not relieved. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *lţrīfal Kishnīzī* in *Nazla Muzmin* (chronic rhinosinusitis)

A study on validation of a Unani pharmacopoeial formulation *ltrīfal Kishnīzī* in the patients of *Nazla Muzmin* (chronic rhinosinusitis) was carried out at RRIUMs, Kolkata and Patna; and CRU, Meerut. The patients received *ltrīfal Kishnīzī* 10 gm twice daily for four weeks.

During the reporting period, 167 patients completed the study. Out of the completed cases, 77 (46.11%) were relieved, 75 (44.99%) partially relieved and 15 (8.98%) were not relieved. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Jawārish Pūdīna* in *Du'f al-Ishtihā'* (anorexia)

A study on validation of a Unani pharmacopoeial formulation *Jawārish Pūdīna* in the patients of *Du'f al-Ishtihā'* (anorexia) was carried out at RRIUM, Kolkata; and CRUs, Meerut, Kurnool and Bhopal. The patients received *Jawārish Pūdīna* 5 g twice daily for two weeks.

During the reporting period, 165 patients completed the study. Out of the completed cases, 70 (42.42%) were relieved, 81 (49.09%) partially relieved and 14 (8.48%) were not relieved. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation Safūf-i-Chobchīnī in Nigris (gout)

A study on validation of a Unani pharmacopoeial formulation $Saf\bar{u}f$ -i-Chobch $\bar{i}n\bar{i}$ in the patients of *Niqris* (gout) was carried out at RRIUMs, Mumbai and Patna, and RRC, Allahabad. The patients received $Saf\bar{u}f$ -i-Chobch $\bar{i}n\bar{i}$ 5 g twice daily for six weeks.

During the reporting period, 21 patients were studied, of which 20 completed the study. Out of the completed cases, 16 (80%) were relieved and four (20%) were partially relieved. One patient dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulations *Maʿjūn-i-ʿUshba* and *Marham-i-* Qūbā in Qūbā (dermatophytosis)

A study on validation of Unani pharmacopoeial formulations $Ma'j\bar{u}n-i$ -'Ushba and Marham-i-Q $\bar{u}b\bar{a}$ in the patients of Q $\bar{u}b\bar{a}$ (dermatophytosis) was carried out at RRIUMs, Mumbai, Chennai, and Patna. The patients received $Ma'j\bar{u}n-i$ -'Ushba 5 g oral and Marham-i-Q $\bar{u}b\bar{a}$ topical twice daily for five weeks.

During the reporting period, 75 patients completed the study. Out of the completed cases, 54 (72%) were relieved, 11 (14.67%) partially relieved and 10 (13.33%) were not relieved. The test drug was found well-tolerated and no adverse effect was observed.



Clinical validation of a Unani pharmacopoeial formulation *Maʿjūn Ḥajr al-Yahūd* in *Ḥaṣāt al-Kulya* (nephrolithiasis)

A study on validation of a Unani pharmacopoeial formulation *Maʿjūn Ḥajr al-Yahūd* in the patients of *Ḥaṣāt al-Kulya* (nephrolithiasis) was carried out at NRIUMSD, Hyderabad; and RRIUMs, Mumbai and Chennai. The patients received *Maʿjūn Ḥajr al-Yahūd* 5 g twice daily for 8 weeks.

During the reporting period, 65 patients were studied, of which 35 completed the study. Out of the completed cases, 22 (62.85%) were relieved, five (14.28%) partially relieved, and eight (22.85%) were not relieved. A total of 27 cases dropped out of the study and 13 were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Qurṣ-i-Anjibār* in *Kathrat al-Ṭamth* (heavy menstrual bleeding)

A study on validation of a Unani pharmacopoeial formulation *Qurṣ-i-Anjibār* in the patients of *Kathrat al-Ṭamth* (heavy menstrual bleeding) was carried out at NRIUMSD, Hyderabad; CRIUM, Lucknow; and RRIUM, New Delhi. The patients received *Qurṣ-i-Anjibār* 2 tablets (500 mg) thrice daily for 12 weeks.

During the reporting period, 86 patients were studied, of which 37 completed the study. Out of the completed cases, seven (18.91%) were relieved, 21 (56.75%) partially relieved and nine (24.32%) were not relieved. A total of 42 cases dropped out of the study and seven were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Laʿūq-i-Shamūn* in *Nazla Ḥārr* (common cold)

A study on validation of a Unani pharmacopoeial formulation $La'\bar{u}q$ -i-Sham $\bar{u}n$ in the patients of Nazla Ḥārr (common cold) was carried out at RRC, Prayagraj; and CRUs, Burhanpur, Bengaluru and Kerala. The patients received $La'\bar{u}q$ -i-Sham $\bar{u}n$ 5 g twice daily for seven days.

During the reporting period, 60 patients completed the study. Out of the completed cases, 50 (83.33%) were relieved and 10 (16.67%) partially relieved. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Maʿjūn-i-Suhāg Sonth in Sayalān al-Raḥim* (excessive abnormal vaginal discharge)

A study on validation of a Unani pharmacopoeial formulation *Maʿjūn-i-Suhāg Sonth* in the patients of *Sayalān al-Raḥim* (excessive abnormal vaginal discharge) was carried out at CRIUM, Lucknow; RRIUM, Srinagar; and CRU, Meerut. The patients received *Maʿjūn-i-Suhāg Sonth* 5 g twice daily for four weeks.

During the reporting period, 109 patients completed the study. Out of the completed cases, 48 (44.04%) were relieved, 51 (46.69%) partially relieved and 10 (9.17%) were not relieved. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation Habb Khabath al- $Had\bar{l}d$ in $S\bar{u}$ al-Qinya (anaemia)

A study on validation of a Unani pharmacopoeial formulation Habb Khabath al- $Had\bar{l}d$ in the patients of $S\bar{u}$ al-Qinya (anaemia) was carried out at CRIUM, Lucknow; and RRIUMs, New





Delhi and Mumbai. The patients received Ḥabb Khabath al-Ḥadīd 1 pill twice daily for 12 weeks.

During the reporting period, 41 patients were studied, of which 20 completed the study. Out of the completed cases, three (15%) were relieved, eight (40%) partially relieved and nine (45%) were not relieved. A total of 18 cases dropped out of the study and three were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Maʿjūn-i-Ispand Sokhtānī* in *Surʿa al-Inzāl* (premature ejaculation)

A study on validation of a Unani pharmacopoeial formulation Ma $j\bar{u}n$ -i-lspand $Sokht\bar{a}n\bar{i}$ in the patients of Sur at al- $lnz\bar{a}l$ (premature ejaculation) was carried out at RRIUM, Bhadrak; and CRUs, Kerala and Burhanpur. The patients received Ma $j\bar{u}n$ -i-lspand $Sokht\bar{a}n\bar{i}$ 5 g twice daily for two weeks.

During the reporting period, 112 patients completed the study. Out of the completed cases, 37 (33.04%) were relieved, 41 (36.61%) partially relieved and 34 (30.36%) were not relieved. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Rawghan-i-Qaranful* in *Wajaʿal-Asnān* (toothache)

A study on validation of a Unani pharmacopoeial formulation *Rawghan-i-Qaranful* in the patients of *Waja* 'al-Asnān (toothache) was carried out at CRUs, Kurnool and Bengaluru; and RRC, Silchar. The patients received *Rawghan-i-Qaranful* for local application twice daily for 3 days.

During the reporting period, 99 patients completed the study. Of them, 50 (50.51%) patients were relieved and 49 (49.49%) partially relieved. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb Hindī D̄īqī* in *D̄īq al-Nafas* (bronchial asthma)

A study on validation of a Unani pharmacopoeial formulation $Habb\ Hind\bar{\iota}\ D\bar{\iota}q\bar{\iota}$ in the patients of $D\bar{\iota}q$ al-Nafas (bronchial asthma) was carried out at RRIUMs, Srinagar, Aligarh, and Patna. The patients received $Habb\ Hind\bar{\iota}\ D\bar{\iota}q\bar{\iota}$ one pill (125 mg) twice daily for four weeks.

During the reporting period, 88 patients were studied, of which 56 completed the study. Out of the completed cases, 26 (46.43%) were relieved, 24 (42.86%) partially relieved and six (10.71%) were not relieved. A total of 22 cases dropped out of the study and 10 were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Maʻjūn Sangdāna Murgh* in *Duʻf al-Miʻda* (functional dyspepsia)

A study on validation of a Unani pharmacopoeial formulation $Ma'j\bar{u}n$ Sangdāna Murgh in the patients of $\bar{D}u'f$ al-Mi'da (functional dyspepsia) was carried out at NRIUMSD, Hyderabad; and RRIUMs Srinagar and Aligarh. The patients received $Ma'j\bar{u}n$ Sangdāna Murgh 5 g twice daily for six weeks.

During the reporting period, 84 patients completed the study. Of them, 51 (60.71%) patients were relieved, 20 (23.81%) partially relieved and 13 (15.48%) were not relieved. Three



patients dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation Jawārish Pūdīna Wilāyatī in Sūʿal-Hadm (dyspepsia)

A study on validation of a Unani pharmacopoeial formulation Jawarish Pūdīna Wilayatī in the patients of Sū al-Hadm (dyspepsia) was carried out at CRIUM, Lucknow; RRIUM, New Delhi; and CRU, Meerut. The patients received Jawārish Pūdīna Wilāyatī 5 g twice daily for six weeks.

During the reporting period, 94 patients were studied, of which 46 completed the study. Out of the completed cases, 21 (45.65%) were relieved, 19 (41.30%) partially relieved and six (13.04%) were not relieved. A total of 40 cases dropped out of the study and eight were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation La un Dīq al-Nafas in Dīq al-Nafas (bronchial asthma)

A study on validation of a Unani pharmacopoeial formulation La una al-Nafas in the patients of *Dīq al-Nafas* (bronchial asthma) was carried out at NRIUMSD, Hyderabad; and RRIUMs, Chennai and Bhadrak. The patients received La uq Dīq al-Nafas 5 g twice daily for four weeks.

During the reporting period, 138 patients were studied, of which 90 completed the study. Out of the completed cases, 36 (40%) were relieved, 19 (21.11%) partially relieved and 35 (38.89%) were not relieved. A total of 32 cases dropped out of the study and 16 were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation Sayalānī in Sayalān al-Raḥim (leucorrhoea)

A study on validation of a Unani pharmacopoeial formulation Sayalānī in the patients of Sayalān al-Raḥim (leucorrhoea) was carried out at RRIUMs; Mumbai and Aligarh; and CRU, Bhopal. The patients received two tablets of Sayalānī twice daily for four weeks.

During the reporting period, 51 patients were studied, of which 41 completed the study. Out of the completed cases, 30 (73.17%) were relieved, 10 (24.39%) partially relieved and one (2.44%) was not relieved. A total of 10 cases dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation Ma'jūn Najāḥ in Mālankhūliyā (mixed anxiety depressive disorder)

A study on validation of a Unani pharmacopoeial formulation Ma jūn Najāh in the patients of Mālankhūliyā (mixed anxiety depressive disorder) was carried out at NRIUMSD, Hyderabad; and RRIUMs, Srinagar, Chennai and Mumbai. The patients received Ma jūn Najāḥ 5 g twice daily for six weeks.

During the reporting period, 108 patients were studied, of which 81 completed the study. Out of the completed cases, 57 (70.37%) were relieved, 23 (28.4%) partially relieved and one (1.23%) showed no response. A total of 27 patients dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.



Clinical validation of a Unani pharmacopoeial formulation Ḥabb 'Irq al-Nasā in Waja' al-Mafāṣil (rheumatoid arthritis)

A study on validation of a Unani pharmacopoeial formulation *Ḥabb ʿIrq al-Nasā* in the patients of *Waja ʿal-Mafāṣil* (rheumatoid arthritis) was carried out at CRIUM, Lucknow; RRIUM, Patna; and RRC, Prayagraj. The patients received two tablets of *Ḥabb ʿIrq al-Nasā* thrice daily for 12 weeks.

During the reporting period, 144 patients were studied, of which 100 completed the study. Out of the completed cases, 35 (35%) were relieved, 48 (48%) partially relieved and 17 (17%) were not relieved. A total of 31 cases dropped out of the study and 13 were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Maʿjūn Khabath al-Ḥadīd* in *Sūʾ al-Qinya* (anaemia)

A study on validation of a Unani pharmacopoeial formulation Ma $j\bar{u}n$ Khabath al- $Had\bar{u}$ in the patients of $S\bar{u}$ al-Qinya (anaemia) was carried out at CRIUM, Lucknow; RRIUMs, Patna and Kolkata; RRCs, Prayagraj and Silchar; and CRU, Burhanpur. The patients received Ma $j\bar{u}n$ Khabath al- $Had\bar{u}$ 5 g twice daily for 12 weeks.

During the reporting period, 98 patients were studied, of which 56 completed the study. Out of the completed cases, 15 (26.79%) were relieved, 31 (55.36%) partially relieved and 10 (17.86%) were not relieved. A total of 12 cases dropped out of the study and 30 were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Khamīra Gaʾuzabān Sādā* in *Khafaqān* (palpitation)

A study on validation of a Unani pharmacopoeial formulation *Khamīra Gaʾuzabā<u>n</u> Sādā* in the patients of *Khafaqān* (palpitation) was carried out at RRIUMs, New Delhi, Mumbai, and Bhadrak. The patients received *Khamīra Gaʾuzabā<u>n</u> Sādā* 5 g twice daily for four weeks.

During the reporting period, 167 patients were studied, of which 83 completed the study. Out of the completed cases, 25 (30.12%) were relieved, 46 (55.42%) partially relieved and 12 (14.46%) were not relieved. A total of 45 cases dropped out of the study and 39 were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *lţrīfal Kabīr* in *Duʿf al-Dimāgh* (cerebrasthenia)

A study on validation of a Unani pharmacopoeial formulation *lţrīfal Kabīr* in the patients of *Du'f al-Dimāgh* (cerebrasthenia) was carried out at CRIUM, Lucknow; RRIUMs, Chennai, Aligarh and Patna. The patients received *lţrīfal Kabīr* 5 g twice daily for six weeks.

During the reporting period, 130 patients were studied, of which 77 completed the study. Out of the completed cases, 35 (45.55%) were relieved, 31 (40.26%) partially relieved and 11 (14.29%) were not relieved. A total of 30 cases dropped out of the study and 23 were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation Ḥabb Luʿāb-i-Behidāna in Suʿāl Yābis (dry cough)

A study on validation of a Unani pharmacopoeial formulation *Ḥabb Luʿāb-i-Behidāna* was conducted in the patients of in *Suʿāl Yābis* (dry cough) at RRC, Prayagraj; and CRU, Meerut.



The patients received <u>Habb Lu'āb-i-Behidāna</u> in the dose of one tablet (250 mg) twice a day for 14 days.

During the reporting period, 156 patients were studied, of which 144 completed the study. Out of the completed cases, 100 (69.44%) were relieved, 29 (20.14%) partially relieved and 15 (10.42%) were not relieved. A total of 11 cases dropped out of the study and one case was under study. The test drug was found well-tolerated and no adverse effect was observed.

A study on validation of a Unani pharmacopoeial formulation *Ḥabb Qulā* was conducted in the patients of in *Suʿāl Yābis* (dry cough) at RRIUM, Aligarh and CRU, Kurnool. The patients received *Ḥabb Qulā* in the dose of one pill (250 mg) twice a day for 14 days.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb Qulā* was conducted in the patients of *Qulā* (stomatitis) at RRIUM, Aligarh and CRU, Kurnool. The patients received *Ḥabb Qulā* in the dose of one tablet (250 mg) twice a day for 10 days.

During the reporting period, 77 patients were studied, of which 62 completed the study. Out of the completed cases, 41 (66.13%) were relieved and 21 (33.87%) partially relieved. A total of 15 cases dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation $Qur_{\bar{s}}$ -i-Zirishk in $S\bar{u}^*$ al-Qinya (anaemia)

A study on validation of a Unani pharmacopoeial formulation Qurş-i-Zirishk was conducted in the patients of in $S\bar{u}$ al-Qinya (anaemia) at NRIUMSD, Hyderabad. The patients received Qurş-i-Zirishk in the dose of one tablet (850 mg) thrice a day for 84 days.

During the reporting period, 88 patients were studied, of which 44 completed the study. Out of the completed cases, 39 (88.64%) were relieved and five (11.36%) partially relieved. A total of 13 cases dropped out of the study and 31 cases were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulations Rawghan Nafa´-i-Waram-i-Niqris and Maʿjūn-i-Yaḥyā bin Khālid in Niqris (gout)

A study on validation of a Unani pharmacopoeial formulation *Rawghan Nafa´-i-Waram-i-Niqris and Maʿjūn-i-Yaḥyā bin Khālid* was conducted in the patients of *Niqris* (gout) at RRIUM, Aligarh. The patients received *Maʿjūn-i-Yaḥyā bin Khālid* in the dose of 5 g twice a day and *Rawghan Nafaʿ-i-Waram-i-Niqris* was applied locally on the affected area for 84 days.

During the reporting period, four patients was registered in the study, out of which one completed the study and was completely relieved.

Clinical validation of a Unani pharmacopoeial formulation *Kushta Bayḍa-i-Murgh* in *Sayalān al-Raḥim* (leucorrhoea)

A study on validation of a Unani pharmacopoeial formulation *Kushta Bayḍa-i-Murgh* was conducted in the patients of *Sayalān al-Raḥim* (leucorrhoea) at RRIUM, New Delhi and CRU, Bhopal. The patients received *Kushta Bayḍa-i-Murgh* in the dose of one tablet (50 mg) twice a day for 28 days.

During the reporting period, 16 patients were studied, of which 13 completed the study. Out of the completed cases, two (15.38%) were relieved, nine (69.23%) partially relieved and two (15.38%) were not relieved. Three cases dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Qurş Dawāʾ al-Shifāʾ* in *paghţ al-Dam Qawī* (hypertension)

A study on validation of a Unani pharmacopoeial formulation *Qurṣ Dawāʾ al-Shifāʾ* was conducted in the patients of *Daghṭ al-Dam Qawī* (hypertension) at RRIUM, Srinagar. The patients received *Qurṣ Dawāʾ al-Shifāʾ* in the dose of two tablets once a day for 84 days.

During the reporting period, 39 patients were studied, of which 17 completed the study. Out of the completed cases, 11 (64.71%) were relieved and six (35.29%) partially relieved. A total of five cases dropped out of the study and 17 cases were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Qurṣ-i-ʿAṭash* in *Ḥumūḍat al-Miʿda* (hyperacidity)

A study on validation of a Unani pharmacopoeial formulation *Qurṣ-i-ʿAṭash* was conducted in the patients of *Ḥumūḍat al-Miʿda* (hyperacidity) at RRIUM, Aligarh. The patients received *Qurṣ-i-ʿAṭash* in the dose of one tablet (850 mg) thrice a day for 42 days.

During the reporting period, 23 patients were studied, of which 15 completed the study. Out of the completed cases, 10 (66.67%) were partially relieved and five (33.33%) were not relieved. Eight cases dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulations *Maʿjūn-i-Adhārāqī* and *Rawghan Surkh* in *Wajaʿal-Mafāṣil* (rheumatoid arthritis)

A study on validation of Unani pharmacopoeial formulations *Maʻjūn-i-Adhārāqī* and *Rawghan Surkh* was conducted in the patients of *Wajaʻ al-Mafāṣil* (rheumatoid arthritis) at RRIUM, Chennai. The patients received *Maʻjūn-i-Adhārāqī* in the dose of 3 g twice a day and *Rawghan Surkh* was applied locally on the affected area for 84 days.

During the reporting period, 77 patients were studied, of which 53 completed the study. Out of the completed cases, 15 (28.3%) were relieved, 26 (49.6%) partially relieved and 12 (22.64%) were not relieved. A total of 14 cases dropped out of the study and 10 were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb 'Irq al-Nasā* in '*Irq al-Nasā* (sciatica)

A study on validation of a Unani pharmacopoeial formulation *Ḥabb ʿIrq al-Nasā* was conducted in the patients of *ʿIrq al-Nasā* (sciatica) at CRIUM, Lucknow. The patients received *Ḥabb ʿIrq al-Nasā* in the dose of two tablets (800 mg) thrice a day for 84 days.

During the reporting period, 41 patients were studied, of which 30 completed the study. Out of the completed cases, seven (23.33%) were relieved, 20 (66.67%) were partially relieved and three (10%) were not relieved. A total of five cases dropped out of the study and six cases were under study. The test drug was found well-tolerated and no adverse effect was observed.



Clinical validation of a Unani pharmacopoeial formulation *Ḥabb-i-Banafsha* in *D̄īq al-Nafas Riʾwī* (bronchial asthma)

A study on validation of a Unani pharmacopoeial formulation *Ḥabb-i-Banafsha* was conducted in the patients of *D̄īq al-Nafas Ri wī* (bronchial asthma) at CRIUM, Lucknow and CRU, Meerut. The patients received *Ḥabb-i-Banafsha* in the dose of two tablet (200 mg each) twice a day for 84 days.

During the reporting period, 119 patients were studied, of which 103 completed the study. Out of the completed cases, 35 (33.98%) were relieved, 45 (43.69%) partially relieved and 23 (22.33%) were not relieved. A total of 16 cases dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Kundurī* in *Salas al-Bawl* (stress urinary incontinence)

A study on validation of a Unani pharmacopoeial formulation *Kundurī* was conducted in the patients of *Salas al-Bawl* (stress urinary incontinence) at RRIUM, Mumbai and CRU, Meerut. The patients received *Kundurī* in the dose of 6 g twice a day for 84 days.

During the reporting period, 94 patients were studied, of which 59 completed the study. Out of the completed cases, 13 (22.03%) were relieved, 37 (62.71%) were partially relieved and nine (15.29%) were not relieved. A total of 14 cases dropped out of the study and 21 were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Maʿjūn-i-Zanjabīl* in *Kathrat al-Tamth* (menorrhagia)

A study on validation of a Unani pharmacopoeial formulation *Maʿjūn-i-Zanjabīl* was conducted in the patients of *Kathrat al-Tamth* (menorrhagia) at RRIUM, Srinagar. The patients received *Maʿjūn-i-Zanjabīl* in the dose of 5 g twice a day for 84 days.

During the reporting period, nine patients were studied, of which three completed the study. Out of the completed cases, two (66.67%) were relieved and one (33.33%) was not relieved. A total of six cases dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Jawārish-i-Dārchīnī Qawī* in *Duʿf al-Miʿda* (dyspepsia)

A study on validation of a Unani pharmacopoeial formulation *Jawārish-i-Dārchīnī Qawī* was conducted in the patients of *Du'f al-Mi'da* (dyspepsia) at CRIUM, Lucknow and RRIUM, Patna. The patients received *Jawārish-i-Dārchīnī Qawī* in the dose of 5 g twice a day for 14 days.

During the reporting period, 16 patients were studied, of which 12 completed the study. Out of the completed cases, one (8.33%) was relieved and 11 (91.67%) were partially relieved. A total of four cases dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.



Clinical validation of a Unani pharmacopoeial formulation Rawghan-i-Banafsha in Sahar (insomnia)

A study on validation of a Unani pharmacopoeial formulation *Rawghan-i-Banafsha* was conducted in the patients of *Sahar* (insomnia) at RRIUMs, Silchar and Chennai; and RRC, Prayagraj. *Rawghan-i-Banafsha* was applied locally on the scalp for 14 days.

During the reporting period, 110 patients were studied, of which 87 completed the study. Out of the completed cases, 58 (66.67%) were relieved, 16 (18.39%) partially relieved and 13 (14.49%) were not relieved. A total of 21 cases dropped out of the study and two were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulations *lţrīfal Mundī* and *Marham Raskapūr* in *Jarab* (scabies)

A study on validation of Unani pharmacopoeial formulations *Iţrīfal Mundī* and *Marham Raskapūr* was conducted in the patients of *Jarab* (scabies) at RRIUM, Bhadrak. The patients received *Iţrīfal Mundī* in the dose of 10 g twice a day and *Marham-i-Raskapūr* was applied locally on the affected area for 14 days.

During the reporting period, 44 patients were studied, of which 19 completed the study, and all of them (100%) were partially relieved. A total of 18 cases dropped out of the study and seven cases were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation 'Araq Chirā'ita in Amrāḍ-i- Jild (skin eruptions)

A study on validation of a Unani pharmacopoeial formulation 'Araq Chirā'ita was conducted in the patients of Amrāḍ-i- Jild (skin eruptions) at NRIUMSD, Hyderabad; and CRU, Kurnool. The patients received 'Araq Chirā'ita 125 ml once a day for 14 days.

During the reporting period, five patients were studied, of which three completed the study. Out of the completed cases, one (33.33%) was relieved and two (66.67%) were partially relieved. A total of two cases were under study.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb Kalaf* in *Bahaq Abyaḍ /Aswad* (pityriasis alba/nigra)

A study on validation of a Unani pharmacopoeial formulation *Ḥabb Kalaf* was conducted in the patients of *Bahaq Abyaḍ /Aswad* (pityriasis alba/nigra) at RRIUM, Bhadrak, and Silchar. *Ḥabb Kalaf* one pill (250 mg) mixed with lemon juice was applied locally on the affected area twice a day.

During the reporting period, 32 patients were studied, of which nine completed the study, and all of them (100%) were partially relieved. A total of seven cases dropped out of the study and 16 were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Maʿjūn Tīwāj* in *Bawāsīr Dāmiya* (bleeding piles)

A study on validation of a Unani pharmacopoeial formulation $Ma'j\bar{u}n T\bar{\imath}w\bar{a}j$ was conducted in the patients of $Baw\bar{a}s\bar{\imath}r D\bar{a}miya$ (bleeding piles) at RRIUM, Patna and CRU, Meerut. The patients received $Ma'j\bar{u}n T\bar{\imath}w\bar{a}j$ in the dose of 5 g twice a day for 42 days.



During the reporting period, 41 patients were studied, of which 26 completed the study. Out of the completed cases, 17 (65.38%) patients were relieved, seven (26.92%) were partially relieved and two (7.69%) were not relieved. A total of seven cases dropped out of the study and eight cases were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Jawārish Zarʿūnī Sādā* in *Ḥaṣāt al-Kulya* (nephrolithiasis)

A study on validation of a Unani pharmacopoeial formulation *Jawārish Zarʿūnī Sādā* was conducted in the patients of *Ḥaṣāt al-Kulya* (nephrolithiasis) at CRIUM, Lucknow. The patients received *Jawārish Zarʿūnī Sādā* in the dose of 5 g twice a day for 56 days.

During the reporting period, 21 patients were studied, of which 11 completed the study. Out of the completed cases, four (36.36%) were relieved, three (27.27%) partially relieved and four (36.36%) were not relieved. A total of six cases dropped out of the study and four were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation Jawārish Qurṭum in lḥtibās al-Ṭamth (amenorrhoea)

A study on validation of a Unani pharmacopoeial formulation *Jawārish Qurṭum* was conducted in the patients of *lḥtibās al-Ṭamth* (amenorrhoea) at RRIUM, Srinagar. The patients received *Jawārish Qurṭum* in the dose of 5 g twice a day for 5 days in a month for 3 months.

During the reporting period, 19 patients were studied, of which one completed the study and was relieved. A total of 18 cases were under study.

Clinical validation of a Unani pharmacopoeial formulation Safūf Sūranjān Zaʿfrānī in Niqris (gout)

A study on validation of a Unani pharmacopoeial formulation *Safūf Sūranjān Zaʿfrānī* was conducted in the patients of *Nigris* (gout) at RRIUM, Srinagar. The patients received *Safūf Sūranjān Zaʿfrānī* in the dose of 2.5 g twice a day for 42 days.

During the reporting period, 57 patients were studied, of which 29 completed the study. Out of the completed cases, 19 (65.52%) were relieved and 10 (34.48%) were partially relieved. A total of 16 cases dropped out of the study and 12 cases were under study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of a Unani pharmacopoeial formulation *Ḥabb Khunāq* in *Waram-i-Ḥanjara* (laryngitis)

A study on validation of a Unani pharmacopoeial formulation *Ḥabb Khunāq* was conducted in the patients of *Waram-i- Ḥanjara* (laryngitis) at RRIUM, Aligarh; and CRU, Meerut. The patients received *Ḥabb Khunāq* in the dose of three pills (1 g each) to be chewed thrice a day for 14 days.

During the reporting period, 22 patients were studied, of which 19 completed the study. Out of the completed cases, seven (36.84%) were relieved, six (31.58%) partially relieved and six (31.58%) were not relieved. Two cases dropped out of the study and one case was under study. The test drug was found well-tolerated and no adverse effect was observed.

New studies initiated

The following studies under validation of Unani pharmacopoeial drugs were initiated during the reporting period:

- Clinical validation of Unani pharmacopoeial formulations Ḥabb Mafāṣil and Ḍimād Muḥallil in Wajaʿal-Mafāṣil (rheumatoid arthritis)
- Clinical validation of a Unani pharmacopoeial formulation *Maʻjūn Balādur* in *Nisyān* (amnesia)
- Clinical validation of a Unani pharmacopoeial formulation Jawārish Kundur in Kathrat-i-Bawl (overactive bladder)
- Clinical validation of a Unani pharmacopoeial formulation La ūq Dīq al-Nafas Balghamī in Dīq al-Nafas (bronchial asthma)
- Clinical validation of a Unani pharmacopoeial formulation Ma'jūn La'na in Du'f-i-A'ṣāb (neurasthenia)
- Clinical validation of Unani pharmacopoeial formulation La ūq Fālij and Rawghan-i-Mom in Fālij (hemiplegia)
- Clinical validation of a Unani pharmacopoeial formulation lţrīfal Aftīmūn in Mālankhūliyā (mixed anxiety depressive disorder)
- Clinical validation of a Unani pharmacopoeial formulation Ḥabb Pachlonā in Sūʾ-i-Haḍm (functional dyspepsia)
- Clinical validation of a Unani pharmacopoeial formulation Marham l'jāz in Qurūḥ (healing ulcers)
- Clinical validation of a Unani pharmacopoeial formulation Rawghan Labūb Şabā Bārid in Sahar (insomnia)
- Clinical validation of a Unani pharmacopoeial formulation Safūf Hāḍim Kalān in Duʿf-i-Ishtihāʾ (anorexia)
- Clinical validation of a Unani pharmacopoeial formulation Ḥabb Kibrīt Ṣaghīr in Qūbā (dermatophytosis)
- Clinical validation of a Unani pharmacopoeial formulation *Tiryāq Raḥim* in *Sayalān al-Raḥim* (leucorrhoea)
- Clinical validation of Unani pharmacopoeial formulations Rawghan-i-Nārjīl and Qurş Aşfar in Qūbā (dermatophytosis)
- Clinical validation of a Unani pharmacopoeial formulation Ḥabb-i-Karanjwā in Ḥummā (fever)
- Clinical validation of a Unani pharmacopoeial formulation La 'ūq-i-Ḥulba in D̄īq al-Nafas (bronchial asthma)
- Clinical validation of a Unani pharmacopoeial formulation Maʿjūn Būlis in Nisyān (amnesia)
- Clinical validation of a Unani pharmacopoeial formulation Marham Gulābī in Jildī Qurūḥ (cutaneous ulcers)

New studies allotted

In addition to the above, the following studies under validation of Unani pharmacopoeial drugs were allotted during the reporting period:



- Clinical Validation of Ḥabb Āb-i-Gandāna and Marham Bawāsīr in Bawāsīr 'Amyā' (non-bleeding piles)
- Clinical validation of Habb Gul-i-Āk and Rawghan-i-Ḥinā in Wajaʿal-Mafāṣil (rheumatoid arthritis)
- Clinical validation of lţrīfal Zamānī and Rawghan Kāhū in Mālankhūliyā (mixed anxiety depressive disorder)
- Clinical validation of *Ḥabb Khardal* in *Waram-i-Ḥalaq* (pharyngitis)
- Clinical validation of Ma 'jūn Rashīdī in Taqtīr al-Bawl (post micturition dribble PMD)
- Clinical validation of La 'ūq Anjīr Qawī and Rawghan Haft Barg in Fālij (hemiplegia)
- Clinical validation of La 'ūq Unșul in Su 'āl Muzmin (chronic cough)
- Clinical validation of Ḥabb Kotwālī and Marham Khall al-Khamr in Dāʾ al-Thaʿlab (alopecia)
- Clinical validation of *Ḥabb Ṣadr* in *Dīg al-Nafas* (bronchial asthma)
- Clinical validation of *Ḥabb Mujarrab* in Shaqīqa (migraine)
- Clinical validation of Qurs Sumbul al-Ţīb in Waram-i-Kabid (steatohepatitis)
- Clinical validation of Jawārish 'Ūd Mulayyin in Du'f-i-Ishtihā' (anorexia)
- Clinical validation of Jawārish Muqawwī-i-Mi'da in Du'f-i-Mi'da (functional dyspepsia)
- Clinical Validation of *Maʿjūn Masīḥī* in *Wajaʿal-Quṭn* (non-specific low backache)
- Clinical validation of Ma 'jūn Adhārāqī in Du 'f-i-A 'ṣāb (neurasthenia)
- Clinical validation of *Mufarriḥ Shaykh al-Ra'īs* in *Khafaqān* (palpitation)
- Clinical validation of Marham Kāfūr in Qurūḥ (non-healing ulcers)
- Clinical validation of *lţrīfal Khabath al-Ḥadīd* in *lḥtibās al-Ṭamth* (amenorrhoea)
- Clinical validation of Safūf Makhānā in Sayalān al-Raḥim (leucorrhoea)
- Clinical validation of Ma jūn Muşaffī A zam in Buthūr (skin eruptions)

Validation of Regimen Therapies

Besides pharmacotherapy, Unani Medicine offers '*llāj bi'l-Tadbīr* (regimen therapy), such as *Ḥijāma* (cupping), *Ta'līq al-'Alaq* (leeching), *Dalk* (massage), *Ḥammām Yābis* (sauna), *Ḥammām al-Bukhār* (steam bath), etc. for certain disease conditions. During the reporting period, various regimen therapy procedures were performed in a total of 13,288 patients with different diseases. These patients showed significant therapeutic effects in subsiding the signs and symptoms of the diseases.

Hijāma bilā-Sharṭ (dry cupping) was performed in 4,961 patients with different diseases including Taḥajjur al-Mafāṣil (osteoarthritis), 'Irq al-Nasā (sciatica), Taḥajjur Mafāṣil al-'Unuq (cervical spondylosis), Taḥajjur Mafāṣil al-Ṣahr (lumbar spondylosis), Katif Mujammad (frozen shoulder), Waja' al-Ṣahr (backache), Waja' al-Katif (shoulder pain), Waja' al-'Unuq (neck pain), Waja' al-Rukba (knee pain), Waja' al-'Aqib (achillodynia), Dawālī (varicose veins), Kathrat al-Ṭamth (menorrhagia), 'Usr al-Ṭamth (dysmenorrhoea), Ṣudā' (headache), Ṣala' (baldness), Ḥuzn (depression), etc. at CRIUM, Lucknow; RRIUMs, Chennai, Bhadrak, Patna, Mumbai, Srinagar, New Delhi and Silchar; Co-Location Centre, AllA, New Delhi and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Hijāma bi'l-Sharţ (wet cupping) was performed in 1,607 patients with different diseases including Nār Fārsī (eczema), Buthūr Labaniyya (acne vulgaris), Dā' al-Tha'lab (alopecia), Bawāsīr (haemorrhoid), Daghṭ al-Dam Qawī (hypertension), 'Uqr (infertility), Waja' al-Mafāṣil (rheumatoid arthritis), Taḥajjur al-Mafāṣil (osteoarthritis), 'Irq al-Nasā (sciatica) and other musculoskeletal disorders at CRIUM, Lucknow; RRIUMs, Chennai, Bhadrak, Patna, Mumbai, Srinagar, and Silchar; Co-Location Centre, AllA, New Delhi and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Hijāma bi'l-Nār (fire cupping) was performed in 714 patients with different diseases including Waja' al-Mafāṣil (rheumatoid arthritis), Taḥajjur al-Mafāṣil (osteoarthritis), 'Irq al-Nasā (sciatica), Waja' al-Zahr (backache), Katif Mujammad (frozen shoulder), Waja' al-Katif (shoulder pain) and Waja' al-Rukba (knee pain) at RRIUMs, Srinagar and Chennai; Co-Location Centre, AllA, New Delhi and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Hijāma Muzliqa (moving cupping) was performed in 2,701 patients with different diseases including Waja' al-Ṣahr (backache) and Katif Mujammad (frozen shoulder) at RRIUMs, Srinagar, New Delhi and Chennai; Co-Location Centre, AIIA, New Delhi and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Hammām al-Bukhār (steam bath) was performed in 407 patients with diseases including Waja'al-Katif (shoulder pain), Qūbā (dermatophytosis) and Siman Mufriţ (obesity) at CRIUM, Lucknow; RRIUMs, Srinagar, New Delhi and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Dalk Mu'tadil (moderate massage) was performed in 1,506 patients with different diseases including Waja' al-Mafāṣil (rheumatoid arthritis), Taḥajjur al-Mafāṣil (osteoarthritis), Taḥajjur Mafāṣil al-'Unuq (cervical spondylosis), Katif Mujammad (frozen shoulder), Waja' al-Zahr (backache), Waja' al-Katif (shoulder pain) and Waja' al-'Aqib (achillodynia) at RRIUMs, Chennai, Bhadrak, New Delhi and Silchar; Co-Location Centre, AllA, New Delhi and Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi

Ḥammām Yābis (sauna) was performed in 37 patients with different diseases including Waja' al-Katif (shoulder pain), Taḥajjur al-Mafāṣil (osteoarthritis), Siman Mufriţ (obesity) at RRIUM, New Delhi.

Naṭūl (Irrigation) was performed in 31 patient of Waja' al-Mafāṣil (rheumatoid arthritis) at RRIUMs, Srinagar and Chennai.

Inkibāb (vaporisation) was performed in 1,452 patients of Waja' al-Mafāṣil (rheumatoid arthritis) and Waja' al-Katif (shoulder pain) at RRIUMs, Chennai and Srinagar.

Munḍij-Mushil therapy was performed in 160 patients of *Baraṣ* (vitiligo) at RRIUMs, Chennai, Bhadrak and New Delhi.

Ta'līq (leeching) was performed in 87 patients of Dawālī (varicose veins) and Takhaththur al-Dam (deep vein thrombosis) at RRIUMs, Chennai, Mumbai and New Delhi

Takmīd (fomentation) was performed in 789 patients of Waja' al-Mafāṣil (rheumatoid arthritis), Taḥajjur al-Mafāṣil (osteoarthritis), Siman Mufriṭ (obesity) and Katif Mujammad (frozen shoulder) at CRIUM, Lucknow; and RRIUMs, Chennai, and Bhadrak.



Faṣḍ (venesection) was performed in five patients of Ḥummā Ajāmiyya (malaria), splenic disorders, Bawāsīr Dāmiya (haemorrhoid), Jarab-o-Ḥikka (scabies and pruritus), Khurāj (boils), and Iltihāb-i-Kabid (hepatitis) at RRIUM, Mumbai.

Other therapies ('Amal-i-Kayy (cauterization), cleaning & dressing, and mechanical massage) were performed in 84 patients at Ayush Wellness Centre, Rashtrapati Bhavan, New Delhi.

Validation of Fundamentals

Theory of Akhlāt wa Mizāj (humours and temperament)

The CCRUM has been conducting studies to validate fundamentals of Unani Medicine at NRIUMSD, Hyderabad. The objective of the project udder this initiative is to test scientifically the concept of *Akhlāṭ* (humours) and *Mizāj* (temperament) and its relevance to the states of health and disease. The project aims at studying the clinical, genetic, physiological, pathological and biochemical parameters of the subjects of different temperaments, conducting clinical assessment of *Mizāj* (temperament) in different diseases, and scientifically establishing correlation among them.

Genetic studies on the theory of humours

Genetic studies on the theory of humours with special reference to diabetes mellitus, essential hypertension, vitiligo, gastritis, and psoriasis were carried out wherein healthy volunteers served as control. Pharmacogenomic studies of Unani formulations in vitiligo were also conducted.

A total of 2,057 healthy volunteers and patients enrolled completed the studies. The first part of the project is an observational study wherein the subjects are analyzed for dominant temperament according to *Ajnās 'Ashara*. Whereas the healthy volunteers and patients are subjected to genomic studies, biochemical, physiological, pathological and pulse wave analysis studies in the second part.

During the reporting period, the following studies were completed under the validation of fundamentals and their technical reports were in the process of compilation.

- Genetic studies on theory of humours with special reference to diabetes mellitus
- Genetic studies on theory of humours with special reference to essential hypertension
- Genetic studies on theory of humours with special reference to vitiligo
- Genetic studies on theory of humours with special reference to hepatitis and other Şafrāwī diseases (gastritis)
- Genetic studies on theory of humours with special reference to cancer and other Sawdāwī diseases (psoriasis)
- Genetic studies on theory of humours with special reference to healthy volunteers
- Pharmacogenomics of Unani formulations in vitiligo

Apart from the above, nine studies involving the following components continued during the reporting period:

- Determination of dominant temperament by Ajnās 'Ashara
- Determination of dominant temperament by special CRF on assessment of temperament
- Genetic marker studies in relation to temperament of each subject



• Study of biochemical, physiological and pathological parameters and pulse wave component analysis in relation to temperament of each subject

Study-wise summary of the progress made during the year 2022–2023 is as under:

A molecular approach towards understanding of Unani philosophy – Temperament susceptibility gene expression studies (IFN-gamma)

The experimental research as well as data analysis was completed. The work on the status paper was in progress.

Genetic studies of liver metabolism genes in relation to clinical phenotyping as per Unani philosophy (APOE gene)

Five *Safrāwī* patients were enrolled during the reporting period and the experimental research work was completed. After data analysis, the work on the status paper was in progress.

Genetic variants of IFN-γ (+874/A and +2109A/G) genes polymorphism and its mRNA expression and inflammatory parameters in vitiligo

Five *Safrāwī* subjects were enrolled during the reporting period and experimental research work and data analysis were completed. The work on the status paper was in progress.

Study on expression of miRNA 146a and complex Th1/17 cells in the treatment and disease pathogenesis of vitiligo

After the approval of the project by the institutional ethics committee, standardization, literature review and sample collection were under process.

Evaluation of *in-vitro* anti-psoriatic activity of a novel polyherbal Unani formulation by multi-parametric analysis

After the approval of the project by the institutional ethics committee, standardization, literature review and sample collection were under process. Extraction and phytochemical analysis of aqueous, hydro, ethanol and methanol extracts of the test drug UNIM 401 were completed.

Effect of Unani formulation on diabetes mellitus in in-vitro studies on HepG2 cell line

After obtaining the approval of the institutional ethics committee, sample collection, standardization of research work, and literature review were under process. Extraction and phytochemical analysis of aqueous, hydro, ethanol and methanol extracts of UNIM 401 was completed.

Gene expression analysis of the inflammatory markers in pathogenesis of Type-2 diabetes to identify underlying molecular mechanisms and biomarkers and its relation to clinical phenotyping of Unani philosophy

After obtaining the approval of the institutional ethics committee, sample collection, standardization of research work, and literature review were under process.

Study of gene expression and gene polymorphism in pathogenesis of rheumatoid arthritis and their relationship with Unani philosophy in Indian population

After obtaining the approval of the institutional ethics committee, sample collection, standardization of research work, and literature review were under process.



Assessment of Leptin gene expression in the pathogenesis of psoriasis in relation to Unani philosophy

The project was approved by the institutional ethics committee. Sample collection, standardization of research work, and literature review were under process.

Clinical Assessment of Mizāj (Temperament)

During the reporting period, assessment of temperament of 163 patients attending the OPD of NRIUMSD, Hyderabad was done. Of them, 49 were *Damawī*, 84 *Balghamī*, 24 *Şafrāwī* and 06 *Sawdāwī*. These included patients of *Dīq al-Nafas* (bronchial asthma), *Du'f al-Dimāgh* (cerebrasthenia), *Ḥaṣāt al-Kulya* (nephrolithiasis), *Sūʾ al-Qinya* (anaemia) and *Mālankhūliyā* (mixed anxiety depressive disorder).

Of 55 patients of $S\bar{u}$ al-Qinya (anaemia), 31 had $Balgham\bar{\imath}$ and 24 had $Safr\bar{a}w\bar{\imath}$ temperament. Among 55 cases of $D\bar{\imath}q$ al-Nafas (bronchial asthma), 22 belonged to $Damaw\bar{\imath}$ temperament and 33 to $Balgham\bar{\imath}$ temperament. Out of 38 patients of $Damaw\bar{\imath}$ temperament and 20 $Damaw\bar{\imath}$ temperament. While all the eight patients of $Damaw\bar{\imath}$ and $Damaw\bar{\imath}$ (cerebrasthenia) revealed $Damaw\bar{\imath}$ temperament, one patient was $Damaw\bar{\imath}$ and six were $Sawd\bar{\imath}$ among seven patients registered with $Damaw\bar{\imath}$ (mixed anxiety depressive disorder).

In these patients, susceptibility for acquiring diseases in relation to different temperaments were also studied. An interim analysis of data revealed that the individuals of *Balghamī* temperament in relation to *Dīq al-Nafas* (bronchial asthma) and *Damawī* temperament in relation to *Du'f al-Dimāgh* (cerebrasthenia) elicited dominance. The persons of *Damawī* temperament were susceptible to *Ḥaṣāt al-Kulya* (nephrolithiasis) followed by *Balghamī* temperament.

Research-oriented Healthcare

General Outpatient Department (GOPD) Programme

The CCRUM undertakes GOPD Programme which also includes Geriatric OPD and RCH / MCH OPD. It is aimed at promoting, protecting, and preserving public health through Unani Medicine. Besides, OPDs for Post-trial Treatment Access (PTA) is also conducted in order to provide treatment facility to the research patients after completing the trial.

During the reporting period, this programme continued at National Research Institute of Unani Medicine (NRIUMSD), Hyderabad; Central Research Institute of Unani Medicine (CRIUM), Lucknow; Regional Research Institutes of Unani Medicine (RRIUMs), Chennai, Bhadrak, Patna, Aligarh, Mumbai, Srinagar, Kolkata, New Delhi and Silchar; Regional Research Centre (RRC), Prayagraj; Clinical Research Units (CRUs), Bengaluru, Bhopal, Burhanpur, Meerut, Kurnool, Edathala and Imphal; Hakim Ajmal Khan Institute for Literary and Historical Research in Unani Medicine, New Delhi; AYUSH Wellness Centre, President's Estate, New Delhi; and All India Institute of Ayurveda, New Delhi. A total of 6,66,025 beneficiaries comprising 5,37,355 in GOPDs, 41,598 in Geriatric OPDs, 12,744 in RCH / MCH OPDs, 26,551 in NCD's OPDs and 47,777 in OPDs for Post-trial Treatment Access (PTA) were treated at different centres. These beneficiaries were also assessed for their temperaments and various other factors responsible for occurrence of the disease, thus generating data for research feedback and Unani treatment was prescribed accordingly. They were treated with Unani pharmacopoeial formulations.

In-patient Department (IPD) Programme

The CCRUM also has IPD facilities at it select research institutes. During the reporting period, IPD programme continued at NRIUMSD, Hyderabad; CRIUM, Lucknow; and RRIUM, Chennai, Bhadrak, Patna, Srinagar and New Delhi. A total of 6,521 beneficiaries were treated with Unani pharmacopoeial formulations at these facilities.

Mobile Clinical Research Programme

The Mobile Clinical Research Programme is aimed at providing healthcare to the population residing in rural areas, urban slums, scheduled caste and scheduled tribe pockets, besides reducing the disease burden in the society by creating health awareness among them. Under this programme, rural areas, urban slums, and pockets predominantly inhabited by Scheduled Caste (SC) / Scheduled Tribe (ST) population with no medical facility are covered. The Council's researchers visit the adopted pockets at regular intervals and provide free Unani treatment to the patients at their door steps, and thus serve as a potential source of healthcare delivery to the masses. Patients are also referred to CCRUM institutes / units and other hospitals for treatment of specific diseases or clinical research. Besides, health awareness is created among the population under coverage particularly women and senior citizens through health lectures and group meetings on the preventive, promotive and curative health aspects based on the principles of Unani Medicine. They are also made aware of the therapeutic uses of medicinal plants growing in their vicinity in the management of different common / seasonal ailments.

During the reporting period, this programme continued at CRIUM, Lucknow; RRIUMs, Aligarh, Patna, Mumbai, New Delhi and Srinagar; RRC, Prayagraj; and CRU, Burhanpur. During the reporting period, 16 rural pockets / urban slums covering over 2.02 lakh population were covered. A total of 23,230 patients were treated in 687 mobile visits made to these pockets. Predominant diseases as observed were rheumatoid arthritis, cough, fever, skin infections, joint pain, constipation, headache, dysentery, leucorrhoea, piles, etc.

3.1.2.4. Literary Research Programme

The Literary Research Programme made significant strides, notably publishing Urdu translations of pivotal texts. Among these is the translation of 'Kitāb al-Masā'il fi'l-Ţibb li'l-Muta'allimīn', originally authored in the 9th century by Ḥunayn ibn Isḥāq, a distinguished scholar and physician associated with Bayt al-Ḥikmat. Ḥunayn's expertise in various sciences, particularly in medical sciences drawing from the works of Hippocrates and Galen, garnered him unparalleled recognition.

'Kitāb al-Masā'il' stands as a comprehensive guide to the principles of Unani Medicine, encompassing theoretical foundations, diagnostics, and therapeutics across its ten chapters. Starting with foundational principles and disease introduction, it delves into causes, symptoms, hygiene, treatment principles, pulse analysis, essentials for existence, fevers, and urinary details. This text holds immense historical significance, being one of the earliest and most impactful translations during the Arabic era of Unani Medicine. Its inclusion in the European medical curriculum during the twelfth century speaks to its widespread influence. In a concerted effort to promote Unani Medicine globally, the CCRUM also released French and Spanish translations of 'Unani Medicine: The Science of Health & Healing - An Overview', covering essential aspects across four chapters: Introduction, Unani Medicine in India, Major Milestones, and Globalization.



The Literary Research Programme achieved milestones in translations, completing the Urdu translation of the Persian book 'Kitāb al-Abniya 'an Ḥaqā'iq al-Adviya', continuing translations of 'Man lā yaḥḍuruhu al-Ṭabīb' and 'Khulāṣa al-Tajārib', while initiating the Urdu translation of 'Kitāb al-Ahwiya wa'l-Miyāh wa'l-Buldān'. Simultaneously, work progressed on monographs focusing on 'Ḥammām' as a component of regimenal therapy and 'Amrāḍ-i-Tanaffus' in Unani Medicine.

Notably, the CCRUM successfully completed work on the WHO's project regarding international terminologies of Unani Medicine, culminating in the publication of the document titled 'WHO International Standard Terminologies on Unani Medicine'.

Moreover, under the Systematized Nomenclature of Medicine—Clinical Terminology (SNOMED-CT) Extension for Unani Medicine project, extensive efforts were made, including term collection, identification, data preparation, translation, and multiple releases of 'India AYUSH Extensions'.

The CCRUM continued updating NUMC Version 1.0, developing 322 addendum codes for integration into NAMASTE Portal and AHMIS. Besides, retrieving/compiling NUMC data from NAMASTE-P was also carried out.

Additionally, as part of the India@75-Azadi Ka Amrit Mahotsav initiative, researchers actively participated in distributing prophylactic Ayush medicines and providing guidelines on diet and lifestyle, with a specific focus on the geriatric population. They also contributed their expertise through tele-counselling in Unani Medicine for the Ayush Covid-19 Helpline.

3.2. Studies under IMR Policy

To utilize full potentials of the researchers working in the different centres and to conduct studies based on region-specific needs, the CCRUM has an Intramural Research (IMR) Policy. The policy aims to conduct studies in a time-bound manner. During the reporting period, the following studies under the IMR policy were conducted:

A comparative clinical study on *Ḥijāma biʾl-Sharṭ* (wet cupping) and Unani pharmacopoeial formulation *Qurṣ Dawāʾ al-Shifāʾ* in the management of *Ḥaght al-Dam Qawī Ibtidāʾī* (essential hypertension)

A clinical study for evaluation of Unani pharmacopoeial formulation *Qurş Dawā ʾ al-Shifā ʾ* in the clinically stable patients of *Daght al-Dam Qawī lbtidā ʾī* (essential hypertension) was done at RRIUM, Patna. The patients were divided into three groups — Group-I received *Qurṣ Dawā ʾ al-Shifā ʾ* 01 tablet twice daily with water after meals; Group-II was treated with *Ḥijāma biʾ l-Sharṭ* (wet cupping); and Group-III was treated with *Qurṣ Dawā ʾ al-Shifā ʾ* 01 tablet twice daily with water after meals and *Ḥijāma biʾ l-Sharṭ* (wet cupping).

During the reporting period, 135 new patients were registered. Of them, 75 patients completed the study and 60 patients dropped out of the study. Out of the completed cases, 60 were relieved, 10 were partially relieved, and 05 showed no response. The study was completed and data analysis was in progress.



Evaluation of the efficacy of a Unani regimen $l t \bar{r} f a l$ Sana \bar{i} , $N a t \bar{u} l$ (irrigation) and D a l k (massage) by $R a w g h a n - i - K a d d \bar{u}$ in $S h a q \bar{i} q a$ (migraine without aura) and its effect on serum biomarkers

A study for evaluation of the efficacy of a Unani regimen *lṭrīfal Sanaī*, *Naṭūl* (irrigation) and *Dalk* (massage) by *Rawghan-i-Kaddū* in *Shaqīqa* (migraine without aura) and its effect on serum biomarkers was carried out at RRIUM, Srinagar. During the reporting period, a total of 45 patients were enrolled in the study. Out of them, 35 patients completed the study and 10 dropped out. Of the completed cases, 21 patients got complete relief, eight got partial relief, and six patients did not get relief from signs and symptoms of migraine. The study drug was found well-tolerated and no adverse effect was reported in the patients. Including the previous year data, a sample size of 85 cases was achieved in the study at the end of the reporting period.

Effect of Unani formulation *Qurṣ Ḥudār* on serum biomarkers in patients with rheumatoid arthritis

A study to evaluate the effect of Unani formulation $Qurs \not\vdash Hudar$ on serum biomarkers in the patients of rheumatoid arthritis was carried out at RRIUM, Srinagar. The patients were divided into two groups. The test group received Unani formulation $Qurs \not\vdash Hudar$ one tablet twice daily with water after meals, whereas the control group comprised of healthy volunteers did not receive any medication. The total duration of the treatment was 6 weeks.

The study was completed with the completion of trial on 52 subjects including 26 patients in the test group and 26 healthy volunteers in the control group. Data analysis was in progress at the end of the reporting period.

Evaluation of therapeutic efficacy and safety of coded Unani drugs PTH-1, PTH-2 and PTH-3 in asymptomatic hepatitis B carriers

A pilot study to evaluate the efficacy and safety of coded Unani drugs PTH-1, PTH-2, and PTH-3 in asymptomatic hepatitis B carriers was conducted at NRIUMSD, Hyderabad. The cases were divided into three treatment groups. The coded Unani drugs PTH-1, PTH-2, and PTH-3 were given in the dose of two capsules (500 mg each) thrice daily orally after food in group-I, II, and III respectively. The duration of treatment was six months in all the groups. With completion of trial on 11 patients in group-I, 17 in group-II, and 16 in group-III, the study was completed. Data analysis was in progress at the end of the reporting period.

The following IMR projects were also initiated at the various institutes of the CCRUM:

- A clinical study to evaluate the efficacy of Mundij and Mushil therapy along with coded Unani drugs UNIM-318 & UNIM-319 and dry fomentation in patients of primary Taḥajjur al-Mafāṣil (Osteoarthritis Grade I & II) (CRIUM, Lucknow)
- To study the effect of coded Unani formulations (UNIM-004 and UNIM-005) on biomarkers in vitiligo patients (NRIUMSD, Hyderabad)
- Shelf-life study on five commonly used Unani pharmacopoeial formulations (RRIUM, Chennai)



3.3. Collaborative Research

Elucidating the therapeutic potential of a Unani formulation in glaucoma

A study on elucidation of therapeutic potential of a Unani formulation in glaucoma was carried out at the Department of Ocular Biochemistry, Dr. R. P. Centre for Ophthalmic Sciences, AIIMS, New Delhi. Identification of active phytochemicals present in the Unani formulation were done by LC-MS/MS. Findings showed that the Unani formulation significantly reduced ROS production in cultured TM cells and HNE-induced oxidative stress in cultured RGCs.

Effect of Unani preparations on macrophage polarization and its role in increased browning of fat leading to amelioration of insulin resistance

A study to evaluate the effect of Unani preparations on macrophage polarization and its role in increased browning of fat leading to amelioration of insulin resistance was carried out at Jamia Hamdard, New Delhi. Findings depict anti-inflammatory activity of 'Araq Mako, 'Araq Kāsnī and Luk Maghsūl and potential in skewing the ratio of macrophages from M1 to M2 state. Administration of the drugs showed decrease in glucose and basal insulin level in HFD mice model. Supplementation with the 'Araqiyāt resulted in reduction in NF-ķB expression in HFD mice.

Evaluation of anti-oxidant and anticancer effect of Unani medicines against liver cancer - A preclinical study

A study to evaluate hepato-protective and antioxidant activities of aqueous extract of herbs followed by formulation of extract into *Qur*ş/suitable Unani formulation (UNIM-HC-I) was carried out at the School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi. The study evaluated the effect of aqueous extracts of Unani herbal drugs against HepG2 carcinoma cell line using MTT assay. It was found that mixture of combined aqueous extract displayed excellent inhibitory activity against HepG2 cells with IC50 value 32.67 μM. It was concluded that *Kalonjī* and the mixture of *Kalonjī* (*Nigella sativa*), *Deodār* (*Cedrus deodara*), *Balela* (*Terminali bellirica*), *Balādur* (*Semecarpus anacardium*), *Kachnār* (*Bauhinia variegate*) and *Kutkī* (*Picorrhiza kurroa*) are potentially active against carcinoma cell line.

Investigation and validation of the molecular mechanism of Unani medicines *in-vitro* and *in-vivo* for the treatment of atopic dermatitis

A study to evaluate anti-inflammatory properties of *Barg-i-Shāhitara*, *Bābchī*, *Bādām Shīrīn*, *Tukhm-i-Khurfa*, and *Halela Siyāh* was carried out at the Faculty of Life Science and Technology, South Asian University, Chanakyapuri, New Delhi. The study found that herbal extracts of *Barg-i-Shāhitara* and *Halela Siyāh* inhibit the LPS induced iNOS and COX-2 in concentration dependent manner in RAW264.7 and HaCaT cell line and possess anti-inflammatory activity.

Ethnobotanical survey, conservation and development of DNA barcodes for Unani medicinal plants in India

The study for ethnobotanical survey, conservation, and development of DNA barcodes for Unani medicinal plants in India was carried out at the Department of Botany, Shivaji College, University of Delhi. The main objective of the study is to conduct survey of Unani endangered species and then developing DNA barcodes for the selected Unani medicinal plants for identification.



TLR4-based cancer immunotherapeutic in cervical cancer using *Abrus precatorius* seed extracts

A study to evaluate TLR4-based cancer immunotherapeutic in cervical cancer using *Abrus precatorius* seed extracts was carried out at Amity Institute of Biotechnology, Amity University Noida. The main objective of the study is to evaluate antioxidant and cytotoxic activity of *Abrus precatorius* in cervical cancer cells.

Reverse pharmacology of Asrin and *Dawā' al-Shifā'* to evaluate their anti-hypertensive efficacy, safety and mechanism of action

A study for reverse pharmacology of Asrin and *Dawāʾ al-Shifāʾ* and to evaluate their anti-hypertensive efficacy, safety, and mechanism of action was carried out at the Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow. The study found the antihypertensive effect of Asrin on hemodynamic parameters in a rat model of hypertension and on cardiac hypertrophy markers. Both formulations possess potent hypertensive as well as cardioprotective properties in SHR model of hypertension.

Pharmacological studies on the probable mechanism of action of *Khamīra Gaʾūzabān Sādā* (KGS) in the management of hypertension, involving quality control and formulation optimization studies for this age old Unani preparation

A study to evaluate the pharmacological studies on *Khamīra Gaʾūzabān Sāda* in the management of hypertension involving cardiac function and development of quality control standards and formulation optimization studies for the test drug was carried out at the Department of Pharmaceutical Technology, Jadavpur University, Kolkata.

Evaluation of neuro-protective potential of Ma jūn Nisyān: A mechanistic study

A study to look into neuro-protective potential of *Maʿjūn Nisyān* was initiated at Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai. The study explored the phytochemical evaluation of *Maʿjūn Nisyān* formulation by TLC/HPTLC and LC-MS/MS.

In-vitro evaluation of antiviral activity of Unani drugs and their green nanoparticles against dengue virus

A study for *in-vitro* evaluation of antiviral activity of Unani drugs and their green nanoparticles against dengue virus was started at the Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi. The study explored cytotoxicity of *Ḥabb Papīta*, *Khamīra Marwārīd* and *Sharbat Anjibār* in Vero cells using MTT assay.

Phytochemical standardization and evaluation of anti-cancer and immune-modulatory activity of Unani formulation *ltrīfal Ghudadī*

A study to evaluate the anti-cancer and immune-modulatory effect and phytochemical standardization of Unani formulation *Iţrīfal Ghudadī* (IG) was carried out at the Interactive Research School for Health Affairs, Pune, Maharashtra. The study explored phytochemical standardisation of individual ingredients and whole formulation of IG using LC-MS analysis. Evidences from the study suggested that the potent activity of IG in Soxhlet aqueous extract was greater than hot water extract and have anticancer potential.



Drug proving studies, mechanistic insight and development of novel drug delivery systems of UNIM-H and UNIM-R used in the treatment of arthritis in Unani Medicine

A study to evaluate phytochemical standardization and HPTLC fingerprint studies of UNIM-H & UNIM-R by MTT assay, DPPH, FRAP, NO, LPO and elucidation of mechanism of anti-inflammatory and anti-arthritic activity of the selected drugs was carried out at the Department of Life Sciences, University of Mumbai.

Targeting Alzheimer's disease by a mixture of Unani plant extract via modulation of human kinase

A study to evaluate the efficacy of Unani plant extract in Alzheimer's disease was carried out at the Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi. The study found that the extract possesses potent activity against Alzheimer's disease via modulating kinase signalling cascade.

Delineating the anti-cancer potential and the mechanism of Unani medicinal formulation *lţrīfal Aftīmūn* in chronic myelogenous leukaemia

A study to evaluate anti-cancer potential and the mechanism of Unani medicinal formulation *lţrīfal Aftīmūn* (IEA) in chronic myelogenous leukaemia (CML) was carried out at the Department of Biochemistry, All India Institute of Medical Sciences, New Delhi. The study found that IEA caused cytotoxicity of leukaemia cells in-vitro in a dose-dependent manner. The mode of cytotoxicity was assessed by Annexin V-FITC/PI assay which showed that percentage of early and late apoptotic cells got increased in cell lines after treatment with IEA. Moreover, apoptotic cells increased further when cells were treated with combination of IEA and Imatinib. The study evaluated potential of IEA as an adjuvant therapy for CML.

3.4. Publications

3.4.1. Books, Monographs, Reports, etc.

During the reporting period, the CCRUM brought out the following books, monographs and reports, etc.:

- Clinical Study of Unani Formulations in Sur'at al-Inzāl (Premature Ejaculation) A Technical Report
- Compendium of General Guidelines for Safety and Toxicity Evaluation of Unani Formulations
- Kitāb al-Masāʾil fiʾl-Ṭibb liʾl-Mutaʿallimīn (Urdu Translation)
- LA MÉDECINE UNANI: LA SCIENCE DE LA SANTÉ ET DE LA GUÉRISON UN APERÇU (French translation of Unani Medicine: The Science of Health and Healing — An Overview)
- LA MEDICINA UNANI: LA CIENCIA DE LA SALUD Y LA CURACI N UNA VISI N GENERAL (Spanish translation of Unani Medicine: The Science of Health and Healing – An Overview)
- Mobile Healthcare Programme under SCSP and TSP An Overview of Activities (2018–2022)
- Recent Researches in Unani Medicine (A Compendium of Abstracts Published during 2018-2022)
- Guidelines for Analysis of ASU Samples in Drug Research Laboratories of Central Council for Research in Unani Medicine



- Souvenir Unani Day 2023 & International Conference on Unani Medicine
- Souvenir National Seminar on Intellectual Property Rights and Public Health Research
- Souvenir National Workshop on Ilāj bi'l-Tadbīr (Regimenal Therapy) in Unani Medicine
- CCRUM Annual Report 2021-22 (English)
- CCRUM Annual Report 2021-22 (Hindi)

3.4.2. Journals / Periodicals

During the reporting period, the CCRUM published the following periodicals:

- Hippocratic Journal of Unani Medicine, Volume-16, Number-1
- Hippocratic Journal of Unani Medicine, Volume-16, Number-2
- Jahan-e-Tib, Volume-23, Issue 1-4
- CCRUM Newsletter, Volume-42, Number-1

3.4.3. Research Papers

During the reporting period, the following research papers authored by the CCRUM officers were published in reputed national and international journals:

- 1. Ahmad, W., Waseem, A., Fazil, M., & Khan, A. A. (2022). Dhāk Butea monosperma - A review on ethnobotanical and Unani prospect as well as phytochemical and pharmacological properties. Indian Journal of Unani Medicine, 15(02), 121–131. https://doi.org/10.53390/ijum.2022.15207
- 2. Ahmed, F., Khan, A. S., Mustafa, A., Ansari, S. A., Alvi, A. I., Mirza, A., Hussain, U., & Meena, R. P. (2021). Standardization of Marham Ḥinā – A popular Unani ointment. Hippocratic Journal of Unani Medicine, 16(2), 51–56.
- 3. Ahmed, N., Zakir, M., Alam, M. A., Javed, G., & Minhajuddin, A. (2022). Management of asthma (Dīq al-Nafas) in Unani system of medicine. International Journal 13036-13054. of Health Sciences, 6(S1), https://doi.org/10.53730/ijhs.v6nS1.8271
- 4. Ahmed, R., Ahmed, M. W., Ansari, S. A., Meena, R. P., & Khan, A. S. (2022). Saffron an Unani drug and concept of adulterant: A comparative assessment. Asian Journal of Pharmacognosy, 7(3), 5–14.
- 5. Ahmed, R., Ahmed, M. W., Meena, R. P., Khan, A. S., & Ansari, S. A. (2022). Bombyx mori cocoon (Abresham): A potent Unani drug. International Journal of Unani and Integrative Medicine, 6(3),33-36. https://doi.org/10.33545/2616454x.2022.v6.i3a.218
- 6. Ahmed, S. Shamim., Fatima, L. & Saifi, N. (2022). Riyazat (exercise): An ancient gem of Unani regimenal therapies for preservation of health. International Journal of Physiology. **Nutrition** and Physical Education, 01–07. 7(2), https://www.journalofsports.com/archives/2022/vol7/issue2/7-1-137
- 7. Akhlag, S., Ara, S. A., Ahmad, B., Fazil, M., Akram, U., Hague, M., & Khan, A. A. (2021). Interventions of Unani Medicine for maintenance of health with special reference to air quality: An evidence-based review. Reviews on Environmental Health, 38(1), 85–96. https://doi.org/10.1515/reveh-2021-0116
- 8. Akhlag, S., Ara, S. A., Fazil, M., Ahmad, B., Akram, U., Hague, M., & Khan, A. A. (2022). Ethno pharmacology, phytochemical analysis, safety profile, prophylactic aspects, and therapeutic potential of Asarum europium L. in Unani medicine: An



- evidence-based appraisal. *Phytomedicine Plus*, 2(2), 100226. https://doi.org/10.1016/j.phyplu.2022.100226
- 9. Akhlaq, S., Ara, S. A., Fazil, M., Borjali, A., Akram, U., Haque, M., Ahmad, S., & Khan, A. A. (2022). Use of Unani Medicine as a potent alternative in oral health promotion: A narrative review. *Indian Journal of Unani Medicine*, *15*(02), 138–146. https://doi.org/10.53390/ijum.2022.15209
- 10. Akram, S. A. W., Christophe, J. J., Raiza, A. J., Mageswari, S., Sri, P. M. D., Selvarani, R., Meena, R. P. & Zaheer, N. (2022). Pharmacognostical and HPTLC analysis of *Azadirachta indica* A. Juss.: Flower. *International Journal of Herbal Medicine*, 10(1), 15–21.
- 11. Alam, F. (2022). Hamdardaana Haiwani Tahqeeq. Tarjuman-e-Tib, 7(1), 92-95.
- 12. Alam, M. A., Zakir, M., Minhajuddin, A., Viquar, U., Ahmad, T. I., & Kuna, L. (2022). Role of the Unani system of medicine in countering epidemic diseases, considering coronavirus pandemic -19. *Journal of Young Pharmacists*, 14(2), 140–155. https://doi.org/10.5530/jyp.2022.14.28
- 13. Anjum, F., Shafie, A., Naime, M., Toteja, G. S., & Ali, S. (2022). Improving the long-term storage stability of all-trans-retinol in biological matrix. *International Journal of Advances in Pharmacy Medicine and Bioallied Sciences*, 10(1), 10–13.
- 14. Ansari, A. P., Ahmed, N. Z., Anwar, N., & Khan, M. F. (2022). Effect of an Unani regimen in the treatment of "Yaraqān" (Jaundice): A Case Report. *Indian Journal of Unani Medicine*, 15(02), 93–101. https://doi.org/10.53390/ijum.2022.15203
- 15. Ansari, H., Ansari, A. P., Qayoom, I., Reshi, B. M., Haseeb, A., Ahmed, Z., & Anwar, N. (2022). *Saqmunia* (*Convolvulus scammonia* L.), an important drug used in Unani system of medicine: A review. *Journal of Drug Delivery and Therapeutics*, 12(5), 231–238. https://doi.org/10.22270/jddt.v12i5.5681
- 16. Ara, S. A., Akhlaq, S., Ahmad, B., Fazil, M., Akram, U., Haque, M., Sayeed, A., & Khan, A. A. (2022). Concept of Unani Jali (detergents/cleansers) drugs and its scientific validation: Scope for new opportunities in dermatological pharmacotherapeutics. *Drug Metabolism and Personalized Therapy*, 38(1), 31–43. https://doi.org/10.1515/dmpt-2022-0121
- 17. Ara, S. A., Akhlaq, S., Fazil, M., Ahmad, B., Haque, M., Akram, U., Sayeed, A., & Khan, A. A. (2021). An evidence-based review of important Unani cardiotonic drugs used as part of cardio therapy in Unani Medicine. *Hippocratic Journal of Unani Medicine*, 16(2), 15–33.
- 18. Ara, S. A., Akhlaq, S., Haque, M., Fazil, M., Akram, U., Borjali, A., Ahmad, S., Viquar, U., & Khan, A. A. (2022). *Clove/Quranful (Syzygium aromaticum* L.): A review on its potential benefits in Unani Medicine, bioactivities and current scientific applications. *Indian Journal of Unani Medicine*, 15(02), 112–120. https://doi.org/10.53390/ijum.2022.15206
- 19. Ara, S. A., Borjali, A., Fazil, M., Akhlaq, S., Akram, U., Haque, M., & Khan, A. A. (2022). *Izkhar* [*Cymbopogon martinii* (Roxb.)] wats: An evidence-based review on its phytochemical aspect and hepatoprotective traditional use in Unani medicine. *Journal of Herbal Medicine*, *34*, 100576. https://doi.org/10.1016/j.hermed.2022.100576
- 20. Arfeen, S., Bari, B., Khanam, R., Akhtar, J., Anjum, N., Khan, M. N., Parveen, N., & Khan, A.A. (2022). Clinical validation of efficacy and safety of Unani pharmacopoeial

- formulations Majoon-e-Suranjan and Habb-e-Azaraqi in patients of *Niqris* (gout). *International Journal of Unani and Integrative Medicine*, 6(1), 22–27. https://doi.org/10.33545/2616454X.2022.v6.i1a.206
- 21. Azmi, F., & Bano, H. (2022). Respiratory Infectious Disease and the COVID-19 Pandemic: A Review of Medieval Unani Medical Literature. *Journal of Natural Remedies*, 22(1), 1–11. https://doi.org/10.18311/jnr/2022/26624
- 22. Bano, H., Sheikh, N., & Qureshi, M. A. (2022). A descriptive review on the therapeutic effect of Tiryaq Faruq A Unani medicine. *Journal of Research in Traditional Medicine*, 8(1), 35–43. DOI: 10.5455/jrtm.2022/80135
- 23. Bashir, F., Akhtar, J., Anjum, N., & Alam, S. (2022). Majoon Supari Paak A polyherbal Unani formulation used in the management of *Sayalan al-Rahim* (leucorrhoea). *Acta Scientific Medical Sciences*, *6*(2), 132–141.
- 24. Chakraborty, A., Pallapolu, P., Thulasamma, S., Kuna, L., Ghali, S. K., Jamil, K., Javed, G., & Kazmi, M. H. (2022). Genetic variations in NLRP1 and Glutathione S-Transferase are associated with Generalized Vitiligo of Phlegmatic Clinical Phenotypes in Unani Medicine Philosophy of South Indian Population. Research Journal of Pharmacy and Technology, 2221–2227. https://doi.org/10.52711/0974-360x.2022.00369
- 25. Chakraborty, A., Thulasamma, S., Ghali, S. K., Pallapolu, P., Kuna, L., Rafeeqi, T. A., Husain, G. M., Jabeen, F., Javed, G., Waheed, M. A., & Kazmi, M. H. (2022). Expression levels of MIF, NLRP1 and FOXP3 genes along with biomarker levels in patients with active form of non-segmental generalized vitiligo: A study in South Indian population. *Songklanakarin Journal of Science and Technology*, *44*(2), 353–360. https://doi.org/10.14456/sjst-psu.2022.50
- 26. Dash, S. L., Mohapatra, R., Mekap, S. K., Masanta, S. R., Katiyar, A. K., Sharma, N., Karwasra, R., & Mishra, S. K. (2023). Toxicological Study of n-hexane and Chloroform Extracts of Lantana camara L. in Experimental Animals. *Indian Journal of Pharmaceutical Education and Research*, *57*(2s), s370–s380. https://doi.org/10.5530/ijper.57.2s.43
- 27. Fatima, A., Khan, M. N., Khanum, R., Raheem, A., Khan, A. A., Singh, V. B., & Sehar, N. (2022). Prevalence of diseases in Kallupurwa (Kursi) area of Barabanki (UP) Lucknow. *Ayushdhara*, 13–22. https://doi.org/10.47070/ayushdhara.v9i1.909
- 28. Fatima, A., Singh, V. B., Arshad, M., & Khan, M. N. (2022). Prevalence of *Su al-Hadm* (dyspepsia) in Kallupurwa (Kursi) area of Barabanki (UP). *International Journal of Creative Research Thoughts*, 10(8), 7545–752.
- 29. Fatima, M., Karwasra, R., Almalki, W. H., Sahebkar, A., & Kesharwani, P. (2023b). Galactose engineered nanocarriers: Hopes and hypes in cancer therapy. *European Polymer Journal*, *183*, 111759. https://doi.org/10.1016/j.eurpolymj.2022.111759
- 30. Fatima, S. H., Ahmad, T., Latha, S., Javed, G., & Minhajuddin, A. (2022). A study of anemia profile in a research hospital in Telangana, South India. *International Journal of Advances in Medicine*, *9*(3), 273–277. https://doi.org/10.18203/2349-3933.ijam20220430
- 31. Fatima, S., Khan, F., Asif, M., Alotaibi, S. S., Islam, K., Shariq, M., Khan, A., Ikram, M., Ahmad, F., Khan, T. A., Meena, R., & Siddiqui, M. A. (2022). Root-knot disease



- suppression in eggplant based on three growth ages of *Ganoderma lucidum*. *Microorganisms*, *10*(5), 1068. https://doi.org/10.3390/microorganisms10051068
- 32. Firdaus, N., Viquar, U., Husain, G. M., & Zakir, M. (2022). Preclinical toxicity study of *Datura metel* L. based Unani formulation *Habb-e-Zeequn Nafas* used in the treatment of asthma. *Phytomedicine Plus*, 2(3), 100303. https://doi.org/10.1016/j.phyplu.2022.100303
- 33. Hazari, S. A., Kaur, H., Karwasra, R., Abourehab, M. A., Khan, A. A., & Kesharwani, P. (2023). An overview of topical lipid-based and polymer-based nanocarriers for treatment of psoriasis. *International Journal of Pharmaceutics*, 638, 122938. https://doi.org/10.1016/j.ijpharm.2023.122938
- 34. Husain, M. T., & Islam, A. (2022). Pharmacovigilance in ASU and H drugs: Standard in healthcare. *International Journal of Recent Advances in Multidisciplinary Topics*, 3(1), 2582–7839.
- 35. Ismail, B. A., Nawab, M., Fatima, S. H., Minhajuddin, A., & Naikodi, M. A. R. (2022). Evaluation of the efficacy and safety of Unani formulations in pityriasis versicolor: A randomized controlled trial. *Journal of Ethnopharmacology*, 298, 115603. https://doi.org/10.1016/j.jep.2022.115603
- 36. Jahangir, U., Khan, A. A., Kapoor, P., Jalees, F., & Urooj, S. (2023). Comparative efficacy of Safoof e Muhazzil and its compressed tablets on parameters of weight reduction. *International Journal of Pharmaceutical Sciences and Research*, *14*(6), 2977–2983
- 37. Javed, G., & Kumar, N. (2022). COMMENT: Bioethics in Unani medicine: Relevant quotes from Kamilussanah, a 10th century manuscript. *Indian Journal of Medical Ethics*, *VII*(1), 1–8. https://doi.org/10.20529/IJME.2022.003
- 38. Kalam, M. A. (2022). *Abzan wa Pashoya (Sitz bath and Foot bath)*. Hidayat Publishers and Distributors, New Delhi.
- 39. Kalam, M. A. (2022). *Jawaharat-i-Ts'a* (*Navratan*) aur *Unke Tibbi Fawaed*. UHCC Unicure Patna
- 40. Kalam, M. A. (2022). *Kaiyy (cauterization): Ek Mufeed Tariqa Ilaj*. Hidayat Publishers and Distributors, New Delhi
- 41. Kalam, M. A., & Ahmad, N. (2022). Chaksini (Peristrophe bicalyculata): A comprehensive review on a lesser known herb of Unani Medicine. Indian Journal of Unani Medicine, 15(1), 27–32.
- 42. Kalam, M. A., Amjad, S., Naved, M., & Habib, A. (2023). *Jund Bedastar* (Castoreum): Medicinal potential of an animal origin drug of Unani Medicine. *Acta Scientific Pharmaceutical Sciences*, 7(1), 23–32. DOI: 10.31080/ASPS.2023.07.0926
- 43. Kalam, M. A., Arshi, A., Wasim, A., Sabiha, A. K., & Sheeraz, M. A. (2023). Deodar (*Cedrus deodara* (roxb.) Loud.): Therapeutic uses and pharmacological studies A review. *Indian Journal of Unani Medicine*, 16(1), 8–16.
- 44. Kalam, M. A., Arzoo, K. S., Habib, A., Fatima, S., Arshi., & Ahmad, A. (2023). Shora Qalmi (Potassium nitrate): A beneficial mineral origin drug of Unani Medicine. International Journal of Creative Research Thoughts, 11(1), c327-c341. http://doi.one/10.1729/Journal.32697



- 45. Kalam, M. A., Avid, M., Ahmad, R., Rehman, R., Qaiyyum, I. A. (2023). *Hajr al-Yahud* (Judas stone): Mineral origin drug of Unani Medicine A review. *International Journal of Novel Research and Development*, 8(1), b261–b272. https://doi.org/10.1729/Journal.32653
- 46. Kalam, M. A., Mariyam, Z., Mobin, S., & Ismail, B. A. (2022). *Bishari booti (Aerva lanata* (L.) Juss. Ex schult): Ethanomedicinal importance of a valuable plant from mother nature. *European Journal of Pharmaceutical and Medical Research*, 9(9), 440–447.
- 47. Kalam, M. A., Siddique, Y., Naved, M., & Haseeb, A. (2022). *Marjan* (coral): A valuable Unani medicine having multifarious medicinal uses. *Acta Scientific Pharmaceutical Sciences*, 6(11), 11–27. DOI: 10.31080/ASPS.2022.06.0903
- 48. Kalam, M. A., Wasim, A., & Ajij, M. A. S., Naved, M., & Habib, A. (2023). *Fil Khartumi* or *Zanabul Aqrab* (*Heliotropium indicum* L.): Medicinal potential of a lesser known plant of Unani Medicine, *International Journal of Research and Analytical Reviews*, 10(1), 59–70.
- 49. Karwasra, R., Ahmad, S., & Singh, S. (2023). Potential profound fluctuation in tacrolimus concentration on consumption of pomegranate rind extract: A pharmacokinetic experiment. *Frontiers in Pharmacology*, 14, 1140706. https://doi.org/10.3389/fphar.2023.1140706
- 50. Karwasra, R., Ahmad, S., Bano, N., Qazi, S., Raza, K., Singh, S., & Varma, S. K. (2022). Macrophage-Targeted punicalagin nanoengineering to alleviate Methotrexate-Induced Neutropenia: A molecular docking, DFT, and MD simulation analysis. *Molecules*, 27(18), 6034. https://doi.org/10.3390/molecules27186034
- 51. Karwasra, R., Ahmad, S., Raza, K., Khanna, K., Singh, S., Sharma, N., Sharma, S., Hasan, N., Kaushik, D., & Varma, S. (2022). Engineering macrophage targeted punicalagin nanoparticles by computational modeling to alleviate methotrexate induced neutropenia. *Research Square* (*Research Square*). https://doi.org/10.21203/rs.3.rs-1441489/v1
- 52. Karwasra, R., Khanna, K., Sharma, N., Malhotra, R., Sharma, S., Singh, S. J., Ali, A., & Verma, S. (2022). Applications of nature-inspired computing and artificial intelligence algorithms in solving personalized therapy complications. In: Raza, K. (Ed.), Nature-inspired intelligent computing techniques in bioinformatics. Studies in Computational Intelligence, (vol. 1066, pp. 205–221). Springer, Singapore. https://doi.org/10.1007/978-981-19-6379-7_11
- 53. Karwasra, R., Khanna, K., Singh, S., Ahmad, S., & Verma, S. (2022). The incipient role of computational intelligence in oncology: Drug designing, discovery, and development. In: Raza, K. (Ed.). *Computational Intelligence in Oncology. Studies in Computational Intelligence*, (vol. 1016, pp. 369–384). Springer, Singapore. https://doi.org/10.1007/978-981-16-9221-5_21
- 54. Khan, A. A., Janardhanan, R., Kishore, J., Karwasra, R., Saeed, S., Das, B. C., Hasan, N., Almalki, W. H., Kesharwani, P., & Selvamurthy, W. (2022). Unani system of medicine and it's development in contemporary healthcare: A comprehensive review. *Journal of Pharmaceutical Negative Results*, 634-645. https://doi.org/10.47750/pnr.2022.13.S09.71

- 55. Khan, A. A., Janardhanan, R., Kishore, J., Awasthi, A. A., Parveen, S., Saeed, S., Shannawaz, M., & Selvamurthy, W. (2022). Awareness and utilization of Unani Medicine among the adult population from East Delhi: A cross sectional survey. *Journal of Pharmacy & Bioallied Sciences*, *14*(3), 157–161. https://doi.org/10.4103/jpbs.jpbs_229_22
- 56. Khan, P., Bano, H., Verma, R. S., Rehman, S., Ayub, S., Devi, N. M. K., Singh, R., Afza, S., Akhtar, J., & Khan, A. A. (2022). Efficacy and safety of Unani drugs to combat chronic gout A preliminary study. *International Journal of Recent Scientific Research*, 12(5), 41723–41728. http://dx.doi.org/10.24327/ijrsr.2021.1205.5949
- 57. Khan, S., Viquar, U., Alam, M. A., Moin, M. S., & Kazmi, M. H. (2021). Phytochemistry, pharmacological actions and uses of *Bel* (*Aegle Marmelos*) with special reference of Unani Medicine: A comprehensive review. *Hippocratic Journal of Unani Medicine*, 16(2), 35–50.
- 58. Khan. M. T., Naseem, M., Anjum, N., Parveen, N. & Khan, A. A. (2021). Assessing safety and efficacy of Unani pharmacopoeial formulation *Jawārish 'Ūd Shīrīn in Du'f al-Ishtihā*' (anorexia). *Hippocratic Journal of Unani Medicine*, 16(2), 79–90.
- 59. Khanday, S., Kalam, M. A., & Rather, S. A. (2022). Adverse effect of Unani pharmacopoeial formulation *Habb-e-Karanjawa*. *Indian Journal of Unani Medicine*, 15(01), 73–75. https://doi.org/10.53390/ijum.2022.15113
- 60. Khatoon, A., Rahman, H., Ahmad, F., Rauf, E., & Khan, M. N. (2022). Jamun (*Eugenia jamboldan*) A review. *World Journal of Pharmacy and Pharmacutical Sciences*, 11(7), 654-657.
- 61. Khatoon, F., Azahar, M., Jabeen, A., Uddin, Q., Husain, N., & Naikodi, M. A. R. (2022). Treatment of chronic plaque psoriasis with herbal Unani formulations: A randomized control trial of efficacy and safety. *Journal of Ethnopharmacology*, 296, 115456. https://doi.org/10.1016/j.jep.2022.115456
- 62. Khatoon, F., Jabeen, A., Uddin, Q., Husain, N., Azahar, M., & Moin, M. S. (2022). Chronic plaque psoriasis treated with topical Unani formulation Marham Ḥina A series of case reports. *Advances in Integrative Medicine*, *9*(3), 197–201. https://doi.org/10.1016/j.aimed.2022.06.005
- 63. Mustehasan, Azhar, M., Naushin, S., Urooj, M., & Husain, G. M. (2022). Overview of *Sang-e-Surma* (Antimony sulphide or lead sulphide): A mineral origin Unani drug. *Traditional and Integrative Medicine*, 7(1), 124–134. https://doi.org/10.18502/tim.v7i1.9069
- 64. Mustehasan, M., & Azhar, M. (2022). *Usrub* (lead) and its compounds used in Unani Medicine: Overview. *International Research Journal of Pharmacy*, 358–366. https://doi.org/10.52711/0974-4150.2022.00064
- 65. Mustehasan., Nausheen, S., & Azhar, M. (2022). Zaj-e-Abyaz (alum) an important styptic drug of Unani Medicine: Review. International Journal of Advances in Pharmacy Medicine and Bioallied Sciences, 10(1), 18–27.
- 66. Pallapolu, P., Ghali, S. K., Javed, G., Kazmi, M. H., & Chakraborty, A. (2021). CYP3A4*2 Gene Polymorphism and its association with clinical phenotyping (temperament) concept of Unani Medicine philosophy in Indian population. *Research Journal of Biotechnology*, *17*(1), 52–59. https://doi.org/10.25303/1701rjbt5259

- 67. Parveen, N., Sheikh, A., Abourehab, M. A., Karwasra, R., Singh, S., & Kesharwani, P. (2023). Self-nanoemulsifying drug delivery system for pancreatic cancer. European Polymer Journal, 190, 111993. https://doi.org/10.1016/j.eurpolymj.2023.111993
- 68. Rahi, T., Islam, N. U., Pandith, R. A., Akbar, S., & Rafeeqi, T. A. (2022). Evaluation of oral and topical herbal formulations used in Unani system of medicine for treatment of psoriasis and its effect on inflammatory biomarkers - a randomized controlled clinical trial. Social Science Research Network. https://doi.org/10.2139/ssrn.4037177
- 69. Raza, R., Ahmad, F., Ansari, Y., & Chishti, D. K. (2022). Zeeg un Nafas (asthma) and their understanding in the past: Unani concept. Global Journal of Science Frontier Research: A Physics and Space Science, 22(5), 69–71.
- 70. Raza, R., Khan, R., Chishti, D. K., & Khan, N. (202). Health status of certain areas of New Delhi under SCSP & TSP Programme. International Journal of Scientific Research, 11(8), 9-10.
- 71. Reshi, M. R., Gulati, K., Khan, A. A., & Ray, A. (2021). Sub-chronic toxicity studies of Dawā' al-Kurkum and its extract in experimental rats. Hippocratic Journal of Unani Medicine, 16(2), 57-67.
- 72. Sagar, P. K., Alam, M., Sajwan, S., Khan, A. S., & Meena, R. P. (2022). HPTLC finger printing studies and evaluation of pharmacopoeial standards for the medicinal plant Adiantum capillus-veneris L. International Journal of Scientific Research in Chemistry, 7(3), 1–15. https://doi.org/10.13140/RG.2.2.14683.54564
- 73. Salam, M., Azeem, M. A., & Goswami, A. (2022). Chronic Idiopathic Thrombocytopenic Purpura (ITP) and its management through Unani system of medicine: A case study. International Journal of AYUSH Case Reports, 6(3), 301-309. https://ijacare.in/index.php/ijacare/article/view/351
- 74. Salim, S., Kalam, A., Khanday, S., & Yousuf, A. (2022). Phytochemical and physicochemical studies on Sosan Asmanjuni (Iris ensata Thunb) found in Kashmir Indian Journal of Unani Medicine, *15*(1), https://doi.org/10.53390/IJUM.2022.15108
- 75. Sehar, N., Ahmad, M., Alam, I., Goswami, A., Ahmad, W. (2022). Clinical efficacy of Sharbat Toot Siyah in Waram-i-Halag (Pharyngitis) NUM CODE-98. Research & Reviews: A Journal of Health Professions, 12(1), 7–22.
- 76. Shah, A., Huma., Iqbal, A., Jahangir, U., Shah, K., Sabia., Hanga, A. H., Urooj, S., & Rafiqi, T. A. (2023). Prospective role of Unani pharmacopeial formulation Safoof Hijrul Yahood in preventing recurrence of nephrolithiasis: An open labeled clinical study. Journal of Biological Life Sciences. 12(1), 144–150. and https://ajbls.com/article/2023/12/1/144-150
- 77. Shamim., Ahmed, S., Amanullah., Khan, A. A. & Fatima, L. (2022), Medicinal properties of Amla (fruit) Phyllanthus emblica L - Unani medicine for promotion of longevity and healthy ageing: A review. International Journal of Pharmacy and Biological Sciences, 12(3), 28–32.
- 78. Shamim., Amanullah., Khan, A. A., Ahmed, S., Bashir, F., & Parveen, S. (2022). Immunomodulatory, anti-oxidant and cardioprotective activities of style & stigma of Z'afrān (Crocus sativus L.): A Unani medicine used for promotion of healthy ageing. International Journal of Pharmacy and Biological Sciences, 12(4), 66–67.

- 79. Sharma, N., Kulkarni, G. T., Bhatt, A. N., Satija, S., Singh, L., Sharma, A., Dua, K., Karwasra, R., Khan, A. A., Ahmad, N., & Raza, K. (2022). Therapeutic options for the SARS-COV-2 virus: Is there a key in herbal medicine? *Natural Product Communications*, 17(9), 1934578X2211263. https://doi.org/10.1177/1934578X221126303
- 80. Sharma, N., Kumari, R., Karwasra, R., & Khanna, K. (2023). Colon cancer and their targeting approaches through nanocarriers: A review. *Asian Pacific Journal of Tropical Biomedicine*, *13*(3), 104. https://doi.org/10.4103/2221-1691.372283
- 81. Sharma, N., Sharma, A., Rai, Y., Karwasra, R., Khanna, K., Nishad, D. K., Bhatt, A. N., Bhatnagar, A., & Kakkar, D. (2022). Protective effect of organ preservation fluid supplemented with Nicorandil and Rutin Trihydrate: A comparative study in a rat model of renal ischemia. *Experimental and Clinical Transplantation*, 20(6), 569–579. https://doi.org/10.6002/ect.2022.0019
- 82. Singh, S. K., Singh, S., Kumar, R., Sharma, A., & Karwasra, R. (2023). An updated review on multidimensional uses of *Bauhinia purpurea* Linn., *Eur. Chem. Bull.*, 12(Special Issue 5), 493–501. doi: 10.31838/ecb/2023.12.si5.059
- 83. Singh, V. B., Fatima, A., Arshad, M., & Khan, M. N. (2022). Concept of amensia (*Nisyan*) and its treatment in Unani system of medicin: (A Review). *International Journal* of *Creative Research Thoughts*, 10(8), 703–711.
- 84. Umar, T., Meena, R. P., & Khan, A. A. (2022). Structure-based drug design of Kynurenine 3-Monooxygenase (KMO) inhibitors: Use of theoretical tools. *International Journal of Scientific Research*, 11(7), 21–24.
- 85. Umar, T., Meena, R. P., Mustehasan, Javed, G., & Khan, A. A. (2022). Treatment strategies for neurodegenerative diseases through important medicinal plants used in Unani Medicine. *International Journal of Pharmaceutical Sciences and Research*, 14(4), 1604–10. https://doi.org/10.13040/IJPSR.0975-8232.14(4).1604-10
- 86. Umar, T., Meena, R. P., Mustehasan, Kumar, P., & Khan, A. A. (2022). Recent updates in the development of small molecules as potential clinical candidates for Alzheimer's disease: A review. *Chemical Biology & Drug Design*, *100*(5), 674–681. https://doi.org/10.1111/cbdd.14133
- 87. Verma, P. (2022). Carbohydrate deficiency. *Research & Reviews: A Journal of Health Professions*, 12(2), 17–19.
- 88. Yousuf, A., Khanday, S., Salim, S., & Kalam, A. (2022). Pharmacognostical, physicochemical and phytochemical evaluation of Rasan root *Inula racemosa* Hook. F. (Asteraceace): An endangered medicinal plant of Kashmir. Indian Journal of Unani Medicine. Indian Journal of Unani Medicine, *15*(1), 1-12. https://doi.org/10.53390/IJUM.2022.15101

3.5. Extension of Healthcare Services

3.5.1. School Health Programme

The School Health Programme is aimed at improving the health and hygiene status of school children and to reduce morbidity rate among them through healthcare and health education. Under this programme, the Council's researchers visit selected Primary and Secondary Schools, particularly those in rural areas and urban slums. A baseline health check-up of

school children is conducted and those found suffering from any ailment are treated with Unani medicines. Thereafter, health education is provided to them through lectures on different preventive, promotive, and curative health aspects, and health related literature is distributed. The children are also educated about the potentialities of the commonly available plants in their vicinity for the management of different diseases. Specific lectures are given on oral hygiene, cleanliness of body and environment, safe drinking water, nutrition, balanced diet, etc.

During the reporting period, this programme continued at Regional Research Institutes of Unani Medicine (RRIUM), Srinagar. The Council's physicians visited two schools that were adopted under the School Health Programme particularly those falling in the pockets adopted under Mobile Clinical Research Programme. A total of 576 school children were covered under this programme. Out of them, health check-up of 576 children was conducted; and 481 children suffering from different ailments were treated in 13 visits made to these schools. With a view to educate the children on healthy living, 13 lectures were delivered on preventive and promotive health aspects. The most common diseases found among them included cold & cough, dental cavities, tonsillitis, helminthiasis, skin infections, otorrhoea and conjunctivitis.

3.5.2. Unani Medical Centres in Allopathic Hospitals

Under the scheme of collocation of AYUSH centres in Allopathic hospitals in Delhi, a Unani Medical Centre was established at Dr. Ram Manohar Lohia (RML) Hospital on 14 January 1998 with a view to provide Unani treatment facility to the patients desirous of taking treatment of this system. On public demand, another Unani Specialty Centre started functioning at Deen Dayal Upadhyay (DDU) Hospital, New Delhi on 01 November 2010. A new Unani Medical Centre was established at VMMC & Safdarjung Hospital, New Delhi on September 13, 2020. These centres are run by the Council. Besides the General Outpatient Department (GOPD) facilities, these centres provide specialized Unani treatment for some selected disorders like vitiligo, eczema, psoriasis, rheumatoid arthritis, bronchial asthma, sinusitis, infective hepatitis, diabetes mellitus, etc.

During the reporting period, 26,811 patients were treated at Unani Medical Centre in Dr. RML Hospital, 29,206 patients at Unani Speciality Centre in DDU Hospital, New Delhi and 14,373 patients at Unani Medical Centre at Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi. Patients visiting the centres were suffering from chronic diseases. Counselling of patients, particularly the senior citizens, was also done to improve their physical activities and mental health.

3.5.3. Health Melas / Camps

The Council organized health camps through its Institutes/Units with a view to create health awareness among the masses and to provide treatment through Unani system of medicine. During the reporting period, 19 health camps were organized and 5,114 patients were treated in these camps. Lectures on preventive and promotive health aspects were also delivered by the physicians of the Council. Referral of the patients to the Council's centres as well as other hospitals was also done.

3.5.4. Activities under Gender Component Plan for Women

The Council continued research and treatment facilities for women under Gender Component Plan. Treatment facilities were made available to women at all clinical centres of the Council. Besides, female patients in the pockets adopted under Mobile Clinical Research

Programme were also treated by the physicians in the Mobile OPD Scheme. During the reporting period, 3,44,576 female patients in different OPDs were treated. Efficacy of Unani pharmacopoeial formulations was also validated under this component. Health lectures / group meetings on preventive and promotive health aspects were also organized in the pockets adopted under Mobile Clinical Research Programme. Published literature on preventive, promotive, and curative health aspects was also distributed among the masses. Clinical studies on the diseases specific to female such as lhibas al-Tamth (amenorrhoea), Sayalan al-Rahim (leucorrhoea), $S\bar{u}$ al-Qinya (Anaemia) and Kathrat al-Tamth (Menorrhagia) also continued.

3.5.5. Activities in the North-Eastern Region

The two centres of the Council in the North-Eastern Region – Regional Research Institute of Unani Medicine Silchar and Clinical Research Unit, Imphal – continued Research/GOPD Programmes. In November 2022, Shri Sarbananda Sonowal, Hon'ble Cabinet Minister, Ministry of Ports, Shipping and Waterways & Ministry of Ayush, Government of India inaugurated the Regional Research Institute of Unani Medicine (RRIUM), Silchar at Veterinary Bazar, Ghungoor, Silchar, Assam.

During the reporting period RRIUM, Silchar and CRU, Imphal continued Research/GOPD Programmes. A total of 18,990 beneficiaries were treated. The most commonly occurring diseases were *Waja' al-Mafāṣil* (rheumatoid arthritis), *Ishāl* (diarrhoea), *Ḥummā* (fever), *Sayalān al-Raḥim* (leucorrhoea), *Sū' al-Haḍm* (dyspepsia), *Ḥummā Ajāmiyya* (malaria) and *Zaḥīr* (dysentery). The patients were treated with Unani pharmacopoeial drugs.

3.5.6. Ayush Wellness Centre - President Estate

Ayush Wellness Clinic was established in President Estate, in the year 2015 with a view to provide medical care through various streams of Ayush (viz. Ayurveda, Yoga and Naturopathy, Unani, Siddha & Homeopathy) to the President, officials of President's Secretariat and residents of the President's Estate.

During the reporting period, health care services were provided through OPD and Regimenal therapy to the patients. A total of 3,645 patients were treated in Unani Out Patient Department and 1646 were treated in Regimenal Therapy.

3.5.7. Mobile Healthcare Programme under Scheduled Caste Sub-Plan

The CCRUM runs Mobile Healthcare Programme under Scheduled Caste Sub-Plan (SCSP) at 12 centres, namely NRIUMSD, Hyderabad; CRIUM, Lucknow; RRIUM, New Delhi, Chennai, Mumbai, Aligarh, Patna, and Kolkata; RRC, Prayagraj; and CRU, Bhopal, Meerut and Bengaluru to extend healthcare services to the SC population at their doorstep. The programme aims to screen / examine the SC population for their health status in Mobile OPDs and health camps and to provide Unani treatment to the patients suffering from different diseases. It also aims to create awareness among the masses on preventive, promotive, and curative health aspects through lectures, group meetings, health camps, and distribution of literature. Five villages predominately having SC population were identified for undertaking the programme at each centre. During the reporting period, 14,15,822 total population including 8,68,233 SC population were covered and a total of 63,192 individuals benefited from the programme.



3.5.8. Mobile Healthcare Programme under Tribal Sub Plan

Just like Mobile Healthcare Programme under Scheduled Caste Sub-Plan, the CCRUM runs Mobile Healthcare Programme under Tribal Sub Plan (TSP) at RRIUM, Bhadrak and Srinagar; and CRU, Burhanpur and Kurnool to extend healthcare services to the ST population at their doorstep. The programme aims to screen / examine the ST population for their health status in Mobile OPDs and health camps and to provide Unani treatment to the patients suffering from different diseases. It also aims to create awareness among the masses on preventive, promotive, and curative health aspects through lectures, group meetings, health camps, and distribution of literature. Five villages predominately having ST population were identified for undertaking the programme at each centre. During the reporting period, 86,590 total population including 61,253 ST population were covered and 16,433 individuals benefited from the programme.

3.6. Linking Education with Research

With a view to link education with research and utilize the comprehensive facilities available at its institutes, the CCRUM is conducting postgraduate (MD) programmes in Unani Medicine at National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad and Regional Research Institute of Unani Medicine (RRIUM), Srinagar in affiliation with Kaloji Narayana Rao University of Health Sciences, Warangal (Telangana) and University of Kashmir, Srinagar respectively. Twenty nine students were admitted during the reporting period with intake of 09 students in each discipline of *Muʻālajāt* (Medicine) and *'Ilm al-Adwiya* (Pharmacology) at NRIUMSD, Hyderabad and 09 students in *Muʻālajāt* and 05 students in *'Ilm al-Adwiya* at RRIUM, Srinagar.

The students were trained through a structured academic schedule comprising theory classes, hands-on practical classes, bedsides teaching and dissertation projects. The institutes also organized monthly meeting for postgraduate training that included clinical and research skills, development of protocols, case presentations, and discussions. Students were posted in various OPDs as well as IPD wards for clinical training on rotation basis. The academic activities also included seminars, journal club, and tutorials. The faculty members conducted classes as per prescribed syllabus. The students were also engaged in their theses work, in addition to attending classes.

During the reporting period, several meetings of Departmental Research Committee, Board of Studies, and Institutional Ethics Committee were organized to deliberate, evaluate, and approve the research proposals for thesis work.



4. INFORMATION, EDUCATION & COMMUNICATION

4.1. Library Services

The CCRUM has a Library and Information Centre (LIC) at the Headquarters which aims to collect and preserve scattered literature on Unani Medicine, and to disseminate information to the researchers, academicians, and practitioners of Unani Medicine.

During the reporting period, services of the LIC remained fully automated through Wide Area Network (WAN). The LIC provided its services to the readers through e-Granthalaya Library Software that controls the Web Online Public Access Catalogue (Web-OPAC), circulation of books, etc. A total of 68 books were acquired on complimentary basis. Data of 68 new additions in the library were also uploaded on e-Granthalaya cloud database.

A total of 1,127 books were in circulation including 212 books that were circulated through Inter-Library Loan Service to the Athens Academy Library and DELNET's member libraries. The library subscribed 3,650 issues of daily newspapers and 208 issues of popular magazines. In addition, 121 issues of journals were received, out of which 31 were in Hindi language and 43 issues related to Unani Medicine.

The LIC carried out physical processing and barcoding of 66 books after binding. The centre provided spiral binding and photocopying, and reference services to the readers. Comb or thermal binding of 284 documents and photocopying of 1,240 pages were carried out. Besides, long and short range reference service was provided through WhatsApp and e-mail to the researchers and allied staff members of the CCRUM. A Facebook page was also maintained during the year with an objective of facilitating the researchers with reference services and recent updates. The LIC collected Rs. 4,640.00 as user charges against annual membership, photocopy and spiral binding services, and consultation.

The library continued digital publication and circulation of Medical News Update Service among 780 subscribers on daily basis. The Selective Dissemination of Information (SDI) service also continued at the LIC. Under this service, 462 news clippings were collected, of which important ones were sent to the Director General & Deputy Director General (Unani) and displayed on the library notice board as well. Besides the digitization of Unani rare manuscripts, books & journals and development of digital repository, the LIC also developed "Digital Archives of CCRUM News Clippings" to preserve the news of the CCRUM and started work on AYUSH Information Hub Project.

The LIC continued institutional membership of British Council Library, Medical Library Association of India, American Resource Centre, and Developing Library Network (DELNET) during the year.

During the reporting period, 272 member and guest researchers visited the LIC to access its resources.

4.2. Organization of Conferences, Seminars, Workshops, etc.

4.2.1. Unani Day and International Conference on Unani Medicine

The CCRUM organized Unani Day Celebration and International Conference on Unani Medicine at Vigyan Bhawan, New Delhi during February 10–11, 2023. Formally inaugurating the event themed on 'Unani Medicine for Public Health' on February 11, Shri Sarbananda Sonowal, Union Minister of Ayush reiterated how India has taken the lead in the field of

Traditional Medicine in the world and emphasized the need for bolstering evidence-based scientific research in Ayush sector. He further said, "Under the visionary leadership of our Prime Minister Shri Narendra Modi, India has taken the initiative of establishing WHO Global Centre for Traditional Medicine. This is an indication that we are taking a leadership role in Traditional Medicine in the world. We need to strengthen our research capabilities and academic facilities and work towards bolstering evidence-based research."

The event was attended by Shri Kiren Rijiju, Union Minister of Law and Justice, Dr. Munjpara Mahendrabhai, Union Minister of State for Ayush, Vaidya Rajesh Kotecha, Secretary, Ministry of Ayush, Shri Pramod Kumar Pathak, Special Secretary, Ministry of Ayush, Dr. M. A. Qasmi, Advisor (Unani), Ministry of Ayush, Prof. Asim Ali Khan, Director General, CCRUM and other officials from the Ministry of Ayush.

Addressing the gathering, Union Minister of Law & Justice, Shri Kiren Rijiju said, "Unani Medicine is India's rich traditional system of medicine. We witnessed how Ayush-based remedies provided relief during COVID-19 pandemic. Our rich traditional medicinal practices can offer us sustainable healthcare solutions which will contribute towards the enrichment of human lives in the country."

Minister of State for Ayush Dr. Munjpara Mahendrabhai paid tribute to revered freedom fighter Hakim Ajmal Khan. He said that Unani Medicine provides detailed guidelines for healthy food habits to maintain health and prevent diseases.

Vaidya Rajesh Kotecha, Secretary, Ministry of Ayush talked about how important the role NABH QCI quality certification could play in gaining more acceptance for Ayush systems.

On this occasion, various publications of CCRUM, conference souvenir, and online portal of Hippocratic Journal of Unani Medicine were released. Also, NABH certificate was given to two CCRUM institutes. A mobile app on common remedies in Unani Medicine developed by CCRUM was also launched.

The international conference had scientific deliberations on 'Unani Medicine - Opportunities in health and wellness sector', 'Accreditation for healthcare services', 'Strengthening immunity – Need of the hour', 'Quality Unani products for healthcare systems - Role of industry', 'Non-communicable diseases (NCDs) – A challenge to combat', 'Planning and implementation of public health programs', 'Recent advancements in research on Unani Medicine', and 'Global opportunities for Unani Medicine'. The conference aimed to debate the value of using Unani Medicine to treat non-communicable illnesses and other chronic conditions while also enabling public health experts to work together, think outside the box, and influence the direction of public health with Unani Medicine.

About 1300 delegates, resource persons, academicians, researchers, and industry representatives participated in the conference.

4.2.2. National Conference on Regimenal Therapy

The CCRUM through its peripheral institute Regional Research Institute of Unani Medicine, Srinagar organized a one-day national conference on "Exploring the Role of Regimenal Therapy ('*Ilāj bi'l-Tadbīr*) in Public Health and Wellness" under the Centre of Excellence (CoE) project on '*Ilāj bi'l-Tadbīr* (Regimenal Therapy) at Convocation Centre, University of Kashmir, Srinagar on March 10, 2023.

Prof. Afshar Alam, Vice Chancellor, Jamia Hamdard, New Delhi was the chief guest in the inaugural session of the conference. Prof. Nelofar Khan, Vice Chancellor, University of Kashmir, Srinagar, Prof. Akbar Masood, Vice Chancellor, Baba Ghulam Shah Badshah University, Rajouri, J&K, Prof. Qayyum Husain, Vice Chancellor, Cluster University Srinagar, J&K, Prof. Shakeel Ahmad Romshoo, Vice Chancellor, Islamic University of Science and Technology (IUST), Awantipora, J&K, Dr. Abdul Kabeer Dar, Secretary (Technical), ARI & Trainings Department, J&K, Prof. Asim Ali Khan, Director General, CCRUM and Dr. Seema Akbar, Assistant Director Incharge, RRIUM, Srinagar graced the occasion and addressed the conference.

During the inaugural session, they talked about the importance of regimenal therapy vis-avis development of healthcare system through Unani Medicine.

The occasion also marked signing of MoU between the CCRUM and IUST by Prof. Asim Ali Khan and Prof. Shakeel Ahmad Romshoo for research collaboration.

On this occasion, 'Recent Researches in Unani Medicine - A Compendium of Abstracts Published during 2018-2022' published by the CCRUM and a monograph based on the work of the Centre of Excellence were also released.

The conference aimed to sensitize, train, and create awareness among researchers, academicians, and students in the field of '*llāj bi'l-Tadbīr* (Regimental Therapy).

4.2.3. Awareness Programme on NABL Accreditation for Ayush Scientists

The CCRUM in collaboration with the National Accreditation Board for Testing and Calibration Laboratories (NABL) organized a one-day awareness programme on 'NABL Accreditation for Ayush Scientists of South Zone' at RRIUM, Chennai on February 21, 2023.

Prof. Asim Ali Khan, Director General, CCRUM graced the event virtually and delivered presidential address. Dr. K. Upadhyaya, Advisor (Ayurveda), Ministry of Ayush, Shri N. Venkateswaran, CEO, NABL, Prof. Dr. R Meenakumari, Director General Incharge, Central Council for Research in Siddha & Director, National Institute of Siddha, Chennai, Dr. R. Ilavarasan, Assistant Director, Captain Srinivasa Murthy Central Ayurveda Research Institute, Chennai and Dr. N. Zaheer Ahmed, Deputy Director, RRIUM, Chennai graced the event.

Ms. S. Gayathri, Joint Director, Operations (Medical), NABL and Ms. Rozina, Accreditation Officer, NABL were the trainers of the programme. They guided the participants about key aspects of third-party assessment of the technical competence of testing and calibration of medical laboratories conducted by NABL for accreditation.

4.2.4. National Seminar on Public Health & Wellness

The RRIUM, New Delhi organized National Seminar on the Role of Unani Medicine in Public Health & Wellness as part of pre-activity of Unani Day 2023 Celebration at Vigyan Bhawan, New Delhi on February 02, 2023.

Addressing the inaugural session of the seminar, Dr. O. P. Mishra, Joint Commissioner of Police, Delhi Police said, 'Unani Medicine and other Traditional Medicine have been serving the mankind for ages and can play an important role in addressing the new challenges concerning public health and wellness'. He added that increase in the ageing population, emergence of chronic diseases, environmental and climate related changes and lack of access to quality health care in many areas are major health challenges faced today and

Unani Medicine with its cost-effective remedies and holistic approach can play an important role in addressing them.

Speaking on the occasion, Prof. Mohammad Afshar Alam, Vice-Chancellor, Jamia Hamdard, New Delhi said that Unani Medicine has great potential to address the modern day health challenges through its time-tested remedies, regimens for healthy living, dietary management, and prophylactic interventions.

Prof. Asim Ali Khan, Director General, CCRUM said that Unani Medicine has great offerings to maintain health and prevent various diseases and CCRUM has been conducting various public health programmes for the benefit of masses.

The inaugural function concluded with the vote of thanks proposed by Dr. Rahat Raza, Deputy Director, RRIUM, New Delhi. The seminar had fruitful deliberations and presentations by subject experts during the technical sessions.

4.2.5. National Seminar on Post-Covid-19 Complications

Hakim Ajmal Khan Institute for Literary and Historical Research in Unani Medicine (HAKILHRUM), New Delhi organized National Seminar on the Role of Unani Medicine in Post-Covid-19 Conditions in New Delhi on January 24, 2023.

Inaugurating the seminar, Prof. Najma Akhtar, Vice Chancellor, Jamia Millia Islamia, New Delhi said that Unani Medicine which focuses on prevention through lifestyle modification, dietary management, prophylactic interventions, and simple remedies based on presentation of symptoms can play significant role in combating post-COVID complications.

Addressing the seminar, Prof. Asim Ali Khan, Director General, CCRUM said that the CCRUM played a significant role during COVID-19 and Unani Medicine has much potential to address post-COVID complications as well.

Speaking on the occasion, Dr. Mohammad Khalid, Assistant Drug Controller, Directorate of Ayush, Delhi suggested for increased collaborations between the CCRUM and Jamia Millia Islamia in the promotion and development of Unani Medicine.

Prof. Nazim Hussain Al-Jafri, Registrar, Jamia Millia Islamia also graced the inaugural function which concluded with the vote of thanks proposed by Dr. Mohammad Fazil, Incharge, HAKILHRUM, New Delhi.

In the two technical sessions of the seminar, Dr. Merajul Haque, HAKILHRUM, Prof. Mohammad Faisal, Jamia Millia Islamia, Dr. Bilal Ahmad, HAKILHRUM, Dr. Sherin Zafar, Jamia Hamdard, Dr. Ahmad Sayeed, HAKILHRUM, Dr. Sadia Nikhat, Jamia Hamdard and Dr. Sohrab Ahmad Khan, Jamia Hamdard delivered their presentations on different aspects of the seminar theme.

4.2.6. Workshop-cum-Hands-on Training in Unani Pharmacy

The RRIUM, Chennai organized a one-day Workshop-cum-Hands-on Training in Unani Pharmacy for Unani medical practitioners and students on January 25, 2023.

The workshop started with the welcome address and introductory remarks by Dr. N. Zaheer Ahmed, Deputy Director, RRIUM, Chennai. Two theoretical sessions were conducted wherein Dr. Athar Parvez Ansari, Research Officer (Unani) Scientist-II delivered a lecture on 'Standard operating procedures of commonly used Unani dosage forms' and Dr. A. Farhath Fathima, Research Associate (Unani) articulated on 'Historical perspective of Unani

pharmacy and the need of compounding drugs'. In four practical sessions, demonstrations and hands-on training were given to the participants on the preparation of various dosage forms. Around 40 delegates from Govt. Unani Medical College, Chennai, practitioners, medical officers, and students actively participated in the workshop. The programme concluded with the closing remarks and vote of thanks by Dr. Noman Anwar, Research Officer (Unani) Scientist-II.

4.2.7. Workshop on Understanding NABH/NABL Accreditation

The RRIUM, Chennai organized Workshop on Understanding NABH/NABL Accreditation on January 12, 2023. It aimed to acquaint Ayush healthcare providers, practitioners, clinicians, medical and drug research laboratory personnel, hospital management, and other stakeholders with the objectives of NABH/NABL accreditation. The workshop focused on significance and impact of NABH / NABL accreditation on safe and quality healthcare delivery, documentation, audits, processes, and levels of accreditation, etc.

The Inaugural programme of the hybrid workshop began with the invocation of Tamil Thaaivazhthu. Dr. N. Zaheer Ahmed, Deputy Director, RRIUM, Chennai welcomed the dignitaries, guests, and audience and delivered introductory address. Prof. Dr. R Meenakumari, Director General Incharge, CCRS, Chennai graced the event as chief guest and addressed the gathering. Prof. Dr. Mohd Idris Ahmed, Assessor & Member-Expert (Unani), Accreditation Committee, NABH was the guest of honour in the event. Two technical sessions were conducted, wherein eminent speakers articulated on the theme of the workshop.

4.2.8. NABL Exposure Training Programme

The CCRUM in collaboration with National Accreditation Board for Testing and Calibration Laboratories (NABL) organised NABL Exposure Training Programme for Ayush Scientists in Kolkata on December 19, 2022.

The programme was inaugurated by Prof. Subhas Singh, Director, National Institute of Homeopathy, Kolkata. Dr. Younis Munshi, Deputy Director, RRIUM, Kolkata welcomed the guests and Dr. Rampratap Meena, Research Officer (Chemistry) Scientist-IV, CCRUM, New Delhi presented vote of thanks.

On the occasion, Ms. S. Gayathri, Joint Director, Operations (Medical), NABL and Ms Shewta Sinha, Deputy Director, NABL were trainers of the programme. They guided the participants about key aspects of third-party assessment of the technical competence of testing and calibration of medical laboratories conducted by NABL for accreditation.

4.2.9. Union Ayush Minister Inaugurates RRIUM, Silchar

Shri Sarbananda Sonowal, Hon'ble Cabinet Minister, Ministry of Ports, Shipping and Waterways & Ministry of Ayush, Government of India inaugurated the Regional Research Institute of Unani Medicine (RRIUM), Silchar at Veterinary Bazar, Ghungoor, Silchar, Assam on November 20, 2022.

Shri Parimal Suklabaidya, Hon'ble Minister of Transport, Fisheries and Excise, Government of Assam, Dr. Rajdeep Roy, Hon'ble Member of Parliament, Silchar, Shri Kripanath Mallah, Hon'ble Member of Parliament, Karimganj, Shri Mihir Kanti Shome, MLA, Udharbond, Shri Aminul Hoque Laskar, Former MLA, Sonai, Shri Pramod Kumar Pathak, Special Secretary, Ministry of Ayush, Government of India, Shri Rohan Kumar Jha, Deputy Commissioner,



Cachar, Silchar and Prof. Asim Ali Khan, Director General, Central Council for Research in Unani Medicine (CCRUM), Ministry of Ayush, Government of India also graced the occasion.

Speaking on this occasion, Shri Sarbananda Sonowal said that Ayush sector is growing and achieving unprecedented milestones under the leadership of Hon'ble Prime Minister Shri Narendra Modi. He said that the RRIUM, Silchar with a 50-bedded hospital would serve healthcare needs of the people of Assam. He further said that there is a vast variety of medicinal herbs and plants in the hills and forests of Assam and this institute would focus on exploiting these resources for the benefit of mankind along with other research and development activities in Unani Medicine.

Shri Parimal Suklabaidya said that the traditional systems of medicine including Unani Medicine always played important role in meeting the global health care needs. He further said that through this institute Unani Medicine is going to play a greater role in improving the standard of health care services in the region.

Dr. Rajdeep Roy said that the Government of India under the leadership of Shri Narendra Modi has been paying a very special attention to the development of indigenous systems of medicine and this institute set up with a cost of around Rs. 45 crore is an important milestone in this direction.

Shri Kripanath Mallah said that Unani Medicine is an integral part of our healthcare system and it is going to play an important role in research as well as healthcare delivery in the region.

Shri Pramod Kumar Pathak said that the Government of India has always paid a very special attention for the development of indigenous systems of medicine in India. It has been providing increasing funds and support for multi-faceted development of Ayush systems including Unani Medicine.

Earlier, Prof. Asim Ali Khan expressed his gratitude to the Ministry of Ayush and Government of Assam for their support in the establishment of RRIUM, Silchar.

The inaugural ceremony concluded with the vote of thanks proposed by Dr. Akhtar Hussain Jamali, Research Officer Incharge, RRIUM, Silchar.

4.2.10. NABL Exposure Training Programme

The CCRUM in collaboration with National Accreditation Board for Testing and Calibration Laboratories (NABL) organised NABL Exposure Training Programme for Ayush Scientists in New Delhi on November 15, 2022.

On the occasion, Shri Pankaj Johri, Director, Operations (Medical), NABL and Ms. S. Gayathri, Joint Director, Operations (Medical), NABL were trainers of the programme. The trainers guided the participants about key aspects of third-party assessment of the technical competence of testing and calibration of medical laboratories conducted by NABL for accreditation.

Dr. Nahid Parveen, Assistant Director (Unani), CCRUM and scientists from other Ayush research councils including CCRUM participated in the training programme. The programme concluded with the vote of thanks proposed by Dr. R. P. Meena, Research Officer (Chemistry) Scientist-IV, CCRUM.



4.2.11. Workshop on Statistical Analysis in Excel

The CCRUM organised a hands-on-training on "Statistical analysis in Excel: Tips and techniques" in hybrid mode on November 10, 2022.

In his introductory remarks, Prof. Asim Ali Khan, Director General, CCRUM underscored that statistical analysis is significant part of clinical research and therefore every researcher should have basic statistical knowledge and should be acquainted with basic statistical tools. He said that the objective of this workshop is capacity building of participants in statistical analytics through the use of Excel software.

Dr. Varsha Chorsiya, Assistant Professor, Delhi Pharmaceutical Sciences and Research University, Government of NCT of Delhi was the resource person of the workshop and provided hands-on-training on how to collect and analyse data, sample size analysis and other useful functions of Excel.

The workshop concluded with the vote of thanks proposed by Dr. Naheed Parveen, Assistant Director (Unani), CCRUM.

4.2.12. National Workshop on 'llāj bi'l-Tadbīr

The CCRUM organized 'National Workshop on '*llāj bi'l-Tadbīr* (Regimenal Therapy) in Unani Medicine: A Public Health Approach' in Srinagar on October 14-15, 2022.

Addressing the workshop, Prof. Asim Ali Khan, Director General, CCRUM informed that the Ministry of Ayush has considered CCRUM's Regional Research Institute of Unani Medicine (RRIUM), Srinagar to be developed as the Centre of Excellence (CoE) in '*llāj bi'l-Tadbīr* (Regimenal Therapy). He said that *llāj bi'l-Tadbīr* comprising simple regimens of Unani Medicine are of immense use in handling public health problems faced by the present world today.

Speaking as the chief guest, Prof. (Dr.) Rakesh Sehgal, Director, National Institute of Technology, Srinagar said that the advancements in the field of information technology have caused drastic positive developments in every walk of life and appreciated the recent IT initiatives of the Ministry of Ayush. Speaking as the guest of honour, Prof. Nazim Husain Al-Jafri, Registrar, Jamia Millia Islamia, New Delhi emphasized the potential of Unani Medicine particularly its regimenal therapies in public health.

The workshop had sessions for lectures and hands-on training on various techniques and therapies under '*llāj bi'l-Tadbīr* by experts from CCRUM and other reputed institutions of Unani Medicine.

The workshop concluded with the vote of thanks proposed by Dr. Seema Akbar, Assistant Director Incharge, RRIUM, Srinagar, J&K.

4.2.13. Seminar on IPR and Public Health

The CCRUM organized National Seminar on 'Intellectual Property Rights (IPR) and Public Health Research: Way Forward in Unani Medicine' at EMMRC Auditorium, University of Kashmir, Srinagar on October 03, 2022.

Addressing the seminar, Prof. Asim Ali Khan, Director General, CCRUM said that the recent pandemic of Covid-19 has pressed the need to focus our efforts on public health research. Unani Medicine which provides preventive, promotive, curative, and rehabilitative health care has much to offer for public health.

Speaking as the chief guest, Prof. Nilofer Khan, Vice Chancellor, University of Kashmir, Srinagar emphasized the potential of Indian traditional systems of medicine, including Unani Medicine, and its possible applications in Intellectual Property Rights.

Dr. Khursheed Bakshi, Institute of Asian Medical Sciences, Zakura, J&K, Dr. Nisar Ahmad Mir, Registar, University of Kashmir and Prof. Afzal Zargar, Registrar, Central University of Kashmir, J&K also addressed the inaugural session.

The inaugural session concluded with a vote of thanks proposed by Dr. Seema Akbar, Assistant Director Incharge, Regional Research Institute of Unani Medicine, Srinagar. Dr. Nighat Anjum, Research Officer (Unani) Scientist-III conducted the proceedings of the inaugural event. The seminar had meaningful deliberations on the theme of the seminar.

4.2.14. Seminar on Intellectual Property Rights

The CCRUM in collaboration with National Medicinal Plants Board (NMPB), Ministry of Ayush, Government of India organized a National Seminar on "Intellectual Property Rights (IPR)" at its Central Research Institute of Unani Medicine (CRIUM), Lucknow on August 30, 2022.

Shri Pramod Kumar Pathak, Special Secretary to the Government of India, Ministry of Ayush was Chief Guest of the function. He highlighted the mandate of the Ministry of Ayush and support provided for the overall development of Unani Medicine. He stressed the importance of obtaining patents particularly for innovations in the field of Ayush systems.

Speaking as the guest of honour, Prof. Javed Musarrat, Vice Chancellor, Integral University, Lucknow emphasized the potential of Indian traditional systems of medicine, including Unani Medicine and its possible applications in IPR.

Prof. Asim Ali Khan, Director General, CCRUM, Ministry of Ayush gave a brief overview of the functioning of the CCRUM and highlighted its achievements in the area of IPR.

The inaugural session concluded with the vote of thanks proposed by Dr. Mohammad Nafees Khan, Deputy Director Incharge, CRIUM, Lucknow.

The seminar had two technical sessions and provided a platform to academia, researchers, regulators, industrialists and students to develop an understanding of IPR, innovations and practices, and promoting Unani Medicine across the globe.

4.2.15. Ayush Minister Inaugurates Unani and Homoeopathy Research Building at Navi Mumbai

Shri Sarbananda Sonowal, Hon'ble Union Cabinet Minister of Ayush and Ministry of Ports, Shipping & Waterways inaugurated the combined building complex of Regional Research Institute of Unani Medicine (RRIUM) and Regional Research Institute for Homoeopathy (RRIH) in Khargar, Navi Mumbai on July 30, 2022.

Shri Prashant Thakur, Hon'ble MLA, Panvel, Prof. Asim Ali Khan, Director General, CCRUM, Dr. Subhash Kaushik, Director General, Central Council for Research in Homoeopathy, Dr. Sangeeta A. Duggal, Advisor (Homoeopathy), Ministry of Ayush, Dr. Anil Khurana, Chairman, National Commission for Homoeopathy and Dr. Raj K. Manchanda, Director of Ayush, Government of NCT of Delhi were present on the occasion.

In his inaugural speech, Hon'ble Minister Shri Sarbananda Sonowal re-iterated that the principles and practices of Ayush systems need to be validated to pave way for further



advancements in medical sciences. He opined that the research institutes of Ayush systems are therefore of paramount importance, which the Ministry of Ayush is developing.

The building inaugurated houses RRIUM, Mumbai & RRIH, Navi Mumbai, the regional research institutes of CCRUM and CCRH, respectively. The three-story building has been constructed on a plot of 1999.82 sqm by City and Industrial Development Corporation. Besides conducting research, the institutes will provide healthcare facilities to the masses.

4.2.16. Refresher Training Program for Community Health Officers (CHOs)

The CCRUM organised a two-day refresher training program for Community Health Officers (CHOs) under Unani stream of Ayush Health & Wellness Centres on June 7–8, 2022.

Inaugurating the online training program, Shri D. Senthil Pandiyan, Joint Secretary, Ministry of Ayush, Government of India said that Ayush systems can play an important role in addressing the growing burden of non-communicable diseases (NCDs). He further said that through the Ayush Health and Wellness Centres (AHWCs) under Ayushman Bharat, a flagship scheme of Government of India, the target is to achieve Universal Health Coverage (UHC). He added that AHWCs would enable demonstration of the effectiveness of Ayushbased wellness model in the strengthening of comprehensive primary healthcare with primary focus on preventive and promotive interventions and would help in reducing disease burden and out of pocket expenditure by educating the masses and providing informed choices.

Earlier in his introductory remarks, Prof. Asim Ali Khan, Director General, CCRUM said that the training program is to refresh the skills of CHOs and enable them to provide comprehensive primary health care services to the community. He further said that the CCRUM has already developed 'Orientation Guidelines for Community Health Officers (Under Unani Stream)' which provides an initial structure for capacity building of Community Health Officers and their team, comprehensive information on different activities to be undertaken at AHWCs and description of practices for promotion of health, prevention and control of diseases through Unani measures and interventions.

The inaugural program concluded with vote of thanks proposed by Dr. M. A. Qasmi, Adviser (Unani), Ministry of Ayush, Government of India.

The training program had presentations on the twelve service delivery areas designed for AHWCs being operationalized by the Ministry of Ayush, Government of India. The trainees were provided practical information on service delivery framework, healthy practices to be followed on daily basis for preservation of health, and prevention and control of disease.

4.2.17. Lecture on Application of Artificial Intelligence in Unani Medicine

The CCRUM organised a lecture on 'Artificial Intelligence (AI) in Unani Medicine: Core Concepts, Clinical Applications and Perspectives' at Ayush Auditorium, Janakpuri, New Delhi on October 18, 2022.

In his introductory remarks, Prof. Asim Ali Khan, Director General, CCRUM stressed the need of tapping the potential of information technology and artificial intelligence for faster growth and development of Unani Medicine and accurate outcomes in research and development activities.

Delivering his extensive lecture on AI, Dr. Khalid Raza, Assistant Professor, Jamia Millia Islamia, New Delhi highlighted important perspectives about incorporation of AI in Unani

Medicine and suggested six key initiatives: (1) Creation of expert system for Unani Medicine for automated query-answering; (2) Al-driven novel Unani formulation; (3) Computational validation of existing Unani formulations and profiling; (4) Development of Al-driven diagnosis methods in Unani Medicine; (5) Personalized Unani Medicine: Considering temperaments (Mizāj) in drug design and discovery; and (6) Bringing Unani Medicine to Digital Medicine.

The lecture concluded with a vote of thanks proposed by Dr. Naheed Parveen, Assistant Director (Unani), CCRUM. Dr. Ritu Karwasra, Research Officer (Clinical Pharmacology), CCRUM, coordinated the lecture as compere.

4.2.18. Sensitization Program on Ayush Information Hub

The CCRUM organized a sensitization program for execution of project related to collection, digitization and uploading of information/documents, having archival value, on Ayush Information Hub (AIH) on June 14, 2022 in New Delhi.

A central team of AIH from National Institute of Indian Medical Heritage (NIIMH), Hyderabad conducted the sensitization program of AIH.

The team provided hands-on-training to each section of the CCRUM headquarters during June 14-20, 2022.

4.2.19. Lecture on Early Detection and Prevention of Diabetes Mellitus

The RRIUM, Chennai organized an awareness lecture on "Early Detection and Prevention of Diabetes Mellitus" on November 14, 2022 to mark World Diabetes Day.

Dr. N. Zaheer Ahmed, Deputy Director, RRIUM, Chennai presided over the event and gave his remarks. On the occasion, screening of non-diabetic patients (NDP) aged 40 years and above for GRBS & urine test was also carried out.

4.2.20. Lecture on Drug Standardization

The Drug Standardisation Research Unit (DSRU) under the CCRUM organized a guest lecture on 'Advanced Analytical Methods in Drug Standardisation' at Ayush Auditorium, Janakpuri, New Delhi on August 25, 2022.

Speaking on the occasion, Prof. Asim Ali Khan, Director General, CCRUM informed that the objective of drug standardization programme of CCRUM is to develop pharmacopoeial standards for single and compound Unani drugs for incorporation in the Unani Pharmacopoeia of India and National Formulary of Unani Medicine.

Participating as the guest of honour, Dr. Subhash Kaushik, Director General, Central Council for Research in Homoeopathy said that standardization of drug means confirmation of its identity and determination of its quality and purity. He further said that the quality of herbal drugs is the sum of all factors, which contribute directly or indirectly to the safety, effectiveness, and acceptability of the product.

Dr. Sayeed Ahmad, Associate Professor, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi delivered a comprehensive lecture on advanced analytical methods for standardization and quality control of herbal drugs.

4.3. Participation in Arogya Fairs/ Expos

The Ministry of Ayush, Government of India in collaboration with state governments and other stakeholders organizes and participates in Arogya fairs/expos and similar events to



propagate Indian systems of medicine, highlight activities and achievements of its research councils, provide free-of-cost diagnosis and treatment to the ailing visitors, and impart awareness about health, hygiene, and curative aspects of ill-health. The CCRUM and its institutes on the direction of the Ministry of Ayush participated in national and state level Arogya fairs and similar events held during the reporting period.

During all these events, the CCRUM showcased its progress in the area of clinical research, drug standardization, survey and cultivation of medicinal plants, and literary research. It also displayed posters and charts highlighting various concepts of Unani Medicine. Besides, some important publications of the CCRUM like Unani Pharmacopoeia of India, National Formulary of Unani Medicine, Hippocratic Journal of Unani Medicine, Standard Unani Medical Terminology, and Standard Unani Treatment Guidelines for Common Diseases were put on display. With a view to create awareness about healthy living and intervention of Unani Medicine in curing diseases and promoting health, free-of-cost literature on Unani Medicine and success stories on treatment of some chronic and common diseases were distributed among the visitors. The CCRUM also deployed its physicians to provide free consultation and treatment to the ailing visitors seeking Unani treatment. Lectures on various health issues were also delivered by CCRUM researchers. The list of the events is as follows:

S. N.	Name of Event	Place	Duration
1.	State Arogya Fair	Varanasi, U.P.	February 24-27 2023
2.	National Arogya Fair	Guwahati, Assam	March 2–5 2023
3.	Yoga Mahotsava	New Delhi	March 13–14 2023
4.	Ayush Camp	Parliament House Annexe, New Delhi	March 20–24 2023
5.	State Arogya Fair	Varanasi, U. P.	February 24–27 2023
6.	National Tribal Festival	New Delhi	February 16–27 2023
7.	4th Health Tech India Exhibition	New Delhi	16–18 February 2023
8.	30th Edition of SATTE	Greater Noida, U. P.	February 9–11 2023
9.	12th East Himalayan Trade Expo	Guwahati, Assam	February 6–12 2023
10.	11th Mega Industrial Exhibition Expo	Vadodara, Gujarat	January 27–30 2023
11.	Bharat Parv	New Delhi	January 26-31 2023
12.	Ayurveda Parv	Puri, Odisha	January 20-22 2023
13.	Ayurveda Parv	Haryana	December 23–25 2022
14.	World Ayurvedic Congress	Goa	December 8–11 2022
15.	Rise in Uttar Pradesh	Ghaziabad, U.P.	November 22–24 2022
16.	State Arogya	Tanakpur, Uttrakhand	November 18–20 2022
17.	State Arogya	Bharatpur, Rajasthan	November 24–27 2022
18.	Ayurveda Parv	Nashik, Maharashtra	November 11–13 2022
19.	India International Trade Fair	New Delhi	November 14-27 2022
20.	Poshan Utsav	Jaipur, Rajasthan	September 29–October 01 2022
21.	Ayurveda Parv	Haryana West Bengal	October 7–9 2022
22.	12th East Himalayan Expo	Shillong, Meghalaya	October 12–19 2022
23.	CII Chandigarh Fair	Chandigarh	October 14–17 2022

S. N.	Name of Event	Place	Duration
24.	State Arogya	Aizawl, Mizoram	October 18–21 2022
25.	Ayurveda Parv	Siliguri, West Bengal	September 2–4 2022
26.	Ayurveda Parv	Imphal, Manipur	September 9–11 2022
27.	Ayurveda Parv	Shillong, Meghalaya	September 15-17 2022
28.	8th iPHEX 2022	Greater Noida, U. P.	September 21–23 2022
29.	Ayurveda Parv	Shirdi, Maharashtra	September 23–25 2022
30.	National Arogya Fair	Bengaluru, Karnataka	July 27-31 2022
31.	Ayurveda Parv	Jammu, J&K	July 1-3 2022
32.	Ayurveda Parv	Thiruvananthapuram,	June 3-5 2022
		Kerala	
33.	Yoga Fest	Guwahati, Assam	June 11-13 2022
34.	Yoga for Humanity	Mysuru, Karnataka	June 21-26 2022
35.	29th Edition of SATTE	Greater Noida, U. P.	May 18–20 2022
36.	Global Ayush Summit-WHO	Ahmedabad, Gujarat	April 19–22 2022

4.4. Participation in Promotion of Official Language

The CCRUM puts its best efforts for promotion of the official language in day-to-day functioning and adopts appropriate measures as per time-to-time instructions and guidance from the Department of Official Language. The CCRUM has central as well regional official language implementation committees at its headquarters and regional research institutes/centres that monitor and review the status of the use of Hindi language in official dealings.

The third sub-committee of the Committee of Parliament on Official Language conducted review of the CCRUM headquarters on April 09, 2022 and review of five of its institutes namely DSRU, New Delhi, RRIUM, Aligarh, RRIUM, Srinagar, RRIUM, New Delhi, and NRIUMSD, Hyderabad on April 09, May 13, July 05, October 06, and November 07, 2022 respectively. The CCRUM achieved success in the review of its headquarters, DSRU, New Delhi, RRIUM, Srinagar and NRIUMSD, Hyderabad. Initially unsuccessful in the review, the RRIUM, Aligarh also attained success after six months. The second review report for RRIUM, New Delhi, which could not be considered successful by the committee during the original review, was awaited at the end of the reporting period.

The CCRUM conducted review meetings, organized Hindi workshops and observed Hindi Pakhwada at its headquarters and institutes during the period under report. The Pakhwada was observed to mark Hindi Diwas on September 14 and motivate employees to create an environment for implementation of the Official Language Policy in day-to-day work.

Apart from organizing the Hindi Pakhwada, the CCRUM participated in the meetings of Town Official Language Implementation Committee and meetings of the Ministry of Ayush pertaining to the official language. The Rajbhasha Section conducted quarterly meetings of official language implementation committee wherein matters related to the organization of workshops, promotion of letter writing in Hindi, review of Hindi works in various sections of the CCRUM, review of quarterly reports of various institutes/centres, etc. were discussed and specific strategy was formulated. Besides, information, education, and communication materials related to the promotion of Unani Medicine were printed in Hindi for distribution in health camps, Arogya fairs, and exhibitions.



4.5. Appointments

- Dr. Abdullah was appointed Research Officer (Unani) at RRIUM, Silchar on April 01, 2022.
- Dr. Mohammad Abdullah was appointed Research Officer (Unani) at CRU, Burhanpur on April 01, 2022.
- Dr. Manumula Komala was appointed Research Officer (Unani) at NRIUMSD, Hyderabad on April 20, 2022.
- Dr. Manumula Rajaram was appointed Research Officer (Unani) at NRIUMSD, Hyderabad on October 14, 2022.
- Dr. Durgesh Kumar Dwivedi was appointed Research Officer (Clinical Pharmacology) at NRIUMSD, Hyderabad on December 31, 2022.

4.6. Promotions

- Dr. Naheed Parveen was promoted as Deputy Director General at CCRUM headquarters, New Delhi on March 13, 2023.
- Dr. Ahmad Minhajuddin was promoted as Director at NRIUMSD, Hyderabad on March 13, 2023.
- Shri Harish Arya was promoted as Assistant Director (Administration) at CCRUM headquarters, New Delhi on February 01, 2023.
- Mohammad Parvez was promoted as Administrative Officer at CCRUM headquarters, New Delhi on March 23, 2023.
- Shri Harender Singh Thapa was promoted as Research Officer (Statistics) at CCRUM headquarters, New Delhi on June 29, 2022.
- Shri Syed Anvaruddin Kirmani was promoted as Junior Administrative Officer at RRIUM, Chennai on February 03, 2023.
- Mohd. Asif Abbasi was promoted as Junior Administrative Officer at RRIUM, New Delhi on February 03, 2023.
- Shri N. P. Sharma was promoted as Junior Administrative Officer at RRIUM, Aligarh on February 03, 2023.
- Smt. Gayatri Chawla was promoted as Junior Administrative Officer at CCRUM headquarters, New Delhi on February 03, 2023.
- Shri Hashmi Syed Tayyab was promoted as Junior Administrative Officer at RRIUM, Mumbai on February 03, 2023.
- Smt. Zaibunnisa Begum was promoted as Assistant at NRIUMSD, Hyderabad on March 24, 2023.
- Smt. Rubina Abbasi was promoted as Assistant at CCRUM headquarters, New Delhi on March 24, 2023.
- Shri Hilal was promoted as Assistant at CRU, Meerut on March 24, 2023.
- Shri Rattan Kumar was promoted as Assistant at CCRUM headquarters, New Delhi on March 24, 2023.
- Shri Shyam Kumar was promoted as Assistant at CCRUM headquarters, New Delhi on March 24, 2023.



- Shri Syed Meirajul Yasin was promoted as Assistant at RRIUM, Srinagar on March 24, 2023.
- Smt. Indraveni was promoted as Assistant at NRIUMSD, Hyderabad on March 24, 2023.
- Shri Rehmatullah Khan was promoted as Assistant at HAKILHRUM, New Delhi on March 24, 2023.
- Shri Rizwanuddin was promoted as Assistant at CCRUM headquarters, New Delhi on March 24, 2023.
- Shri L. Bichaya was promoted as Assistant at NRIUMSD, Hyderabad on March 24, 2023.

4.7. Retirements

- Smt. Shashi Bala Sharma, Assistant at CCRUM headquarters, New Delhi retired on superannuation on April 30, 2022.
- Shri Ghulam Rasool Bhat, Attendant at RRIUM, Srinagar retired on superannuation on April 30, 2022.
- Shri Shafi Ahmad, Messenger at RRIUM, Patna retired voluntarily on April 09, 2022.
- Shri Sudhanshu S. Rout, MTS at RRIUM, Bhadrak retired on superannuation on May 31, 2022.
- Shri Onnittan M. A., Assistant at CRU, Bhopal retired on superannuation on May 31, 2022.
- Dr. Syed Ahmed Khan, Assistant Director (Unani), CCRUM headquarters, New Delhi retired on superannuation on May 31, 2022.
- Shri Silinbder Singh, Radiographer at RRIUM, Srinagar retired on superannuation on May 31, 2022.
- Shri Mohammad Hashim, Driver at RRIUM, New Delhi retired on superannuation on June 30, 2022.
- Shri Vithal Narayan Parab, MTS at RRIUM, Mumbai retired on superannuation on June 30, 2022.
- Mohammad Reazuddin, Driver at RRIUM, Kolkata retired on superannuation on July 31, 2022.
- Shri Riyazuddin, Chowkidar at RRIUM, Aligarh retired on superannuation on August 31, 2022.
- Shri Parvez Akhtar, Assistant at RRIUM, Patna retired on superannuation on August 31, 2022.
- Dr. Hakimuddin Khan, Deputy Director, RRIUM, Bhadrak retired on superannuation on August 31, 2022.
- Smt. Roofa Qadri, UDC at RRIUM, Srinagar retired voluntarily on September 01, 2022.
- Dr. Rafat Khanam, Research Officer (Unani), CRIUM, Lucknow retired on superannuation on September 30, 2022.
- Shri Kapil Charan Sethi, Storekeeper at RRIUM, Bhadrak retired on superannuation on October 31, 2022.
- Shri Ghulam Murtaza, MTS (Cook) at CRIUM, Lucknow retired on superannuation on October 31, 2022.



- Shri Kushal Pal Singh, Lab Technician at RRIUM, Aligarh retired on superannuation on November 30, 2022.
- Mohammad Sabir, Assistant at CRIUM, Lucknow retired on superannuation on December 30, 2022.
- Dr. T. Shahida Begum, Research Officer (Unani) at RRIUM, Chennai retired voluntarily on December 08, 2022.
- Smt. Sathi Vipin Kumar, Junior Administrative Officer at RRIUM, Mumbai retired on superannuation on January 31, 2023.
- Shri Vinod Kumar, MTS at RRIUM, New Delhi retired voluntarily on February 01, 2023.
- Shri Abdul Mobin Khan, Pharmacist at CRIUM, Lucknow retired on superannuation on February 28, 2023.
- Shri Ramzan Khan, UDC at CCRUM headquarters, New Delhi retired on superannuation on February 28, 2023.

4.8. Deaths

 Shri Rajinder Mehra, UDC at CCRUM headquarters, New Delhi died in harness on June 02, 2022.



5. FINANCIAL STATEMENT

5.1. Audit Report

SEPARATE AUDIT REPORT OF THE COMPTROLLER & AUDITOR GENERAL OF INDIA ON THE ACCOUNTS OF CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE FOR THE YEAR ENDED 31 MARCH 2023

We have audited the attached Balance Sheet of Central Council for Research in Unani Medicine (Council) as at 31 March 2023, the Income & Expenditure Account and Receipts & Payments Account for the year ended on that date under Section 20(1) of the Comptroller and Auditor General's (Duties, Powers & Conditions of Service) Act, 1971. The audit has been entrusted for the period upto 2023–24. These financial statements include the accounts of nine regional offices of the Council. These financial statements are the responsibility of the Council's management. Our responsibility is to express an opinion on these financial statements based on our audit.

- 2. This Separate Audit Report contains the comments of the Comptroller and Auditor General of India on the accounting treatment only with regard to classification, conformity with the best accounting practices, accounting standards and disclosure norms, etc. Audit observations on financial transactions with regard to compliance with the Laws, Rules & Regulations (Propriety and Regularity) and efficiency-cum- performance aspects, etc., if any, are reported through Inspection Reports/Comptroller and Auditor General's Audit Reports separately.
- 3. We have conducted our audit in accordance with auditing standards generally accepted in India. These standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatements. An audit includes examining, on a test basis, evidences supporting the amounts and disclosure in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluating the overall presentation of financial statements. We believe that our audit provides a reasonable basis for our opinion.
- 4. Based on our audit, we report that:
 - (i) We have obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purpose of our audit.
 - (ii) The Balance Sheet, Income & Expenditure Account and Receipts & Payments Account dealt with by this report have been drawn up in the format approved by the Ministry of Finance, Government of India.
 - (iii) In our opinion, proper books of accounts on double entry system of accounting have been maintained by the Council in so far as it appears from our examination of such books.
 - (iv) We further report that:
 - A. Balance Sheet
 - A.1. Assets
 - A.1.1. Fixed Assets (Schedule 8): ₹124.45 crore
 - A.1.1.1 The Council had awarded the work related to the construction of Regional Research Institute of Unani Medicine (RRIUM), Silchar, Assam to M/s National Projects Construction Corporation Limited (NPCC). As per Fund Utilisation Statement, total expenditure incurred was ₹ 50.83

crore, out of which the Council has paid ₹ 46.30 crore. The building has been handed over to the Council on 08 October 2022 and was inaugurated on 20 November 2022.

Since March 2021, the Council has not included the funds amounting to ₹ 20.17 crore under Work in Progress. As the building has been handed over to the Council, the same shall be included in the Fixed Assets (Schedule - 8) under the head 'Buildings'. The Council has not shown RRIUM, Silchar as its Building under Fixed Assets (Schedule 8). This has resulted in understatement of Fixed Assets (Building) by ₹ 46.30 crore and overstatement of Work-in-Progress by ₹ 26.13 crore and overstatement of Advances by ₹20.17 crore.

B. Income and Expenditure Account

B.1. As per Uniform Format of Accounts, Grant-in-Aid should be properly segregated and only grant for revenue purpose is recognised as income in income & expenditure account. The grant for capital expenditure should be routed through Balance Sheet. The Council received ₹ 4.87 crore as Capital Grants and taken it as income in Income & Expenditure Accounts by the Council. This has resulted in overstatement of Income as well as overstatement of Excess of Income over Expenditure by ₹4.87 crore. Similar observation was issued to the Council on accounts for the year 2020–21 (Comment No. A.1.1.1) and for the year 2021-22 (Comment No. B.3). However, no remedial action has been taken by the Council.

In its reply, Council assured that the grant of capital and revenue nature would be segregated accordingly in next year's annual accounts.

- B.2. The Council has shown an amount of ₹ 1.80 crore as part of Schedule 18 (Other Income) under the head 'OPD/Regn fee from patients'. However, it may be shown as Income from Sales/Services. This resulted in understatement of Income from Sales/Service and overstatement of Other Income by ₹ 1.80 crore.
- B.3. The Council has shown an amount of ₹ 74.29 lakh as 'NPS Corpus Amount received from PFRDA in Schedule 18 (Other Income). This includes the part of Government contribution which should have been refunded to the Ministry. However, as per Schedule 20 (Establishment Expenses) of the Income & Expenditure Accounts, the Council has refunded ₹ 30.13 lakh. This has resulted in overstatement of Income and understatement of Current Liabilities & Provisions (Schedule 7) by ₹44.16 lakh.

C. General

- C.1. The Council has outstanding Contingent Advances of ₹ 10.98 crore since 2000–01. The Council needs to review and adjust these advances at the earliest.
- C.2. The Council has pending Capital work in progress amounting ₹ 46 crore of the period 1985–86 to 2012–13. These work in progress are related to various RRIUM and lying incomplete despite considerable time been

lapsed. The Council need to adjust/expedite the work towards completion/adjustment.

- C.3. The provision for retirement benefit was not made as per Actuarial valuation as prescribed in AS-15.
- C.4. The Council had not disclosed the details of lands purchased/received as gift or received on lease basic etc. in the Annual Accounts.

D. Grants-in-Aid

(i) Health Account

The Council had received Grants in Aid of ₹ 173.42 crore during 2022–23. The Council had an unspent balance of Grants-in-Aid of ₹ 4.41 crore of previous year and had earned interest on Grants-in-aid during the year of ₹ 65.87 lakh. The Council utilized a sum of ₹ 175.93 crore leaving unspent balance of ₹ 2.56 crore (Capital - ₹1.90 crore & interest on Grants-in-aid - ₹ 65.87 lakh) as on 31 March 2023.

(ii) Specific Project Account

The Council has not received any specific project grant but has an unspent balance of previous year of ₹ 63.45 lakh. It had its own receipt of ₹ 5.3 lakh. Thus, out of available amount of ₹ 68.75 lakh, Council utilized ₹ 33.71 lakh, leaving an unutilized balance of ₹ 35.04 lakh as on 31 March 2023.

E. Management Letter

Deficiencies which have not been included in the Audit Report have been brought to the notice of management of the Council through a management letter issued separately for remedial/corrective action.

- (v) Subject to our observations in the preceding paragraphs, we report that the Balance Sheet, Income & Expenditure Account and Receipts & Payments Account dealt with by this report are in agreement with the books of accounts.
- (vi) In our opinion and to the best of our information and according to the explanations given to us the said financial statements read together with the Accounting Policies and Notes on Accounts and subject to the significant matters stated in comment no B.1 above and other matters mentioned in audit report and annexure to this Audit Report, do not give a true and fair view in conformity with accounting principles generally accepted in India.
 - a. In so far as it relates to the Balance Sheet, of the state of affairs of the Central Council for Research in Unani Medicine as at 31 March 2023 and
 - b. In so far as it relates to Income and Expenditure Account of the surplus for the year ended on that date.

For and on behalf of C&AG of India

(Sd/) Rajiv Kumar Pandey Director General of Audit (Central Expenditure)

Place: New Delhi Date: 30.01.2024



ANNEXURE

1. Adequacy of internal audit system

The internal audit of the Council was conducted upto 2018–19 by the Ministry of Health & Family Welfare. However, report is yet to be received.

2. Adequacy of internal control system

Internal control system was not adequate as risk assessment was not done by the management. Further, 16 paras pertaining to the period 2014–19 were outstanding for settlement.

3. System of physical verification of fixed assets

The physical verification of fixed assets was conducted up to 2022–23 and no discrepancy was reported. Physical verification of fixed assets at RRIUM, Okhla has not been conducted.

4. System of physical verification of inventory

- (a) The physical verification of Library Books at Council Headquarters was conducted upto 31.03.2023. However, physical verification of Priced Publication is pending for the period from 2017–18 to 2022–23.
- (b) Physical verification of stationery and consumables etc. was conducted upto 2022–23.
- (c) Physical verification of books and publications at RRIUM, Okhla has not been conducted.

5. Regularity in payment of statutory dues

As per accounts, no payments for over six months in respect of statutory dues were outstanding as on 31.03.2023.



5.2. Audited Statement of Accounts

Index of the Annual Accounts for the Year 2022–2023

S. No.	Name of the Accounts	Page No.	Schedules at Page No.
1.	Balance Sheet	94	104–117
2.	Income & Expenditure Account	95	118–129
3.	Receipt & Payment Account	96–103	130–165
4.	Notes on Accounts	166	-



Balance Sheet as on 31st March 2023

Corpus/Capital Fund and Liabilities	Schedule	Current Year	Previous Year
Corpus/Capital Fund	1	134,62,46,983.13	133,47,59,265.00
Reserve and Surplus	2	-	-
Earmarked/Endowmend Funds	3	35,03,727.00	61,54,940.50
Secured Loans and Borrowings	4		
Unsecured Loans and Borrowings	5		1
Deferred Credit Liabilities	9		•
Current Liabilities and Provisions	7	33,09,77,046.84	115,32,34,172.54
Current Liabilities and Provisions (Other A/Cs)		88,58,68,072.96	1
	Total	256,65,95,829.93	249,41,48,377.04
Assets	Schedule	Current Year	Previous Year
Fixed Assets	8	124,46,88,837.00	1,25,94,35,575.00
Investments-from Earmarked/Endowment Funds	o		1
Investments Others	10	67,60,27,854.99	66,08,31,199.99
Current Assets, Loans, Advances, etc.	11	64,58,79,138.44	57,38,81,602.05
Current Assets (Other A/Cs)			1
	Total	256,65,95,829.93	249,41,48,377.04
	-		

(Dr. N. Zaheer Ahmed) Director General

(Shakaib Hasan) Consultant (IA)

(Mohammad Parvez) Administrative Officer

(Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Incharge

Income & Expenditure A/c for the Year Ending 31st March 2023

Income	Schedule	Current Year	Previous Year
Income from Sales/Services	12	ı	
Grants	13	173,42,56,000.00	1,56,28,56,498.00
Fees	14	47,86,680.00	37,36,420.00
Income from Investments (Income on Invest from earmarked/endow. Funds transferred to Funds)	.0 15	1	1
Income from Publication, etc.	16	98,722.00	1,38,471.00
Interest Earned	17	65,87,434.00	66,55,613.00
Other Income	18	2,99,27,036.01	2,92,55,460.00
Less: Capitalized	19	•	(-)84,29,056.00
Total (A	T	177,56,55,872.01	1,59,42,13,406.00
Expenditure	Schedule	Current Year	Previous Year
Establishment Expenses	20	+30,13,061.00 111,14,35,795.00	107,82,86,226.00
Other Administrative Expenses etc.	21 (A-D)	63,49,73,215.88	41,62,57,619.00
Expenditure on Grants, Subsidies etc.	22		
Interest	23		1
Unspent Balance 2020-2021	FW -21 (E)		
Depreciation (Net Total at the Year End – Corresponding to Schedule 8)	H - 21 (E)	1,94,65,525.00	2,09,79,090.00
Total (B)	3)	176,88,87,596.88	1,51,55,22,935.00
Balance Being Excess of Income Over Expenditure (A-B)		67,68,275.13	7,86,90,471.00 1,44,43,502.00
Balance being Surplus/(Deficit) Carried to Capital Fund		67,68,275.13	6,42,46,969.00

(Dr. Ram Pratap Meena) Sd/-

> (Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Receipt & Payment A/c for the Year Ending 31st March 2023

Total Health A/C Other Specific A/C Pension NPS A/C Specific A/C NPS A/C NPS A/C Specific A/C NPS A/C NPS A/C Specific A/	U.	Receipts		Curren	Current Year			Previous Year	Is Year	
Pension Pens	Z		Health A/c	Other	GPF/GIS/	Total		Other Specific	GPF/GIS/	Total
Opening Balance 5,83,336.22 4,48,000.00 - Cash-in-Hand 5,83,336.22 4,48,000.00 - Climprest) Charles (17,272.15) 63,45,172.5010,69,39,759.97 15,68,57,204.84 1,39,95,502.002,85,06,985.00 7,97,98,638.57 Total (1) 4,41,55,608.37 63,45,172.5010,69,39,759.97 15,74,40,540.84 1,44,43,502.002,85,06,985.00 7,97,38,638.57 Grant in Aid A,87,50,000 A,87,50,000 6,56,00,000 6,56,00,000 - Revenue 168,556,000 0 173,42,56,000 0 173,42,56,000 - Revenue 168,556,000 0 6,56,000,000 6,56,000,000 - - Revenue 168,556,000 0 173,42,56,000 0 6,56,000,000 - - Revenue 168,556,000 0 0 173,42,56,000 0 - - Revenue 168,556,000 0 0 0 173,42,56,000 0 - - - - - - - - -					Pension NPS A/c			Νc	Pension NPS A/c	
Cash at Bank 4,35,72,272.15 63,45,172.5010,69,39,759,97 15,68,57,204.84 1,39,95,502.002,85,00,985.00 7,97,98,638.57 Total (I) 4,41,55,608.37 63,45,172.5010,69,39,759,97 15,74,40,540.84 1,44,43,502.002,85,06,985.00 7,97,98,638.57 Total (I) 4,87,50,000.00	-	Opening Balance								
Cash at Bank 4,35,72,272.15 63,45,172.50 10,69,39,759.97 15,68,57,204.84 1,39,95,502.00 2,85,06,985.00 7,97,98,638.57 Total (I) 4,41,55,608.37 63,45,172.50 10,69,39,759.97 15,74,40,540.84 1,44,43,502.00 2,85,06,985.00 7,97,98,638.57 Grant in Aid From Govt. of India 4,87,50,000.00 4,87,50,000.00 4,87,50,000.00 6,56,00,000.00			5,83,336.22			5,83,336.22	4,48,000.00	-	-	4,48,000.00
Aid vt. of India 4,41,55,608.37 63,45,172.50 0,69,39,759.97 15,74,40,540.84 1,44,43,502.00 2,85,06,985.00 7,97,98,638.57 Aid vt. of India 4,87,50,000.00 4,87,50,000.00 6,56,00,000.00 - - om seceived 173,42,56,000.00 0	b.		4,35,72,272.15		10,69,39,759.97	15,68,57,204.84	1,39,95,502.00		7,97,98,638.57	12,23,01,125.57
Ajd vt. of India Ajd Avt. of India		Total (I)	4,41,55,608.37	63,45,17	10,69,39,759.97	15,74,40,540.84	1,44,43,502.00		7,97,98,638.57	12,27,49,125.57
vt. of India 4,87,50,000.00 6,56,00,000.00 - - 168,55,06,000.00 168,55,06,000.00 151,17,00,000.00 84,00,000.00 - 173,42,56,000.00 0 0173,42,56,000.00 157,73,00,000.00 84,00,000.00 - om 173,42,56,000.00 0 0173,42,56,000.00 157,73,00,000.00 84,00,000.00 - om 173,42,56,000.00 0 0173,42,56,000.00 157,73,00,000.00 84,00,000.00 - om 173,42,56,000.00 0 0173,42,56,000.00 157,73,00,000.00 84,00,000.00 - 342334937.85 SE Funds 0 028,97,08,798.40 28,97,08,798.40 - - - 342334937.85 Received 0 028,97,08,798.40 95,25,522.00 62,34,578.00 6,65,085.00 66,22,547.00 ome 1,31,055.00 1,31,055.00 4,21,035.00 - - - - ome 1,31,055.00 4,21,035.00 - - - - - - om	=	Grant in Aid								
4,87,50,000.00 4,87,50,000.00 6,56,00,000.00 -		From Govt. of India								
168,55,06,000.00 168,55,06,000.00 168,55,06,000.00 173,42,578.00 173,42,34937.85 173,43,437.00 173,43,437.00 173,43,437.00 173,43,578.00	a.		4,87,50,000.00			4,87,50,000.00		-		6,56,00,000.00
173,42,56,000.00 0 0173,42,56,000.00 84,00,000.00 84,00,000.00 - - - - - - 342334937.85 - - - 342334937.85 - - - - 342334937.85 -	b.		168,55,06,000.00			168,55,06,000.00	151,17,00,000.00	84,00,000.00	-	152,01,00,000.00
of nislan Funds Lagrange Color (1,56,992.00) 31,80,526.00 et al. 88,004.00 Lagrange Color (1,31,055.00) Lagrange Color (1,			173,42,56,000.00	0	0	173,42,56,000.00	157,73,00,000.00	84,00,000.00		158,57,00,000.00
of nsion Funds Funds 0 028,97,08,798.40 28,97,08,798.40 342334937.85 eived	≡	. Income from		. 4	28,97,08,798.40	28,97,08,798.40		1	342334937.85	34,23,34,937.85
ved 61,88,004.00 1,56,992.00 31,80,526.00 95,25,522.00 62,34,578.00 6,65,085.00 66,22,547.00 1,31,055.00 1		Investments of GPF/GIS/Pension fund & NPS Funds								
ved 61,88,004.00 1,56,992.00 31,80,526.00 95,25,522.00 62,34,578.00 6,65,085.00 66,22,547.00 61,88,004.00 1,56,992.00 31,80,526.00 95,25,522.00 62,34,578.00 6,65,085.00 66,22,547.00 1,31,055.00 1,31,055.00 4,21,035.00 - - -		Total (III)	0	0	28,97,08,798.40		1	•	342334937.85	342334937.85
61,88,004.00 1,56,992.00 31,80,526.00 95,25,522.00 62,34,578.00 6,65,085.00 66,22,547.00 61,88,004.00 1,56,992.00 31,80,526.00 95,25,522.00 62,34,578.00 6,65,085.00 66,22,547.00 1,31,055.00 1,31,055.00 4,21,035.00 - - -	-	/Interest Received								
61,88,004.00 1,56,992.00 31,80,526.00 95,25,522.00 62,34,578.00 6,65,085.00 66,22,547.00 1,31,055.00 4,21,035.00 - - - -	a	. Bank Interest	61,88,004.00		31,80,526.00		62,34,578.00	6,65,085.00	66,22,547.00	1,35,22,210.00
1,31,055.00 - 1,31,055.00		Total (IV)	61,88,004.00	1,56,992.00	31,80,526.00	95,25,522.00	62,34,578.00	6,65,085.00	66,22,547.00	1,35,22,210.00
- 1,31,055.00 e 1,31,055.00	>	. Other Income								>
	а	. Interest on Refundable Advances	1,31,055.00			1,31,055.00	4,21,035.00	•	ı	4,21,035.00

(Dr. Ram Pratap Meena)

(Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Research Officer (Chemistry)/ Administrative Incharge

Receipt & Payment A/c for the Year Ending 31st March 2023

Sidlesex		Currer	Current Year			Previo	Previous Year	
	Health A/c	Other	GPF/GIS/	Total	Health A/c	Other Specific	GPF/GIS/	Total
		Specific A/c	Pension NPS A/c			A/c	Pension NPS A/c	
b. Other Misc. Income	2,18,30,386.51	3,56,025.00	56,63,661.00	2,78,50,072.51	2,92,57,554.00	ı	1	2,92,57,554.00
(As per Schedule H/8)								
c. Sale of Publications	98,722.00			98,722.00	1,38,431.00	•		1,38,431.00
d. Unani Academic	47,86,680.00			47,86,680.00	37,36,420.00	1	•	37,36,420.00
Courses Fee, etc.								
Total (V)	2,68,46,843.51	3,56,025.00	56,63,661.00	3,28,66,529.51	3,35,53,440.00	_	-	3,35,53,440.00
VI. Amount Borrowed					ī	T	-	-
VIIOther Receipts								
a. Refund against by	29,00,330.50			29,00,330.50	11,80,860.00			11,80,860.00
Adjustment of								
ances								
Pertaining to								
vious Year								
b. Recoveries of	8,28,971.00			8,28,971.00	18,05,883.00			18,05,883.00
Refundable								
Advances to Govt.								
Servants								
c. Recoveries for	1,64,25,419.00	16,598.00	1,84,09,262.00	3,48,51,279.00	13,40,27,532.00	17,356.00	17,356.00 1,02,01,093.00	14,42,45,981.00
Remittances								
d. Recoveries of			4,76,78,037.00	4,76,78,037.00	-	-	4,97,99,106.00	4,97,99,106.00
Subscription &								
Advance								

(Dr. N. Zaheer Ahmed) Director General (Dr. Ram Pratap Meena) Sd/-

Sd/-

Research Officer (Chemistry)/ Administrative Incharge

(Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Receipt & Payment A/c for the Year Ending 31st March 2023

	Total	95,000.00	39,57,095.00	10,825.00	22,78,569.00			5,00,000.00	36,62,17,877.00	1,25,12,634.00
Previous Year	GPF/GIS/ Pension NPS A/c	131	39,57,095.00					5,00,000.00	36,62,17,877.00	62,56,317.00
Previo	Other Specific A/c									
	Health A/c	95,000.00		10,825.00	22,78,569.00					62,56,317.00
	Total	1,50,000.00	88,53,280.82					2,00,000.00	32,53,79,943.00	
Current Year	GPF/GIS/ Pension NPS A/c							2,00,000.00	32,53,79,943.00	
Curre	Other Specific A/c									
	Health A/c	1,50,000.00	88,53,280.82							
Receipts		e. Security Deposit (CCRUM)	f. Receivable Amount Received	g In-Transit Amount Received	h. Amount Received but to be Refunded to Other	Decentralized Institutes	i. Investment Received	j. LIC Amount Received from LIC for Disbursement	k. Pension Fund Transfer from Health A/c Received in Pension Fund A/c	I. Govt. Contribution of Non-Pran Member
Ś	ż	9. 0.	4.	<u>-</u> Б	다 소요화	<u> </u>	. <u></u>	·	<u> </u>	
			L	·	l			·	l	

(Dr. N. Zaheer Ahmed) Director General

> (Shakaib Hasan) Consultant (IA)

(Mohammad Parvez) Administrative Officer

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)



Receipt & Payment A/c for the Year Ending 31st March 2023

S.	Receipts		Curre	Surrent Year			Previo	Previous Year	
ż		Health A/c	Other	GPF/GIS/	Total	Health A/c	Other Specific	GPF/GIS/	Total
			Specific A/c	Pension			A/c	Pension	
				NPS A/c				NPS A/c	
E.	m.Receipts on Closing Bank A/c					2,02,17,495.70			2,02,17,495.70
ے ا	n. NPS Corpus Amount	74,28,539.50			74,28,539.50	74,28,539.50 1,84,46,591.37		1,00,06,342.40	2,84,52,933.77
o.	o. Unspent Balance (Previous Year)					6,41,214.00			6,41,214.00
ō.	p. Unspent Balance (Current Year)	81,67,538.12			81,67,538.12	20,61,940.00			20,61,940.00
φ.	q. Interest on FDRs			1,51,96,655.00	1,51,96,655.00 1,51,96,655.00		_	2,95,49,938.00	2,95,49,938.00
ŗ.	r. Fund Transfer	1,97,50,400.00		1,73,45,900.00	00.006,36,900.00 3,70,96,300.00				
	Total (VII)	6,45,04,478.94		42,42,09,797.00	16,598.0042,42,09,797.00 48,87,30,873.94 18,70,22,227.07	18,70,22,227.07		47,64,87,768.40	17,356.00 47,64,87,768.40 66,35,27,351.47
			68,74,787.50	82,97,02,542.32	$187,59,50,933.82 \mid 68,74,787.50 \mid 82,97,02,542.32 \mid 271,25,28,263.64 \mid 181,85,53,747.07 \mid 3,75,89,426.00 \mid 90,52,43,891.80 \mid 2,76,13,87,064.87 \mid 187,59,50,933.82 \mid 187,59,79,79,79,79,79,79,79,79,79,79,79,79,79$	181,85,53,747.07	3,75,89,426.00	90,52,43,891.80	76,13,87,064.87
	VII) of Receipt Side								

(Dr. Ram Pratap Meena) Sd/-

> (Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Research Officer (Chemistry)/ Administrative Incharge

Receipt & Payment A/c for the Year Ending 31st March 2023

တ်	. Payments		Curre	Current Year			Previous Year	s Year	
Ż		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total
<u>-</u>	Expenses								
ю́.	Establishment Expense	102,88,84,495.00			102,88,84,495.00 107,82,86,226.00	107,82,86,226.00			107,82,86,226.00
	Total I	102,88,84,495.00			102,88,84,495.00 107,82,86,226.00	107,82,86,226.00			107,82,86,226.00
=		29,77,53,870.00		4,012.00	29,77,57,882.00 22,94,97,876.00	22,94,97,876.00			22,94,97,876.00
	Expense (Corresponding to Schedule 21)								
:= :	ii. Material & Supplies	20,99,95,515.00			20,99,95,515.00	9,45,10,750.00			9,45,10,750.00
i≡	. Other Charges	11,07,22,370.00 33,34,306.00	33,34,306.00		11,40,56,676.00	10,33,06,088.00	63,48,563.00		10,96,54,651.00
.≥	iv. Publication Expenses								
	Total (II)	61,84,71,755.00 33,34,306.00	33,34,306.00	4,012.00	62,18,10,073.00	42,73,14,714.00	63,48,563.00		43,36,63,277.00
=	III. Investment Made Out of GPF, GIS, Pension Fund & NPS A/c			30,49,05,453.35	30,49,05,453.35		34	45,18,85,170.90	45,18,85,170.90
	Total (III)			30,49,05,453.35	30,49,05,453.35		34	45,18,85,170.90	45,18,85,170.90
2	IV. Expenditure on Fixed Assets and Capital Work in Progress	3,38,55,422.00		ı	3,38,55,422.00	6,56,00,550.00			6,56,00,550.00
							=		

(Dr. N. Zaheer Ahmed) Director General

(Mohammad Parvez) Administrative Officer

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

(Shakaib Hasan) Consultant (IA)

Receipt & Payment A/c for the Year Ending 31st March 2023

	Payments		Curre	rrent Year			Previous Year	is Year	
		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total
P. Ÿ.	Purchase of Fixed Assets	47,19,443.00	ı	ı	47,19,443.00	64,59,180.00			64,59,180.00
בֿן	Fund Transfer	1	I	1,73,60,900.00	1,73,60,900.00				
PFI Ta	IPR Fund Transfer		I	ı	ı	20,00,000.00			20,00,000.00
1ot	Total (IV)	3,85,74,865.00		1,73,60,900.00	5,59,35,765.00	7,40,59,730.00			7,40,59,730.00
Ref	V. Refund of								
Sul	Surplus Money & Loans								
10	To Govt. of India								
ည်ကို	To the States Govt.								
ဂ္	To Other								
P	Provider of Funds								
트	VI. Finance Charges (Interest)								
듐	VII Other Payments								
4	a. Advances to	31,48,260.00		1	31,48,260.00	37,23,500.00			37,23,500.00
Reg	Remittance of	8,66,48,988.00	16598.	00 2,40,92,059.00	11,07,57,645.00	15,03,87,441.30	10,170.00	10,170.00 1,02,70,067.00	16,06,67,678.30
ا کِا	0,000								

Sd/-

(Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Receipt & Payment A/c for the Year Ending 31st March 2023

		0	0	0	0	То	Ю		0	[
	Total	55,47,118.00	6,64,920.00	78,823.00	1,91,12,259.00	4,00,000.00	32,41,77,261.00		2,07,57,457.00	2,02,16,763.88
Previous Year	GPF/GIS/ Pension NPS A/c	1,44,615.00				4,00,000.00	32,32,87,071.00		1,23,17,208.00	
Previo	Other Specific A/c				46,68,757.00					2,02,16,763.88
	Health A/c	54,02,503.00	6,64,920.00	78,823.00	1,44,43,502.00		8,90,190.00		84,40,249.00	
	Total		15,89,152.00		2,27,11,375.00	2,00,000.00	38,41,15,897.00			
rrent Year	GPF/GIS/ Pension NPS A/c					2,00,000.00	36,43,65,497.00			
Curre	Other Specific A/c				20,156.00					
	Health A/c		15,89,152.00		2,26,91,219.00		1,97,50,400.00			
Payments		Amount Payable Paid/Adjusted	Refund of EMD	Amount disburse to RRI Chennai	f. Unspent Balance Refunded to the Ministry of Avush	LIC Amount Received from LIC Disbursed	Other Misc. Payments, Transfer	Undisbursed Amount Disbursed	j. NPS Empl. Fund paid (Non-Pran)	Funds Transfer on Specific A/c Closure
တ်	z	ن ن	þ	e. t	+	Б	-i	:		₹ <u> </u>

(Dr. Ram Pratap Meena)

Research Officer (Chemistry)/ Administrative Incharge

(Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Receipt & Payment A/c for the Year Ending 31st March 2023

တ်	Payments		Curre	rrent Year			Previou	Previous Year	
ż		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total
-	I. Outstanding Advances	1,88,31,811.00			1,88,31,811.00	11,95,234.00			11,95,234.00
Ë	m. NPS corpus amount paid	30,13,061.00			30,13,061.00				
	Total (VII) (a to m) 15,56,72,891.00	15,56,72,891.00	36,754.	38,86,57,556.00	00 38,86,57,556.00 54,43,67,201.00 19,59,84,362.00 2,48,95,691.38 34,64,18,961.00 55,65,41,014.18	19,59,84,362.00	2,48,95,691.38	34,64,18,961.00	55,65,41,014.18
	VIII Closing Balance								
a.	Cash-in-Hand (Imprest)					3,88,250.00			
Ď.	b. Cash at Bank	3,43,46,927.82	35,03,727.50	11,87,74,620.97	3,43,46,927.82 35,03,727.50 11,87,74,620.97 15,66,25,276.29	4,25,20,464.97		10,69,39,759.97	15,61,93,647.44
	Total VIII (a+b)	3,43,46,927.82	35,03,727.50	11,87,74,620.97	$3,43,46,927.82 \mid 35,03,727.50 \mid 11,87,74,620.97 \mid 15,66,25,276.29 \mid 4,29,08,714.94 \mid 63,45,172.50 \mid 10,69,39,759.97 \mid 15,61,93,647.44$	4,29,08,714.94	63,45,172.50	10,69,39,759.97	15,61,93,647.44
	Total (I to VIII) of Payment Side	187,59,50,933.82	68,74,787.50	82,97,02,542.30	187,59,50,933.82 68,74,787.50 82,97,02,542.30 271,25,28,263.64 181,85,53,747.27 3,75,89,426.38 90,52,43,891.9 2,76,13,87,065.52	181,85,53,747.27	3,75,89,426.38	90,52,43,891.9	2,76,13,87,065.52

Sd/-

(Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Capital Fund of Balance Sheet for the Year Ending 31st March 2023 (Schedule-1)

s,		Current Year	ear	Previous Year	Year
ż		Health A/c	F.W.	Health A/c	F.W.
	Balance at the Beginning of the Year	133,47,59,265.00		1,24,76,37,800.00	1,938.00
	Addition During the Year	47,19,443.00		84,29,056.00	-
	Less: Refunds	-		-//>	
	Less: Write off	1			1
	Total (Rs.)	133,94,78,708.00		125,60,66,856.00	1,938.00
	Add/Deduct Balance of Net Income/Expenditure Transferred from the Income and Expenditure A/c	67,68,275.13		7,86,90,471.00	
	Total (Rs.)	134,62,46,983.13		133,47,57,327.00	1,938.00
	Net Balance	134,62,46,983.13	83.13	133,47,59,265.00	:65.00

(Dr. N. Zaheer Ahmed) Director General Sd/-

> (Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Schedule Forming Part of Balance Sheet as on 31st March 2023 (Schedule-3) Earmarked/Endowment Funds

(a) Opening Balance 35,94,007.00 1,90,232.00 Total (a) 35,94,007.00 1,90,232.00 (b) Additions Grant-in-Aid Other Additions A/c of • Bank Interest • From Health A/c • Receivable received • Misc. Receipts Total (b) Total (b) Total (a+b) (c) Utilization/Expenditure i) Capital expenditure • Assets • Others	laπ	S.N. Name of the Scheme	LT. A/c	Herb F Garden A/c	Oublication of Text Books	UPS A/c	DSOP A/c	Publication UPS A/c DSOP A/c Pharmacovigilance Unani Day of Text I A/c Books		AIIUM A/c	WHO A/c
Opening Balance Total (a) Additions Grant-in-Aid Other Additions A/c of Bank Interest From Health A/c Recoveries for Remittances Misc. Receipts Total (b) Total (a+b) Utilization/Expenditure Capital expenditure Assets Others			(1)	(2)	(3)	(4)	(2)	(9)	(7)	(8)	(6)
Total (a) Additions Grant-in-Aid Other Additions A/c of Bank Interest From Health A/c Remittances Remittances Misc. Receipts Total (b) Total (a+b) Utilization/Expenditure i) Capital expenditure c Assets Others	be	ning Balance	35,94,007.00	1,90,232.00					13,92,933.50		
Additions Grant-in-Aid Other Additions A/c of • Bank Interest • From Health A/c • Recoveries for Remittances • Misc. Receipts Total (b) Total (a+b) Utilization/Expenditure i) Capital expenditure control or Additions or Additi	ota	I (a)	35,94,007.00	1,90,232.00					13,92,933.50		
Grant-in-Aid Other Additions A/c of Bank Interest From Health A/c Recoveries for Remittances Misc. Receipts Misc. Receipts Total (b) Total (a+b) Total (a+b) Assets Assets Others	ddi	tions									
Other Additions A/c of Bank Interest From Health A/c Remittances Remittances Misc. Received Misc. Receipts Total (b) Total (b) Total (a+b) Capital expenditure Discrepance of the control	ìrar	ıt-in-Aid									
 Bank Interest From Health A/c Recoveries for Remittances Receivable received Misc. Receipts Total (b) Total (a+b) Utilization/Expenditure Capital expenditure Assets Others 	the	r Additions A/c of									
 From Health A/c Recoveries for Remittances Receivable received Misc. Receipts Total (b) Total (a+b) Utilization/Expenditure i) Capital expenditure e Assets Others 	ш	3ank Interest		74,020.00					21,502.00		
 Recoveries for Remittances Receivable received Misc. Receipts Total (b) Total (a+b) Utilization/Expenditure Capital expenditure Assets Others 	ъ	rom Health A/c									
Receivable received Misc. Receipts Total (b) Total (a+b) Utilization/Expenditure Assets Assets Others	<u> </u>	Recoveries for Remittances							16,598.00		
 Misc. Receipts Total (b) Total (a+b) Utilization/Expenditure i) Capital expenditure Assets Others 	╵╙	Receivable received									
Total (b) Total (a+b) Utilization/Expenditure i) Capital expenditure • Assets • Others	_	Aisc. Receipts							2,32,416.00		
Total (a+b) Utilization/Expenditure i) Capital expenditure • Assets • Others	ota	(a) I		74,020.00					2,70,516.00		7
	ota	I (a+b)	35,94,007.00	2,64,252.00					16,63,449.50		
i) Capital expenditureAssetsOthers	Itiliz	:ation/Expenditure									
AssetsOthers	Ca	pital expenditure									
Others	1	Assets									
		Others									
ii) Revenue Expenditure	A.	evenue Expenditure									

(Dr. Ram Pratap Meena) Sd/-

> (Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Schedule Forming Part of Balance Sheet as on 31st March 2023 (Schedule-3) Earmarked/Endowment Funds

S.N. Name of the Scheme	scheme	I.T. A/c	Herb Garden A/c	Publication of Text Books	UPS A/c I	DSOP A/c	Publication UPS A/c DSOP A/c Pharmacovigilance Unani Day AllUM A/c of Text I A/c Books	Unani Day	AIIUM A/c	WHO A/c
		(1)	(2)	(3)	(4)	(2)	(9)	(7)	(8)	(6)
Salaries/Wages Allowances	səbe									
Other Adr Expenditure	Iministrative	Other Administrative 11,78,046.00 Expenditure						10,81,166.00		
Material & Supplies	Supplies									
Remittance Recoveries	of							16,598.00		
Amount Payable Paid	yable Paid									
Unspent Balan Refunded to Ministry	Balance o Ministry							20,156.00		
Transfer to Healt on A/c of Closure	Transfer to Health A/c on A/c of Closure									
Total (c)		11,78,046.00						11,17,920.00		
Net Balance (a+b (-)c)	1+b (-)c)	24,15,961.00 2,0	2,64,252.00					5,45,529.50		

(Dr. N. Zaheer Ahmed) Director General Sd/-

> (Shakaib Hasan) Consultant (IA)

Sd/-

(Mohammad Parvez) Administrative Officer

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Schedule Forming Part of Balance Sheet as on 31st March 2023 (Schedule-3) Earmarked/Endowment Funds

S.N.	N. Name of the Scheme	IPR	International	DST A/c	CRISM A/c	South African	Total	tal
			Events Conference A/c			A/c	Current Year	Previous Year
		(10)	(11)	(12)	(13)	(14)	(15)	(16)
(a)) Opening Balance	11,68,000.00					63,45,172.50	2,85,06,985.00
	Total (a)	11,68,000.00					63,45,172.50	
(q)) Additions							
	Grant-in-Aid							84,00,000.00
	Other Additions A/c of							
	 Bank Interest 	61,470.00					1,56,992.00	6,65,085.00
	From Health A/c							
	 Recoveries for Remittances 						16,598.00	17,356.00
	Receivable Received							
	Misc. Receipts	1,23,609.00					3,56,025.00	
	Total (b)	1,85,079.00					5,29,615.00	90,82,441.00
	Total (a+b)	13,53,079.00					68,74,787.50	3,75,89,426.00
(c)) Utilization/Expenditure							
	i) Capital Expenditure							
	 Assets 							
	 Others 							
	ii) Revenue Expenditure							

(Dr. N. Zaheer Ahmed) Director General

Sd/-

(Mohammad Parvez) Administrative Officer

Research Officer (Chemistry)/ (Dr. Ram Pratap Meena)

Sd/-

Administrative Incharge

(Shakaib Hasan) Consultant (IA)

Schedule Forming Part of Balance Sheet as on 31st March 2023 (Schedule-3) Earmarked/Endowment Funds

S.N.	Name of the Scheme	IPR	International	DST A/c	CRISM A/c	South African	Total	tal
			Events Conference A/c			A/c	Current Year	Previous Year
		(10)	(11)	(12)	(13)	(14)	(15)	(16)
	 Salaries/Wages Allowances 							
	 Other Administrative Expenditure 	10,75,094.00					33,34,306.00	63,48,563.00
	 Material & Supplies 							
	 Remittance of Recoveries 						16,598.00	10,170.00
	 Amount Payable Paid 							
	 Unspent Balance Refunded to Ministry 						20,156.00	46,68,757.00
	 Transfer to Health A/c on A/c of Closure 							2,02 16,763.70
	Total (c)	10,75,094.00					33,71,060.00	3,12,44,253.70
	Net Balance (a+b (-)c)	2,77,985.00					35,03,727.50	63,45,172.30

(Dr. N. Zaheer Ahmed) Director General Sd/-

(Shakaib Hasan) Consultant (IA)

Sd/-

(Mohammad Parvez)

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Administrative Officer



Current Liabilities & Provisions [Schedule-7 (2022–2023)]

s S		Name of the Scheme		Current Year		Previous Year
7(A)(5)	7(A)(5) Statutory Liabilities: Duties and taxes			32,83,	32,83,280.00	1,24,920.00
			Total 7 (A) (5)	32,83,	32,83,280.00	1,24,920.00
7(A)(6)	7(A)(6) Other Current Liabilities					
	Secured Deposits (CCRUM)			16,17,	16,17,443.00	14,67,443.00
	Short Payments Payable			23,	23,798.00	23,798.00
	Undisbursed Amounts (Decentralized Instt.)	ntralized Instt.)		19;	79,948.00	16,103.00
	Undisbursed Amounts (Decentralized Instt.)	ntralized Instt.)				63,845.00
	Recoveries not Received Details	ails		2,5	2,289.00	2,289.00
	F.W. A/c			171	17090.00	1
	New Pension Scheme Recoveries	eries				
	Advances from VIdya Peeth	Advances from Vldya Peeth (Decentralized Instt Srinagar)		2,50,	2,50,000.00	2,50,000.00
	Amount Received but Detail not Received (Kol)	not Received (KoI)		16,	16,469.00	16,469.00
	Received from CCRAS for UPC			30,00,	30,000,000.00	30,00,000.00
	Payable by RRI., New Delhi to Hqrs	o Hqrs, ND			36.00	36.00
	Security Deposit (CCCBC)			4,03,	4,03,000.00	4,03,000.00
	Unspent Balance Payable to Ministry of Ayush	Ministry of Ayush		2,56,10,081.27	081.27	2,26,91,219.27
	Unspent Balance of Specific Accou	Accounts		2,02,17,	495.70	2,02,17,495.70
	Expenses Payable			23,96,	53,96,277.00	
	Deduction from salaries			37,70,	37,70,588.00	
	Salary payable			1,21,59,226.00	226.00	
			Total	7,25,63,740.97	740.97	4,81,51,697.97
7(B)	Provisions For Retirement Benefits	nefits		25,51,30,025.30	025.30	28,23,29,258.87
	-/pS	Sd/-	-/ps			-/pS
	(Shakaib Hasan) Consultant (IA)	(Mohammad Parvez) Administrative Officer	(Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Incharge	p Meena) Chemistry)/ ncharge	(Dr. N. Z Direct	(Dr. N. Zaheer Ahmed) Director General



Current Liabilities & Provisions [Schedule-7 (2022–2023)]

S. N.	Name of the Scheme	Current Year	Previous Year
	Total 7 (B)		28,23,29,258.87
	Total 7 (A+B) C/f	33,09,77,045.84	33,06,05,876.84
7(C)	NPS A/c		
	NPS Liability to NPS Subscribers	1,26,98,039.30	64,11,064.00
	 Bank Interest Earned and Accrued 		1,30,53,053.00
7(D)	GPF A/c		
	GPF Liability to GPF Subscribers	45,16,31,316.29	28,41,64,862.00
	GPF Current Liability		2 C C C C C C C C C C C C C C C C C C C
	Bank Interest Earned and Accrued		10,61,24,355.33
	GPF Advance		00.506,06,06
7(E)	GIS A/c		
	Amount from LIC to be Disbursed	2,43,47,509.84	5,00,000.00
	GIS Liability to GIS Subscribers		2,46,24,209.84
	Excess Received		0.020.1
	 CGHS Wrongly Credited in GIS A/c to be Transferred to Health A/c 		
7(F)	Pension Fund A/c		
	 Pension Funds Bank Interest and Payment of Pension, FP Commutation of 	39,71,91,207.53	31,98,82,051.53
	Pension From		
	Total 7(C) to 7(F) Rs.	88,58,68,072.96	82,26,28,297.70

(Dr. N. Zaheer Ahmed) Director General

(Shakaib Hasan) Consultant (IA)

(Mohammad Parvez) Administrative Officer

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Consolidated Schedule of Fixed Assets as on 31st March 2023 (Schedule-8)

S.N	S.N. Name of the Assets	Opening Balance			Gross Block	
		as on 01.04.2022	Addition	Deductions	Transferred to/from M/E A/c from WLP A/c	Total
		(1)	(2)	(3)	(4)	(5)
<u> </u>	Machinery (H) Equipment (FW)	17,00,15,728.00	23,70,524.00			17,23,86,252.00
2.	Furniture & (H) Fixture (FW)	9,75,44,033.00	11,61,978.00			9,87,06,011.00
რ.	Computers	3,61,03,899.00	3,14,332.00			3,64,18,231.00
4.	Land	27,85,336.00				27,85,336.00
5.	Works in Progress	111,13,04,634.00				111,13,04,634.00
6.	Books & Journals (H) (FW)	3,56,18,096.00	1,75,127.00			3,57,93,223.00
7.	Vehicles	79,24,684.00	6,97,482.00			86,22,166.00
∞.	Building	13,43,46,873.00				13,43,46,873.00
9.	Council's Publications (Priced)					
	TOTAL					
10.	10. Councils Publications Priced not Fixed Assets so Deducted from here					
	Total (H) (FW)	159,56,43,283.00	47,19,443.00			160,03,62,726.00

(Dr. N. Zaheer Ahmed) Director General Sd/-Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Sd/-

(Mohammad Parvez) Administrative Officer

Sd/-

(Shakaib Hasan) Consultant (IA)



Consolidated Schedule of Fixed Assets as on 31st March 2023 (Schedule-8)

S.N.	Name of the Assets			Depreciation			Net Block	lock
		Rate of Peprecia	Opening Balance As on 01.04.22	On addition	On Deductions	Total	As on 31.03.2023	As on 31.03.2022
		(9)	(7)	(8)	(6)	(10)	(11)	(12)
-	Machinery (H) Equipment (FW)		9,31,05,085.00	78,37,861.00		10,09,42,946.00	7,14,74,104.00	7,69,42,097.00
2	Furniture & (H) Fixture (FW)		6,60,05,776.00	32,16,051.00		6,92,21,827.00	2,94,88,973.00	3,15,43,046.00
3.	Computers		3,13,88,247.00	28,76,096.00		3,42,64,343.00	21,53,888.00	47,15,652.00
4.	Land						27,85,336.00	27,85,336.00
5.	Works in Progress						111,13,04,634.00	111,13,04,634.00
9.	Books & Journals (H) (FW)		2,34,84,114.00	29,88,430.00		2,64,72,544.00	45,58,113.00	73,71,416.00
7.	Vehicles		00.392.00	1,96,177.00		00.695,96,89	17,65,597.00	12,64,292.00
∞	Building		11,08,37,771.00	23,50,910.00		11,31,88,681.00	2,11,58,192.00	2,35,09,102.00
6	Council's Publications (Priced)							
	TOTAL							
10.								
	Priced not Fixed Assets so Deducted from here							
	Total (H) (FW)		33,14,81,385.00	1,94,65,525.00		35,09,46,910.00	124,46,88,837.00	125,94,35,575.00
	(

(Dr. N. Zaheer Ahmed) Director General Sd/-

(Shakaib Hasan) Consultant (IA)

(Mohammad Parvez) Administrative Officer

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)



Schedule of Investments Out of the Following Funds as on 31st March 2023 (Schedule-10)

Z.		Current Year	Previous Year
<u>~</u> :	GPF	37,04,86,711.00	36,43,49,895.00
2.	GIS	1,90,02,345.00	1,87,02,242.00
က်	Pension Fund	28,19,46,325.00	27,31,86,589.00
4.	SdN	45,92,473.99	45,92,473.99
	Total S/5C	67,60,27,854.99	66,08,31,199.99

(Dr. Ram Pratap Meena) Sd/-

> (Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge

(Dr. N. Zaheer Ahmed) Director General

(Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Incharge

> (Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Schedule of Current Assets (Schedule-11)

Ξ	Health A/c	Current Year	Previous Year
<u>-</u>	Contingent advance	10,98,33,036.00	11,05,99,722.00
2.	Exhibitions advance	73,000.00	73,000.00
က်	T.A. Advance	2,14,939.00	2,01,785.00
4	Excess paid to be recovered/adjusted	8,107.00	8,107.00
5.	LTC Advance	5,73,786.00	6,93,083.00
9	Advance for Seminar	20,96,019.00	16,51,019.00
7.	Capital Advance	26,17,09,210.00	23,67,01,300.00
æ	Scooter Advance (39456 - 1500)	37,956.00	39,456.00
9.	Fan Advance	768.00	768.00
10.	Car Advance		
17.	Computer Advance (7659721 - 182336)	5,83,636.00	7,65,972.00
12.	House Building Advance (7584327 + 1499564)	90,83,891.00	75,84,327.00
13.	In Transit Amount	18,200.15	18,200.15
14.	Security Deposits	4,70,311.00	4,70,311.00
15.	Medical Advance	3,28,265.00	3,28,265.00
16.	Receivable from IPR A/c	70,960.00	
17.	Receivable from LIC	1,351.50	1,351.50
18.	Excess TDS to be recovered/adjusted	19,706.00	19,706.00
19.	Training Advance (450225 - 81773 -14900)	3,53,552.00	4,50,225.00
20.	Ethics Committee Advance	1,17,024.00	97,024.00
21.	Share amount receivable from CCRYN, N. Delhi	2,62,992.00	2,62,992.00
22.	Advance for A-HMIS	1,34,200.00	1,34,200.00
23.	Receivable from F.W. A/c	17,090.00	17,090.00
24.	Swachhta Action Plan Advance	11,83,059.00	18,55,596.00



(Dr. N. Zaheer Ahmed) Director General

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

> (Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Sd/-

Sd/-

Schedule of Current Assets (Schedule-11)

3	Health A/c	Current Year	Previous Year
25.	Maintenance Advance	34,991.00	
26.	Hindi workshop	2,64,150.00	
27.	IT maintenance	12,700.00	
28.	Machinery and equipment advance	88,47,512.00	
29.	Material & supplies advance	4,50,000.00	
30.	Office Expense advance	1,42,066.50	
31.	Security with Decentralised Institutes	24,03,000.00	
32.	Bank Balance lying with RRI Kolkata to be received/adjustments	19,323.00	19,323.00
33.	Hindi Pakhwada Advance	1,93,100.00	1,38,100.00
34.	Advance for Health Camp	1,59,928.00	1,59,928.00
35.	Excess Transfer to Pension Fund A/c to be received in Health A/c		
36.	Arogya Advance	1,51,706.00	51,706.00
37.	DD received from decentralized Institutes returned due to time barred now to be received therefrom.		
38.	International Conference & Unani Day Advance	7,21,730.00	3,02,705.00
	A- Total (Rs.)	39,81,88,265.15	36,26,45,261.51
(B)	Family Welfare A/c:		NO 7 NO C
Ć	NPS A/C		2
)	(ii) Accrued Bank Interest on FDRs Invested	2,08,509.00	16,16,750.00
<u>a</u>	GPF A/c		
	(i) Current Assets	5,76,28,160.00	33,852.98
	-		58,50,583.00
	(III) Accrued Bank Interest on FDKs Invested		3,98,04,614.54
<u>(E</u>	GIS A/c (i) Current Assets Subscription in Transit	13,70,345.00	180.00

115

Schedule of Current Assets (Schedule-11)

(A)	Health A/c	Current Year	Previous Year
	(ii) Accrued Bank Interest on FDRs Invested (iii) Receivable from NPS A/c as Payment Wrongly Paid from GIS A/c		200.00 19,50,331.00
E C	Pension Fund A/c		
	 Accrued Bank Interest on FDRs Invested 	3,18,58,583.00	57,84,134.00
	Total (B to F) Rs. Clf	9,10,65,597.99	41,76,87,954.61

(Dr. N. Zaheer Ahmed) Director General

(Mohammad Parvez) Administrative Officer

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

(Shakaib Hasan) Consultant (IA)

Break-up of Closing Balance as on 31st March 2023 (Schedule-11)

335,60,493.60 Health A/c	2,03,098.00	5,83,336.22	3,43,46,927.82	2,35,16,445.29 GPF A/c	39,74,819.84 GIS A/c	8,33,86,299.53 Pension A/c	78,97,056.31 NPS A/c	11,87,74,620.97	15,31,21,548.79	24,15,961.00 IT A/c	NIL AIIUM A/c	NIL UPS Aligarh	2,64,252.00 Herb Garden A/c	2,77,985.00 IPR A/c	NIL Publication of Text Books	NIL DSOP A/c	NIL International Events Conferences	NIL Unani Chair South African	NIL DST A/c	NIL WHO A/c	NIL (i) Pharmacovigilance A/c	35,03,727.50	15,66,25,276.29	64,58,79,139.43	-/PS
16602	Decentralized Institutes Bank Balances	mprest- Decentralized Institutes	Total (A)	16601	16640	8477	1088	Total (B)	Grand Total (A + B) Schedule S/5A	3988	11685	19612	17450	17450	2226	25291	3654	6063	190312	24656	7704	Fotal (C)	Total (A+B +C) of G	Total (A+B TO F+G)	705
(G) Bank of India (A)				-do- (B)	-do-	Bank of Baroda 8	SBI 1			-do- (C) 3	-do-	Bank of India	-do-	-do-	-do-	-do-	-do-	9 -op-	-do-	-do-	State Bank of India 7				-/PS

(Dr. Ram Pratap Meena)

(Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge



Schedule of Grant-in-Aid for the Year Ending 31st March 2023 Schedule of Income & Expenditure A/c

Schedule-13 (Grants)

Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2023

Previous Year	157,73,00,000.00	157,73,00,000.00	
Current Year	173,42,56,000.00	173,42,56,000.00	
aid		Total	
Grant in aid	Central Government		
ż	Ą.		

(Dr. N. Zaheer Ahmed) Director General Sd/-

> Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

> > (Mohammad Parvez) Administrative Officer Consultant (IA)

(Shakaib Hasan) Sd/-



Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2023 Schedule-14 (Fees/Subscription)

Previous Year	37,36,420.00	37,36,420.00	Sd/- (Dr. N. Zaheer Ahmed) Director General
Current Year	47,86,680.00	47,86,680.00	Sd/- (Dr. Ram Pratap Meena) (Bresearch Officer (Chemistry)/ Administrative Incharge
		Total	(Dr. Ra Research
	se/Fees		Sd/- (Mohammad Parvez) Administrative Officer
	Unani Academic Course/Fees		Sd/- (Shakaib Hasan) Consultant (IA)
ż	B.		



Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2023 Schedule-16 (Income from Publication)

Current Year Previous Year		98,722.00 1,38,471.00	Sd/- (Dr. N. Zaheer Ahmed) Director General
On		Total	Sd/- (Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Incharge
	of Publication		Sd/- (Mohammad Parvez) Administrative Officer
	Income from Sale of Publication		Sd/- (Shakaib Hasan) Consultant (IA)



(Dr. N. Zaheer Ahmed) Director General

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

> (Mohammad Parvez) Administrative Officer

> (Shakaib Hasan) Consultant (IA)

Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2023 Schedule-17(2) (Interest Earned)

	62,34,578.00	4,21,035.00	66,55,613.00
Previous Year			
	00:	00:	00'
ent Year	61,88,004.00	3,99,430.	65,87,434.
Curr			
			Total
	nts	dvances	
	On Saving Accounts	On Refundable Advances	
	On S	On R	

Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2023 Schedule-18 (Other Income)

S.N.	18(4) Miscellaneous Income	Current Year	Previous Year
•	OPD/Regn Fee from Patients	1,80,45,220.00	1,34,39,196.00
•	Recoveries of Excess Payment/Provision in Previous Year	9,65,807.00	
•	RTI	370.00	786.00
•	Sale of Tender Form		
•	Sale of Raddi, etc.	5,471.00	7,121.00
•	Application Fees		
•	NPS Dormant A/c		
•	LS & PC		
•	Library User Charges		
•	CGHS Recovery		12,47,800.00
•	Water and Electricity Charges	28,080.00	33,485.00
•	Licence Fees	1,33,403.00	1,31,088.00
•	I Card Fees		
•	Auction Money	9,635.00	39,500.00
•	Cancellation of DD		3,600.00
•	Sale of Magazine		860.00
•	Photocopy Charges		442.00
•	VAT A/c Closed		00.797
•	Unspent Research Project		2,49,930.00
•	Secruity Deposit		15,000.00
•	Tender Fee	19,500.00	2,000.00
•	GIS Recovery		2,000.00
•	Lab Fee		38,470.00

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

> (Mohammad Parvez) Administrative Officer

> (Shakaib Hasan) Consultant (IA)

Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2023 Schedule-18 (Other Income)

S.N.	18(4) Miscellaneous Income	Current Year	Previous Year
•	Sale of Security Paper	00.000,6	10,000.00
•	Admn. Fee		8,205.00
•	Room Rent		10,800.00
•	Sale of Stamps	17,774.00	17,325.00
•	Scrap/Condemn Items	78,035.00	9,047.00
•	Misc. Receipts	29,23,725.51	44,47,403.00
•	Other Receipts (Decentralized Institute)		95,42,729.00
•	Return wrongly paid	15,368.00	
•	NPS Corpus Amount	74,28,539.50	
•	Exam paid received	3,416.00	
•	EOL receipt	00.987	
•	DTL project	62,470.00	
•	Parking fees	00.000,9	
٠	Auditorium fees	20,000.00	
•	Refund/Receipt	1,54,436.00	
	Total	2,99,27,036.01	2,92,57,554.00

(Dr. N. Zaheer Ahmed) Director General Sd/-

(Shakaib Hasan) Consultant (IA)

(Mohammad Parvez) Administrative Officer

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Sd/-



Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2023 Non-recurring/Capital Expenditure (Schedule-19)

S.N.	Non-Recurring/Capital Expenditure	Current Year	Previous Year
•	Machinery & Equipment SAP	23,70,524.00	41,25,398.00
•	Vehicles	6,97,482.00	-
•	Furniture & Fixture (SAP) F/F	11,61,978.00	12,15,895.00
•	Books & Journal	1,75,127.00	5,51,296.00
•	Computers	3,14,332.00	25,36,467.00
	Total	47,19,443.00	84,29,056.00

(Dr. N. Zaheer Ahmed) Director General

(Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

Administrative Officer

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Sd/-

Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2023 Income & Expenditure A/c (Schedule-20) Establishment Expenses

S.N.		Current Year	Previous Year
(4)	Salaries	68,76,50,749.00	60,51,11,877.00
	Contribution to Other Fund	35,38,58,110.00	40,22,87,245.00
	NPS 2,84,78,167.00		
	Pension 32,53,79,943.00		
	DLIS NIL		
	<u>35,38,58,110.00</u>		
	Expenses on Employees Retirement Benefits	6,99,26,936.00	7,08,87,104.00
	Total (A)	111,14,35,795.00	107,82,86,226.00
(B)	NPS Corpus Amount Paid	30,13,061.00	1
	Total (A+B)	111,14,35,795.00	107,82,86,226.00
		30,13,061.00	

(Dr. Ram Pratap Meena) Sd/-

(Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Schedule of Expenditure Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2023 Schedule-21 (Other Administrative Expenses, etc.)

z. Z		Current Year	Previous Year
Ä.	Other Administrative Expenses		
	• T.A.	69,56,476.00	20,52,623.00
	Wages Including Contractual Staff Remuneration	11,71,05,378.00	11,34,53,917.00
	• Office Expenses (Stationary & Printing, Electricity, Water, Telephone, Cartage/Freight,	8,46,93,563.88	5,68,74,016.00
	Advocate Fees, Refreshment, Advertisement Charges, etc.		
	 Rent & Taxes (Rent of Building & Property Tax) 	1,30,23,757.00	51,73,982.00
	Maintenance & Repair, Petrol Diesel Expenses, etc.	93,68,606.00	1,20,60,845.00
	Information Technology (Recurring Expenses, i.e. Repair of Computers Cartridge, Net	64,33,243.00	1,05,95,100.00
	Charges, Website Charges, etc.)		
	Consolidated Expenses on A/c SCP/TSP Wages/Remuneration of Staff/Stationary & Other	5,69,27,902.00	1,44,13,341.00
	Miscellaneous expenses		
	Total Schedule -21 (A)	29,45,08,925.88	21,46,29,824.00
æ.	Material & Supplies (Medicines, Chemicals, Glasswares & Lab Investigation Charges, etc.)	20,01,19,612.00	9,45,10,750.00
	Total 21-(B)	20,01,19,612.00	9,45,10,750.00
ن	Other Charges		
	Medical Expenses	1,35,45,094.00	1,48,68,052.00
	Survey Expenses	ı	-
	Arogya Fair	1,77,178.00	15,52,680.00
	Health Camps	I	•
	Unani Academic Course	6,51,07,628.00	5,86,22,053.00
	Swatchta Action Plan	32,76,226.00	24,20,173.00
	COVID-19 Expenses		50,886.00
	Mobile Health Visits		22,66,280.00
	EMR Expenses		2000.00

Sd/(Mohammad Parvez)

Administrative Officer

(Shakaib Hasan) Consultant (IA)

(Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Incharge

Sd/-

Schedule of Expenditure Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2023 Schedule-21 (Other Administrative Expenses, etc.)

S. N.		Current Year	Previous Year
	Research Activities	4,47,30,998.00	1,84,44,879.00
	Training Programmes		
	Seminar	14,59,332.00	1,41,600.00
	Ethics Committee Expenses	63,283.00	I
	Unani Day & Seminar	38,89,772.00	7,74,787.00
	Hindi Pakhwada	7,20,853.00	54,100.00
	GIA to Chemical Research Unit- Aligarh	-	24010
	IEC Expenses	20,650.00	3,44,350.00
	Health Mela Expenses		•
	Ayurveda Parv		1
	NPCDCS	99,711.00	42,48,812.00
	AHMIS	1,16,880.00	71,803.00
	Council CGHS Contribution	25,19,973.00	24,75,829.00
	Exhibition Mela	66,306.00	1,41,600.00
	EOI Project Review Committee Expenses		3990.00
	Council Contribution to GIS	•	5,36,503.00
	IPR Expenses	-	12,658.00
	Ph.D. Programme	7,08,000.00	12,658.00
	• NABH	1,16,253.00	00.000,09
	Hindi Workshop	37,26,541.00	-
	Total S. No. 21 (C)	C) 14,03,44,678.00	10,71,17,045.00
	Grand Total Schedule 21 (A to C)	C) 63,49,73,215.88	41,62,57,619.00

-/pS

(Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ (Dr. Ram Pratap Meena) Administrative incharge

Schedule of Expenditure Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2023 Schedule-21(E)

Ż)	Current Year			Previous Year	
<u>(</u>	Depreciation	Health	(F.W)	Total	Health	(F.W)	Total
(<u>.</u>	Machinery & Equipment	7,83,786.00		7,83,786.00	84,67,167.00		84,67,823.00
 (≡	Furniture & Fixtures	3,21,605.00	1	3,21,605.00	34,43,251.00	-	34,43,251.00
(E)	Computers	28,76,096.00	1	28,76,096.00	15,50,720.00		15,50,720.00
<u>(</u> 2	Books & Journals	29,88,430.00	1	29,88,430.00	47,65,353.00	ı	47,65,353.00
<u>(</u> >	Vehicles	1,96,177.00	1	1,96,177.00	1,40,477.00	-	1,40,477.00
(iv	Building	23,50,910.00	-	23,50,910.00	26,12,122.00	1	26,12,122.00
	Total Rs.	1,94,65,525.00	=	1,94,65,525.00 2,09,79,090.00	2,09,79,090.00	=	2,09,79,090.00
	Grand Total	1,94,65,525.00	25.00		2,09,79	2,09,79,090.00	

(Dr. N. Zaheer Ahmed) Director General

(Shakaib Hasan) Consultant (IA)

(Mohammad Parvez) Administrative Officer

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Schedule of Income & Expenditure A/c (Unspent Balance Refundable to M/o Ayush)

Previous Year	2,26,91,219.27		Sd/- (Dr. N. Zaheer Ahmed)	Director General
Current Year	2,56,10,081.00	-/pS	(Dr. Ram Pratap Meena)	Administrative Incharge
			SG/- (Mohammad Parvez)	Administrative Officer
	Unspent Balance		Sd/- (Shakaib Hasan)	Consultant (IA)
S.N.	•			



Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

S. N. Name of the Scheme Opening Balance GIA Previous Year Current Year Previous Year Previo								
(a) Health Scheme A/C (Imprest) (1) Health Scheme A/C (Imprest) (1) Health Scheme A/C (Imprest) (2) (2) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3	z S		Opening		(IS	4	Bank In	iterest
(a) Cash-in-Hand (Cherne A/C (Cherthan Imprest) (b) Cash-in-Hand (Cherne A/C (Cherthan Imprest) (c) Cash-in-Hand (Cherthan Imprest) (d) Cash-at-bank (Cherthan Imprest) (c) Cash-at-bank (Cherthan Imprest) (d) Cash-at-bank (Cherthan Imprest) (e) Cash-at-bank (Cherthan Imprest) (f) Cash-at-bank (Cherthan Imprest) (f) Cash-at-bank (Cherthan Imprest) (f) IPR (Cherthan Impres			Current Year	Previous Year	Current Year		Current Year	Previous Year
(a) Cash-in-Hand 5,83.36.22 4,48,000.00 1,68,55,06,000.00 6,56,00,000.00 6,88,004.00 62,34, [Imprest) (Other than Imprest) (Other than)	1)	(2		8))
(a) Loash-in-Hand (imprest) 5.83.336.22 (wi) Loash-in-Hand (imprest) 4.48,000.00 4.87,50,000.00 6.56,00,000.00 6.56,00,000.00 6.188,004.00 6.34,004.00	-							
(b) Cash-in-Hand (Other than Imprest) 17,92,250.00 1,39,95,502.00 1,68,55,06,000.00 1,51,17,00,000.00 0		prest)	5,83,336.22		4,87,50,000.00	6,56,00,000.00	61,88,004.00	62,34,578.00
(c) Cash-arbank 4,17,80,022.15 0		(b) Cash-in-Hand (Other than Imprest)	17,92,250.00		1,68,55,06,000.00	1,51,17,00,000.00	0	0
Total (Health A/C) S.N.1 4,41,55,608.37 1,44,43,502.00 1,73,42,56,000.00 1,57,73,00,000.00 61,88,004.00 62,34,007.00 Other Specific Accounts 11,68,000.00 2,68,997.00 0 20,00,000.00 61,470.00 1,15 (i) IPR 11,68,000.00 2,68,997.00 0 20,00,000.00 61,470.00 1,15 (ii) Pub. of Text Books 0 61,249.00 0 74,020.00 1,15 (iv) UPS A/c I 0 51,485.00 0 0 0 0 (iv) DS A/c I 0 51,485.00 0 0 0 0 1,4020.00 1,4020.00 (iv) DSOP 0 2,33,631.00 0 2,33,631.00 0 0 0 0 0 0 0 45 (vi) AllUM A/c 35,94,007.00 36,58,499.00 0 64,00,000.00 21,502.00 41, (vii) Intani Day 0 0 0 0 0 0 0 0 0 0 0 0 0		(c) Cash-at-bank	4,17,80,022.15		0	0	0	0
Other Specific Accounts 2,68,997.00 2,68,997.00 61,470.00 1,15 (i) IPR 11,68,000.00 2,68,997.00 0 20,00,000.00 61,470.00 1,15 (ii) IPR 1,90,232.00 74,256.00 0 74,020.00 1,15 (iii) Pub. of Text Books 0 61,249.00 0 74,020.00 1,15 (iv) UPS A/c I 0 51,485.00 0 0 0 0 1,15 (iv) UPS A/c I 0 2,33,631.00 0 0 0 0 0 5,5 (vi) AllUM A/c 35,94,007.00 35,95,499.00 0 0 0 0 0 0 45,000.00 (vii) I.T. A/c 35,92,933.50 4,66,057.00 0 64,00,000.00 21,502.00 41,000.00 21,502.00 41,000.00		Total (Health A/C) S.N.1	4,41,55,608.37		1,73,42,56,000.00	1,57,73,00,000.00	61,88,004.00	62,34,578.00
11,68,000.00 2,68,997.00 0 20,000,000.00 61,470.00 1,15 1,90,232.00 74,256.00 0 74,020.00 1,15 1,90,232.00 61,249.00 0 74,020.00 1,15 1,10,20,232.00 61,2485.00 0 0 0 1,15 1,249.00 2,33,631.00 0 0 0 6 45 35,94,007.00 36,58,322.00 0 0 0 45 35,94,007.00 36,66,057.00 0 64,00,000.00 21,502.00 41,4	2.	Other Specific Accounts						
1,90,232.00 74,256.00 0 0 74,020.00 1,15 0 61,249.00 0 0 0 1,15 1 51,485.00 0 0 0 0 0 0 1,15 0 2,33,631.00 0 0 0 0 5,2 35,94,007.00 0 0 0 45,0 35,94,007.00 36,58,322.00 0 0 0 0 0 45,0 1,39,29,33.50 4,66,057.00 0 64,00,000.00 21,502.00 41,0		(i) IPR	11,68,000.00		0	20,00,000.00	61,470.00	0
1. 61,249.00 0 0 0 1. 0 51,485.00 0 0 0 0 0 5 1. 35,94,007.00 35,95,499.00 0 0 0 45,1502.00 41,39,29,33.50 4,66,057.00 0 64,00,000.00 21,502.00 41,4		(ii) Herb Garden A/c	1,90,232.00		0	0	74,020.00	1,15,976.00
0 51,485.00 0 0 0 5 2 33,631.00 0 0 0 5 35,94,007.00 35,95,499.00 0 0 0 45, 1,39,29,33.50 4,66,057.00 0 64,00,000.00 21,502.00 41,		(iii) Pub. of Text Books A/c			0	0	0	1,497.00
0 2,33,631.00 0 <th< td=""><td></td><td>(iv) UPS A/c 1</td><td>0</td><td></td><td>0</td><td>0</td><td>0</td><td>542.00</td></th<>		(iv) UPS A/c 1	0		0	0	0	542.00
35,94,007.00 36,58,322.00 0 0 0 0 0 1,39,29,33.50 4,66,057.00 0 64,00,000.00 21,502.00		(v) DSOP	0		0	0	0	5,711.00
35,94,007.00 35,95,499.00 0 0 0 1,39,29,33.50 4,66,057.00 0 64,00,000.00 21,502.00 41,011.0		(vi) AIIUM A/c	0		0	0	0	45,188.00
1,39,29,33.50		(vii) I.T. A/c	35,94,007.00		0	0	0	0
		(viii) National Conference on Unani Day			0	64,00,000.00	21,502.00	41,011.00

(Dr. Ram Pratap Meena)

(Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

S. S.	S. N. Name of the Scheme	Opening Bala	Balance	GIA		Bank Interest	terest
		Current Year Prev	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(1)		(2)		(3)	
	(ix) WHO A/c	0	2,456.00	0	0	0	60.00
	(x) International Events Conference A/c	2 0	7,98,334.00	0	0	0	17,399.00
	(xi) DST A/c	2 0	7,64,357.00	0	0	0	129.00
	(xii) Pharmacovigilance Workshop A/c	9 0	6,90,000.00	0	0	0	0
	(xiii) CRISM A/c	0 1,72	1,72,93,526.00	0	0	0	4,24,155.00
	(xiv) South African A/c	3 0	5,48,816.00	0	0	0	13,417.00
	Total S.N. 2	63,45,172.50 2,85	2,85,06,985.00	0	84,00,000.00	1,56,992.00	6,65,085.00
3.	(i) NPS A/c	76,88,547.31	59,26,026.31	0	0	2,08,509.00	1,60,157.00
	(ii) CPF/GPF A/c	5,02,49,455.29 2,36	2,36,17,032.29	0	0	11,06,892.00	48,10,552.00
	(iii) GIS A/c	50,09,435.84	77,60,272.84	0	0	1,36,274.00	1,90,108.00
	(iv) Pension Fund A/c	4,39,92,321.53 4,24	4,24,95,307.13	0	0	17,28,851.00	14,61,730.00
	Total S. N. 3	10,69,39,759.97 7,97	7,97,98,638.57	0	0	31,80,526.00	66,22,547.00
	Grand Total S. N. 1 to 3 15,74,40,540.84	15,74,40,540.84 12,27	12,27,49,125.57	1,73,42,56,000.00	1,58,57,00,000.00		95,25,522.00 1,35,22,210.00

(Dr. N. Zaheer Ahmed) Director General Sd/-

(Mohammad Parvez) Sd/-

> (Shakaib Hasan) Consultant (IA)

Administrative Officer

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

-/ps

(Dr. N. Zaheer Ahmed) Director General

> Research Officer (Chemistry)/ Administrative Incharge

(Dr. Ram Pratap Meena)

(Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)



Schedule of Receipts & Payments A/c Schedule of Receipts for the Year Ending 31st March 2023

0) 2	S. Name of the Scheme N.	Miscellaneous Receipts	ineous ipts	Interest on Refundable Advances	Refundable nces	Refunds against by Adjustment of Advances Pertaining to Previous Years	by Adjustment Pertaining to Years
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(4)		(5)		(9)	
	1. Health Scheme A/c	2,18,30,386.51	2,92,57,554.00	1,31,055.00	4,21,035.00	1,54,436.00	11,80,860.00
						27,37,267.50	
						8,626.00	
	Total (H) S.N.1	2,18,30,386.51	2,92,57,554.00	1,31,055.00	4,21,035.00	29,00,329.50	11,80,860.00
7	2. Other Specific Accounts						
	(i) IPR	1,23,609.00	0	0	0	0	0
	(ii) Herb Garden A/c	0	0	0	0	0	0
	(iii) Pub. of Text Books A/c	0	0	0	0	0	0
	(iv) UPS A/c 1	0	0	0	0	0	0
	(v) DSOP	0	0	0	0	0	0
	(vi) AIIUM A/c	0	0	0	0	0	0
	(vii) I.T. A/c	0	0	0	0	0	0
	(viii) National Conference on Unani Day	2,32,416.00	0	0	0	0	0
	(ix) WHO A/c	0	0	0	0	0	0
	(x) International Events Conference A/c	0	0	0	0	0	0
	(xi) DST A/c	0	0	0	0	0	0

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

ഗ്മ്	Name of the Scheme	Miscellaneous Receipts	ineous ipts	Interest on Refundable Advances	Refundable nces	Refunds against by Adjustment of Advances Pertaining to Previous Years	t by Adjustment Pertaining to s Years
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(4)	((2)		(9)	()
	(xii) Pharmacovigilance workshop A/c	0	0	0	0	0	0
	(xiii) CRISM A/c	0	0	0	0	0	0
	(xiv) South African A/c	0	0	0	0	0	0
	Total S.N. 2	3,56,025.00	0	0	0	0	0
3.	(i) NPS A/c	0	0	0	0	0	0
	(ii) CPF/GPF A/c	0	0	0	0	0	0
	(iii) GIS A/c	0	0	0	0	0	0
	(iv) Pension Fund A/c	56,63,661.00	0	0	0	0	0
	Total S.N. 3	56,63,661.00	0	0	0	0	0
	Grand Total S.N. 1 to 3	2,78,50,072.51	2,92,57,554.00	1,31,055.00	4,21,035.00	29,00,329.50	11,80,860.00

(Dr. Ram Pratap Meena) Sd/-

> (Mohammad Parvez) Administrative Officer

> (Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Schedule of Receipts & Payments A/c Schedule of Receipts for the Year Ending 31st March 2023

Z (7.	Name of the Scheme	Recoveries of Ref	Recoveries of Refundable Advances	Sale of Council's Publications	"s Publications
		Current Year	Previous Year	Current Year	Previous Year
			(7)	(8)	3)
←	(i) Health Scheme A/c	8,28,971.00	18,05,883.00	98,722.00	1,38,431.00
	Total S.N.1	8,28,971.00	18,05,883.00	98,722.00	1,38,431.00
2.	Other Specific Accounts:				
	(i) IPR	0	0	0	0
	(ii) Herb Garden A/c	0	0	0	0
	(iii) Pub. of Text Books A/c	0	0	0	0
	(iv) UPS A/c 1	0	0	0	0
	(v) DSOP	0	0	0	0
	(vi) AIIUM A/c	0	0	0	0
	(vii) I.T. A/c	0	0	0	0
	(viii) National Conference on Unani Day	0	0	0	0
	(ix) WHO A/c	0	0	0	0
	(x) International Events Conference A/c	0	0	0	0
	(xi) DST A/c	0	0	0	0
	(xii) Pharmacovigilance workshop A/c	0	0	0	0
	(xiii) CRISM A/c	0	0	0	0
	(xiv) South African A/c	0	0	0	0
	Total S.N. 2				
	Sd/- (Shakaib Hasan) (Mohammad Parvez) Consultant (IA) Administrative Officer	(Dr. F Researd Admii	Sd/- (Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Incharge	S (Dr. N. Zal Director	Sd/- (Dr. N. Zaheer Ahmed) Director General

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

S. S.	Name of the Scheme	Recoveries of Ref	Recoveries of Refundable Advances	Sale of Council's Publications	s Publications
		Current Year	Previous Year	Current Year	Previous Year
		()	7)	(8)	
_ن	3. (i) NPS A/c	0	0	0	
	(ii) CPF/GPF A/c	0	0	0	
	(iii) GIS A/c	0	0	0	
	(iv) Pension Fund A/c	0	0	0	
	Total S.N. 3	0	0	0	
	Grand Total S.N. 1 to 3	8,28,971.00	18,05,883.00	98,722.00	1,38,431.00

(Dr. Ram Pratap Meena) Sd/-

> (Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Research Officer (Chemistry)/ Administrative Incharge

(Dr. N. Zaheer Ahmed) Director General Sd/-

135

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

s. S.	Name of the Scheme	Recoveries for Remittance	Remittance	Recovery of Subscription/Advances	of vances	Interest	Interest on FDRs	
		Current Year	Previous Year	Current Year Previous Year	ious Year	Current Year Previous Year	Previous Y	ear
		(6)		(10))	(11)	
-	Health Scheme A/c	1,64,25,419.00	13,40,27,532.00	0	0		0	0
	Total (H) S.N.1	1,64,25,419.00	13,40,27,532.00	0	0		0	0
2	Other Specific Accounts :-							
	(i) IPR	0	0					
	(ii) Herb Garden A/c	0	0					
	(iii) Pub. of Text Books A/c	0	0					
	(iv) UPS A/c I	0	0					
	AOSa (v)	0	0					
	(vi) AIIUM A/c	0	0					
	(vii) I.T. A/c	0	0					
	(viii) National Conference on Unani Day	16,598.00	17,356.00					
	(ix) WHO A/c	0	0					
	(x) International Events Conference A/c	0	0					
	(xi) DST A/c	0	0					
	(xii) Pharmacovigilance workshop A/c	0	0					
	7/PS	-/DS		-/ps		-/PS	7	
	(Shakaib Hasan) Consultant (IA)	(Mohammad Parvez) Administrative Officer		(Dr. Ram Pratap Meena) Research Officer (Chemistry) Administrative Incharge)(X	(Dr. N. Zaheer Ahmed) Director General	ser Ahmed) General	

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

S. S.	Name of the Scheme	Recoveries for Remittance	Remittance	Recovery of	ery of	Interest on FDRs	on FDRs
				Subscription/Advances	n/Advances		
		Current Year	Previous Year	Current Year	Current Year Previous Year Current Year Previous Year	Current Year	Previous Year
		(6)		(10)	(0	(1	(11)
	(xiii) CRISM A/c	0	0				
	(xiv) South African A/c	0	0				
	Total S.N. 2	16,598.00	17,356.00	0	0	0	0
3.	(i) NPS a/c	0	0	0	8,52,712.00	0	0
	(ii) CPF/GPF A/c	0	0	0 4,67,60,317.00 4,82,50,114.00	4,82,50,114.00		61,36,816.00 2,71,15,609.00
	CPF/GPF A/c Subscription	0	0	8,83,928.00	6,96,280.00	3,00,103.00	0
	(iii) GIS A/c	0	0				
	(iv) Pension Fund A/c	1,84,09,262.00	1,02,01,093.00	33,792.00	0	87,59,736.00	24,34,329.00
	Total S.No. 3	1,84,09,262.00	1,02,01,093.00	4,76,78,037.00	1,02,01,093.00 4,76,78,037.00 4,97,99,106.00 1,51,96,655.00	1,51,96,655.00	2,95,49,938.00
	Grand Total S.No. 1 to 3	3,48,51,279.00		4,76,78,037.00	14,42,45,981.00 4,76,78,037.00 4,97,99,106.00 1,51,96,655.00 2,95,49,938.00	1,51,96,655.00	2,95,49,938.00

(Dr. N. Zaheer Ahmed) Director General Sd/-

(Shakaib Hasan) Consultant (IA)

Administrative Officer

Sd/-

Research Officer (Chemistry)/ Administrative Incharge

(Dr. Ram Pratap Meena)

-/pS

(Mohammad Parvez)

Schedule of Receipts & Payments A/c Schedule of Receipts for the Year Ending 31st March 2023

1. Health Scheme A/c 28:53.280.82.00 1.50.000.00 35.000.00 1. Health Scheme A/c 28:53.280.82.00 0 1.50.000.00 35.000.00 1. Health Scheme A/c 28:53.280.82.00 0 1.50.000.00 35.000.00 1. Health Scheme A/c 28:53.280.82.00 0 1.50.000.00 35.000.00 1. Health Scheme A/c 38:53.280.82.00 0 1.50.000.00 35.000.00 1. Herb Garden A/c 38:53.280.82.00 0 0 0 0 1. Herb Garden A/c 38:53.280.82.00 36.000.00 36.000.00 1. Herb Garden A/c 38:53.280.82.00 0 0 0 0 1. Herb Garden A/c 38:53.280.82.00 38:53.280.82 38:53.280.	S. N.	Name of the Scheme	Receivable Amount Received	ount Received	Security Deposi	Security Deposit Lying with the Council	<u>ci</u>
Health Scheme A/C 88.53,280.82.00 1.50.000.00 95.000.00 The least of the scheme A/C 88.53,280.82.00 1.50.000.00 95.000.00 The least of the			Current Year	Previous Year	Current Year	Previous Year	
Health Scheme A/C 88,53,280.82.00 0 1,50,000.00 95,000.00 Total S.N.1 88,53,280.82.00 0 1,50,000.00 95,000.00 Other Specific Accounts:			(12	5)		(13)	
Total S.N.1 88,53,280.82.00 0 1,50,000.00 95,000.00 Other Specific Accounts:	- -	Health Scheme A/c	88,53,280.82.00	0	1,50,000.		00.00
Other Specific Accounts: (i) IPR (ii) PIR (ii) Herb Garden Alc (iii) Pub. of Text Books Alc (iii) Pub. of Text Books Alc (iii) Pub. of Text Books Alc (iv) UPS Alc I (iv) DSOP (i		Total S.N.1	88,53,280.82.00	0	1,50,000.		00.00
b Garden A/c b Garden A/c c of Text Books A/c c	2.	Other Specific Accounts:					
Ks A/C		(j) IPR					
Ray Sd/-		(ii) Herb Garden A/c					
Ayc Sd/- S		(iii) Pub. of Text Books A/c					
Salustrative Officer Administrative Incompared Page		(iv) UPS A/c I					
Ay		(v) DSOP					
Sd/-		(vi) AIIUM A/c					
Jay Sd/-		(vii) I.T. A/c					
A/C		(viii) National Conference on Unani Day					
Sd/-		(ix) WHO A/c					
Sd/-							
Sd/-		(xi) DST A/c					
Sd/-		(xii) Pharmacovigilance workshop A/c					
Sd/- Sd/- Sd/- Sd/- Sd/- Sd/- Sd/- Sd/- Sd/- Administrative Officer Administrative Incharge Administrative I		(xiii) CRISM A/c					
same Mohammad Parvez) Research Officer (Ahmistrative Officer Administrative Incharge Sd/- Sd/- Sd/- Sd/- Administrative Incharge Sd/- Sd/- Sd/- Administrative Incharge Sd/- Sd/- Director General		(xiv) South African A/c					
Sd/- Sd/- (Mohammad Parvez) Research Officer (Chemistry)/ Administrative Officer Administrative Incharge		Total S.N. 2	0	0		0	0
(Mohammad Parvez) (Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Officer Administrative Incharge				-/ps		Sd/-	
				(Dr. Ram Pratap Mee search Officer (Chemi Administrative Inchard		Dr. N. Zaheer Ahmed) Director General	

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

S. N.	Name of the Scheme	Receivable Am	Receivable Amount Received	Security Deposit Ly	Security Deposit Lying with the Council
		Current Year	Previous Year	Current Year	Previous Year
		(1)	(12)		(13)
ج ن	3. (i) NPS A/c	0	39,49,175.00		
	(ii) CPF/GPF A/c	0	0		
	(iii) GIS A/c	0	7,920.00		
	(iv) Pension Fund A/c	0	0		
	Total S.N. 3	0	39,57,095.00	0	3
	Grand Total S.N. 1 to 3	88,53,280.82.00	39,57,095.00	1,50,000.00	95,000.00

(Dr. Ram Pratap Meena) -/pS

> (Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

S. S.	Name of the Scheme	In Transit Amo	Transit Amount Received	Academic Course Fee	course Fee	Amount Receive Other Ins	Amount Received but Payable to Other Institute/Units
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(1)	(14)	(15)			(16)
.	(i) Health Scheme A/c		10,825.00	47,86,680.00	37,36,420.00		2,78,569.00
	(ii) Health Scheme A/c						20,00,000.00
	(iii) T.D.S.						
	Total S.N.1		10,825.00	47,86,680.00	37,36,420.00		22,78,569.00
2.	Other Specific Accounts						
	(i) IPR						
	(ii) Herb Garden A/c						
	(iii) Pub. of Text Books A/c						
	(iv) UPS A/c I						
	(v) DSOP						
	(vi) AIIUM A/c						
	(vii) I.T. A/c						
	(viii) National Conference on						
	Unanı Day						
	(ix) WHO A/c						
	(x) International Events Conference A/c						
	(xi) DST A/c						

(Dr. Ram Pratap Meena)

(Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

S. Z.	Name of the Scheme	In Transit Amo	In Transit Amount Received	Academic Course Fee	Sourse Fee	Amount Receiv Other Ins	Amount Received but Payable to Other Institute/Units
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		1)	(14)	(15)	5)		(16)
	(xii) Pharmacovigilance workshop A/c						
	(xiii) CRISM A/c						
	(xiv) South African A/c						
	Total S.N. 2	0	0	0	0	0	0
رى ن	(i) NPS A/c						
	(ii) CPF/GPF A/c						
	(iii) GIS A/c						
	(iv) Pension Fund A/c						
	Total S.N. 3	0	0	0	0	0	0
	Grand Total S.N. 1 to 3	0	10,825.00	47,86,680.00	37,36,420.00	0	22,78,569.00

(Dr. N. Zaheer Ahmed) Director General Sd/-

(Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

Administrative Officer

Sd/-

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Sd/-

Schedule of Receipts & Payments A/c Schedule of Receipts for the Year Ending 31st March 2023

Z	Namo of the Scheme	boyiood taomtooyal	Doviced	of fallows of 1	10 Amount for Disbursoment
; j			Necely Gu		T CISOURSCHIEFIE
		Current Year	Previous Year	Current Year	Previous Year
		(11)		5	(18)
<u>_</u>	Health Scheme A/c				
	(i) Health Scheme				
	Total S. N. 1				
2	Other Specific Accounts				
	(i) IPR				
	(ii) Herb Garden A/c				
	(iii) Pub. of Text Books A/c				
	(iv) UPS A/c I				
	(v) DSOP				
	(vi) AIIUM A/c				
	(vii) I.T. A/c				
	(viii) National Conference on Unani Day				
	(ix) WHO A/c				
	(x) International Events Conference A/c				
	(xi) DST A/c				
	(xii) Pharmacovigilance workshop A/c				
	(xiii) CRISM A/c				
	(xiv) South African A/c				
	Total S.N. 2	0	0	0	0
က်	(i) NPS A/c	0	1,32,00,000.00	0	0
	(ii) CPF/GPF A/c	10,10,85,099.40	30,01,96,359.00	0	0
	700		-/ps	V	/PO
	asan) (Moham ((IA) Adminis	(Dr. Ran Research C	(Dr. Ram Pratap Meena) Research Officer (Chemistry)/	, (Dr. N. Za Directo	(Dr. N. Zaheer Ahmed) Director General
		Administ	Administrative Incharge	::::::::::::::::::::::::::::::::::::::	

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

S. N.	Name of the Scheme	Investment Received	Received	LIC Amount fo	LIC Amount for Disbursement
		Current Year	Previous Year	Current Year	Current Year Previous Year
		(11)	((1)	(18)
	(iii) GIS A/c	57,47,987.00	0	2,00,000.00	5,00,000.00
	(iv) Pension Fund A/c	18,28,75,712.00	2,89,38,578.00	0	0
	Total S.N. 3	28,97,08,798.40	34,23,34,937.90	2,00,000.00	5,00,000.00
	Grand Total S.N. 1 to 3	28,97,08,798.35	34,23,34,937.85	2,00,000.00	5,00,000.00

(Dr. Ram Pratap Meena) -/pS

> (Mohammad Parvez) Administrative Officer

(Shakaib Hasan) Consultant (IA)

Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

s S	Name of the Scheme	Pension Fund Health	Pension Fund Transfer from Health Account	Govt. Contribut	Govt. Contribution of Non-Pran Members	Receipts on Closing of Bank	osing of Bank
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		.)	(19)	(2	(20)	(21)	
1.	Health Scheme A/c						
	(i) Health Scheme	0	0	0	62,56,317.00	0	2,02,17,495.70
	Total S.N. 1	0	0	0	62,56,317.00	0	2,02,17,495.70
2.	Other Specific Accounts						
	(i) IPR						
	(ii) Herb Garden A/c						
	(iii) Pub. of Text Books A/c						
	(iv) UPS A/c I						
	(v) DSOP						
	(vi) AIIUM A/c						
	(vii) I.T. A/c						
	(viii) National Conference on Unani						
	(ix) WHO A/c						
	(x) International Events Conference A/c						
	750		/P'S		-/pS		/6V
	(Shakaib Hasan) Consultant (IA)	(Moh: Admir	(Mohammad Parvez) Administrative Officer	(Dr. R Research Admin	(Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Incharge		(Dr. N. Zaheer Ahmed) Director General

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

Govt. Contribution of Non-Pran Receipts on Closing of Bank Members	Ir Previous Year Current Year Previous Year	$(20) \qquad (21)$				0 0 0				0 62,56,317.00 0 0	0 62,56,317.00 0 0	
Current Year Previous Year (20)	(20)					0 0 0				0	0	4 35 43 53 400
Current Year Previous Year (19)						0				32,53,79,943.00 36,62,17,877.00	32,53,79,943.00 36,62,17,877.00	00 22 20 042 00 25 62 47 677 00
(xi) DST A/c (xii) Pharmacovigilance workshop A/c	(xi) DST A/c (xii) Pharmacovigilance workshop A/c	(xi) DST A/c (xii) Pharmacovieliance workshop A/c	(xii) Pharmacovieilance workshop A/c	 (xiii) CRISM A/c	(xiv) South African A/c	Total S.N. 2	3. (i) NPS A/c	(ii) CPF/GPF A/c	(iii) GIS A/c	(iv) Pension Fund A/c	Total S.N. 3	00 07 03 06 0 -7 F N 3 1-7-1 P

(Dr. N. Zaheer Ahmed) Director General Sd/-

(Mohammad Parvez) Sd/-

Administrative Officer

Research Officer (Chemistry)/ Administrative Incharge

(Dr. Ram Pratap Meena)

Sd/-

(Shakaib Hasan) Consultant (IA)

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

က် က	. Name of the Scheme	NPS Corpus Amount	s Amount	Unspent Balance (Previous Year)	Unspent Balance (Previous Year)	Unspent Balance (Current Year)	Balance t Year)
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(22)	2)	(23)	3)	(24)	(1
1.	Health Scheme A/c						
	(i) Health Scheme	74,28,539.50	1,84,46,591.37	0	6,41,214.00	81,67,538.12	20,61,940.00
	Total S.N. 1	74,28,539.50	1,84,46,591.37	0	6,41,214.00	81,67,538.12	20,61,940.00
2.	Other Specific Accounts						
	(i) IPR						
	(ii) Herb Garden A/c						
	(iii) Pub. of Text Books A/c						
	(iv) UPS A/c I						
	(v) DSOP						
	(vi) AIIUM A/c						
	(vii) I.T. A/c						
	(viii) National						
	Conference on Unani						
	(ix) WHO A/c						
	(x) International Events Conference A/c						
	(xi) DST A/c						

(Dr. N. Zaheer Ahmed) Director General

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

> (Mohammad Parvez) Administrative Officer

> (Shakaib Hasan) Consultant (IA)

Sd/-

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

S. N.	Name of the Scheme	NPS Corpus Amount	us Amount	Unspent Balance (Previous Year)	Jnspent Balance (Previous Year)	Unspent Balance (Current Year)	alance Year)
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(22)	2)	(2	(23)	(24)	
-	(xii) Pharmacovigilance workshop A/c						
	(xiii) CRISM A/c						
	(xiv) South African A/c						
	Total S.N. 2	0	0	0	0	0	0
رى ب	(i) NPS A/c						
	(ii) CPF/GPF A/c						
	(iii) GIS A/c						
	(iv) Pension Fund A/c		1,00,06,342.40	0	0	0	0
	Total S.N. 3	0	1,00,06,342.40	0	0	0	0
	Grand Total S.N. 1 to 3	74,28,539.50	2,84,52,933.77	0	6,41,214.00	81,67,538.12	20,61,940.00

(Dr. N. Zaheer Ahmed) Director General Sd/-

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

> (Mohammad Parvez) Administrative Officer

> (Shakaib Hasan) Consultant (IA)

Sd/-

Sd/-

147

Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

S. N.	Name of the Scheme	Fund Transfer	ınsfer	Total F	Total Receipts
		Current Year	Previous Year	Current Year	Previous Year
		(25)		3	(26)
-	Health Scheme A/c				
	(i) Health Scheme	19,7,50,400.00		1,87,59,50,933.82	181,85,53,747.00
	Total S.N. 1	19,7,50,400.00		1,87,59,50,933.82	181,85,53,747.00
2	Other Specific Accounts				
	(i) IPR			13,53,079.00	0 22,68,997.00
	(ii) Herb Garden A/c			2,64,252.00	0 1,90,232.00
	(iii) Pub. of Text Books A/c				62,746.00
	(iv) UPS A/c I				52,027.00
	(v) DSOP				2,39,342.00
	(vi) AIIUM A/c				37,03,510.00
	(vii) I.T. A/c			35,94,007.00	35,95,499.00
	(viii) National Conference on Unani Day			16,63,449.50	0 69,24,424.00
	(ix) WHO A/c				2,516.00
	(x) International Events Conference A/c				8,15,733.00
	(xi) DST A/c				7,64,486.00
	(xii) Pharmacovigilance				6,90,000.00
	(xiii) CRISM A/c				1,77,17,681.00
	-/oS	./PS		Sd/-	-/PS
	(Shakaib Hasan) Consultant (IA)	(Mohammad Parvez) Administrative Officer		(Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Incharge	(Dr. N. Zaheer Ahmed) Director General



Schedule of Receipts for the Year Ending 31st March 2023 Schedule of Receipts & Payments A/c

S.N.	Name of the Scheme	Fund Transfer	ansfer	Total Receipts	eipts
		Current Year	Previous Year	Current Year	Previous Year
		(25)	2)	(26)	
	(xiv) South African A/c				5,62,233.00
	Total S.N. 2	0	0	68,74,787.50	3,75,89,426.00
3.	(i) NPS A/c			78,97,056.31	2,40,88,070.31
	(ii) CPF/GPF A/c			20,53,38,579.64	40,39,89,667.14
	(iii) GIS A/c			1,22,77,727.84	91,54,580.84
	(iv) Pension Fund A/c	1,73,45,900.00	0	60,41,89,178.53	46,80,11,573.53
	Total S.N. 3	1,73,45,900.00	0	82,97,02,542.32	90,52,43,891.82
	Grand Total S.N. 1 to 3	3,70,96,300.00	0	2,71,25,28,263.64	2,76,13,87,064.89

(Dr. N. Zaheer Ahmed) Director General Sd/-

(Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

Administrative Officer

Sd/-

Research Officer (Chemistry)/ Administrative Incharge

(Dr. Ram Pratap Meena)

Sd/-

149

		- 2 - 1	L		L		1
Z	. Name of the scheme	Establishmer	=stabilsnment Expenses	Administrativ	Administrative Expenses	Material & Supplies Expenses	sesuedx= seile
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(1)		3)	(2)	(3)	(3)
<u>-</u>	Health Scheme						
	(i) Health scheme A/c	1,02,88,84,495.00	1,07,82,86,226.00	29,77,53,870.00		22,94,97,876.00 20,99,95,515.00	9,45,10,750.00
	Total(H) S.N.1	1,02,88,84,495.00 1,07,82,86,226.00	1,07,82,86,226.00	29,77,53,870.00	29,77,53,870.00 22,94,97,876.00 20,99,95,515.00	20,99,95,515.00	9,45,10,750.00
2	Other Specific Accounts						
	(i) IPR						
	(ii) Herb Garden A/c						
	(iii) Pub. of Text Books A/c						
	(iv) UPS A/c 1						
	(v) DSOP						
	(vi) AIIUM A/c						
	(vii) I.T. A/c						
	(viii) National Conference on						
	(ix) WHO A/c						
	(x) International Events Conference A/c						
	(xi) DST A/c						
	(xii) Pharmacovigilance workshop A/c						
	(xiii) CRISM A/c						
	(xiv) South African A/c						
	Sd/- (Shakaib Hasan) Consultant (IA)	Sd/- (Mohammad Parvez) Administrative Officer		Sd/- (Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Incharge	o Meena) Chemistry)/ ncharge	Sd/- (Dr. N. Zaheer Ahmed) Director General	/- ser Ahmed) 3eneral

S.N.	. Name of the Scheme	Establishment Expenses	nt Expenses	Administrativ	Administrative Expenses	Material & Supplies Expenses	olies Expenses
		Current Year	Current Year Previous Year Current Year Previous Year Current Year Previous Year	Current Year	Previous Year	Current Year	Previous Year
		1)		Z)	(2)	(3)	3)
	Total S.N. 2	0	0	0	0	0	0
3.	(i) NPS A/c	0	0				
	(ii) CPF/GPF A/c	0	0	4,012.00			
	(iii) GIS A/c	0	0				
	(iv) Pension Fund A/c	0	0				
	Total S.N. 3	0	0	4,012.00	0	0	0
	Grand Total S.N. 1 to 3	1,02,88,84,495.00	1,02,88,84,495.00 1,07,82,86,226.00 29,77,57,882.00 22,94,97,876.00 20,99,95,515.00 9,45,10,750.00	29,77,57,882.00	22,94,97,876.00	20,99,95,515.00	9,45,10,750.00

(Dr. Ram Pratap Meena) Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Administrative Officer (Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

(Dr. N. Zaheer Ahmed) Director General -/ps

vi Vi	. Name of the Scheme	Ass	Assets	Publications (Priced)	s (Priced)	Advances to Sen	Advances to Government Servants
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Current Year Previous Year
		7)	(4)	(9))	(9)
←	Health Scheme						
	(i) Health scheme A/c	47,19,443.00	64,59,180.00	0	0	31,48,260.00	37,23,500.00
	Total(H) S.N.1	47,19,443.00	64,59,180.00	0	0	31,48,260.00	37,23,500.00
2.	Other Specific Accounts						
	(i) IPR						
	(ii) Herb Garden A/c						
	(iii) Pub. of Text Books A/c						
	(iv) UPS A/c I						
	(v) DSOP						
	(vi) AIIUM A/c						
	(vii) I.T. A/c						
	(viii) National Conference						
	(ix) WHO A/c						
	(x) International Events						
	(xi) DST A/c						
	(xii) Pharmacovigilance						
	(xiii) CRISM A/c						
				768			
	-/pS	ŏ	-/pS	1/DC	(0000)	Й	-/pS
	(Shakaib Hasan) Consultant (IA)	(Mohamma Administra	(Mohammad Parvez) Administrative Officer	(Dr. Kall Fratab Meella) Research Officer (Chemistry) Administrative Incharge	dp ivieeria) (Chemistry)/ Incharge	(Dr. N. Zah Director	(Dr. N. Zaheer Ahmed) Director General

S.N.	. Name of the Scheme	AS	Assets	Publications (Priced)	s (Priced)	Advances to	Advances to Government
						Ser	Servants
		Current Year	Previous Year	Current Year	Previous Year Current Year Previous Year	Current Year	Previous Year
			(4)	(5))	(9)
	(xiv) South African A/c						
	Total S.N. 2	0	0	0	0	0	0
	(i) NPS A/c						
	(ii) CPF/GPF A/c						
	(iii) GIS A/c						
	(iv) Pension Fund A/c						
	Total S.N. 3	0	0	0	0	0	0
	Grand Total S.N. 1 to 3	47,19,443.00	64,59,180.00	0	0	31,48,260.00	37,23,500.00

(Dr. Ram Pratap Meena) Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Administrative Officer (Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

(Dr. N. Zaheer Ahmed) Director General -/ps

S. N.	l. Name of the Scheme	Outstandin	Outstanding Advances	Other Charges	harges	Capital Payment	ıyment
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		<u> </u>	(7)	(8)		(6)	
<u>-</u>	Health Scheme A/c	1,88,31,811.00	1,19,53,234.00	11,07,22,370.00	11,07,22,370.00 10,33,06,088.00	2,28,47,512.00	6,56,00,550.00
	SAP					1,10,07,910.00	
	Ethics						
	Seminar						
	LIC Contingona,						
	COILINGEILCY						
	Total S.N.1	1,88,31,811.00	1,19,53,234.00	11,07,22,370.00	12,39,64,652.00	3,38,55,422.00	6,56,00,550.00
2.	Other Specific Accounts						
	(i) PR			10,75,094.00	8,32,000.00		
	(ii) Herb Garden A/c						
	(iii) Pub. of Text Books A/c						
	(iv) UPS A/c 1						
	(v) DSOP						
	(vi) AIIUM A/c						
	(vii) I.T. A/c			11,78,046.00			
	(viii) National Conference			10,81,166.00	55,16,563.00		
	on Unani Day						
	(ix) WHO A/c						
	(x) International Events						
	Conference A/c						
	(xi) DST A/c						

(Dr. Ram Pratap Meena) Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Administrative Officer (Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

(Dr. N. Zaheer Ahmed) Director General

S.N.	. Name of the Scheme	Outstanding	nding Advances	Other Charges	harges	Capital Payment	ayment
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		2)	7)	(8)		(6)	
	(xii) Pharmacovigilance workshop A/c						
	(xiii) CRISM A/c						
	(xiv) South African A/c						
	Total S.N. 2	0	0	33,34,306.00	63,48,563.00	0	0
3,	(i) NPS A/c						
	(ii) CPF/GPF A/c						
	(iii) GIS A/c						
	(iv) Pension Fund A/c						
	Total S.N. 3	0	0	0	0	0	0
	Grand Total S.N. 1 to 3	1,88,31,811.00		1,19,53,234.00 11,40,56,676.00 10,96,54,651.00	10,96,54,651.00	3,38,55,422.00	6,56,00,550.00

(Dr. N. Zaheer Ahmed) Director General Sd/-Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Sd/-

(Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

Administrative Officer

155

S. S.	Name of the Scheme	IPR Fund Transfer	ransfer	Remittance of Recoveries	Recoveries	Amount D RRIUM,	Amount Disbursed to RRIUM, Chennai
		Current Year F	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(10)		(11)			(12)
۲.	Health Scheme						
	(i) Health Scheme A/c	0	20,00,000.00	8,24,60,501.00	15,03,87,420.00	0	78,823.00
	Health Scheme A/c			41,88,487.00	21.30		
	Total S.N.1	0	20,00,000.00	8,66,48,988.00	15,03,87,441.30	0	78,823.00
2	Other Specific Accounts						
	(i) IPR						
	(ii) Herb Garden A/c						
	(iii) Pub. of Text Books A/c						
	(iv) UPS A/c I						
	(v) DSOP						
	(vi) AIIUM A/c						
	(vii) I.T. A/c				1,492.00		
	(viii) National Conference on Unani Day			16,598.00	8,678.00		
	(ix) WHO A/c						
	(x) International Events Conference A/c						
	(xi) DST A/c						
	(xii) Pharmacovigilance workshop A/c						
	700	7/6/5		-/pS		7760	
	(Shakaib Hasan) Consultant (IA)	(Mohammad Parvez) Administrative Officer		(Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Incharge	Meena) hemistry)/ charge	(Dr. N. Zaheer Ahmed) Director General	er Ahmed) seneral

S.N.	. Name of the Scheme	IPR Func	IPR Fund Transfer	Remittance o	Remittance of Recoveries	Amount Disbursed RRIUM, Chennai	Amount Disbursed to RRIUM, Chennai
		Current Year	Previous Year	Current Year	Previous Year Current Year Previous Year	Current Year	Previous Year
		1)	(10)	(11)	1)	1)	(12)
	(xiii) CRISM A/c						
	(xiv) South African A/c						
	Total S.N. 2	0	0	16,598.00	10,170.00	0	0
3,	(i) NPS A/c			0	0		
	(ii) CPF/GPF A/c			19,807.00	0		
	(iii) GIS A/c			0	0		
	(iv) Pension Fund A/c			2,40,72,252.00	1,02,70,067.00		
	Total S.N. 3	0		0 2,40,92,059.00	1,02,70,067.00	0	0
	Grand Total S.N. 1 to 3	0	20,00,000.00	20,00,000.00 11,07,57,645.00 16,06,67,678.00	16,06,67,678.00	0	78,823.00

Sd/-

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

> Administrative Officer (Mohammad Parvez)

> (Shakaib Hasan) Consultant (IA)

(Dr. N. Zaheer Ahmed) Director General Sd/-

S.N. Name of the Scheme NPS Employee Contribution Paid to Investments A/C Received from LIC Disbursed Disbursed								
Current Year Previous Year Current Year (15) Health Scheme 84,40,249.00 (14) (15) Health Scheme A/c 84,40,249.00 (17) (18) Total S.N.1 84,40,249.00 (19) (19) Chi Peath Scheme A/c (10) (10) (10) (11) PR (11) (12) (11) PR (13) (14) (11) PR (17) (18) (11) PR (19) (19) (11) Pub. of Text Books A/c	S. S.		NPS Employee Co Non F	ntribution Paid to ^o ran	Investme	ents A/c	Received of Disbull	from LIC rsed
(13)			Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
Health Scheme			(13	(8)	(1,	4)	(15	
(i) Health Scheme A/c Total S.N.1 Other Specific Accounts (i) IPR (ii) Herb Garden A/c (iii) Pub. of Text Books A/c (iv) UPS A/c I (v) DSOP (vi) AllUM A/c (vii) National Conference on Unani Day (ix) WHO A/c (xi) International Events Conference A/c (xi) Pharmacovigilance (xii) Pharmacovigilance (xii) Pharmacovigilance (xiii) Pharmacovigilance	Ψ.	Health Scheme						
Total S.N.1 Other Specific Accounts (i) IPR (ii) Herb Garden A/c (iii) Hub. of Text Books A/c (iv) UPS A/c I (v) DSOP (vi) AllUM A/c (vii) I.T. A/c (viii) National Conference on Unani Day (ix) WHO A/c (x) International Events Conference A/c (xi) DST A/c (xii) Pharmacovigilance (xiii) Pharmacovigilance (xiiiiiii) Pharmacovigilance		(i) Health Scheme A/c		84,40,249.00				
		Total S.N.1		84,40,249.00				
(i) IPR (ii) Herb Garden A/c (iii) Pub. of Text Books A/c (iv) UPS A/c (iv) White A/c	2	Other Specific Accounts						
(ii) Herb Garden A/c (iii) Pub. of Text Books A/c (iii) Pub. of Text Books A/c (iv) UPS A/c I (iv) DSOP (iv) DSOP (vi) AllUM A/c (vi) AllUM A/c (viii) National Conference on Unani Day (viii) National Events (x) International Events (x) International Events (x) International Events (xi) DST A/c (xi) DST A/c (xi) DST A/c (xii) Pharmacovigilance workshop A/c (xii) Pharmacovigilance		(i) IPR						
(iii) Pub. of Text Books A/c (iv) UPS A/c I (iv) UPS A/c I (v) DSOP (vi) AllUM A/c (vi) AllUM A/c (vii) I.T. A/c (viii) I.T. A/c (viii) I.T. A/c (viii) I.T. A/c (viii) I.T. A/c (viii) I.T. A/c (viii) NHO A/c (viii) NHO A/c (x) International Events (x) International Events (x) International Events (x) International Events (xi) DST A/c (xi) DST A/c (xii) Pharmacovigilance (xiii) Pharmacovigilance		(ii) Herb Garden A/c						
(iv) UPS A/c I (v) DSOP (vi) AllUM A/c (vii) AllUM A/c (viii) I.T. A/c (viii) National Conference on Unani Day (viii) National Conference on Unani Day (ix) WHO A/c (x) International Events (x) International Events (xi) DST A/c (xi) DST A/c (xi) Pharmacovigilance workshop A/c (xii) Pharmacovigilance		(iii) Pub. of Text Books A/c						
(vi) DSOP (vi) AllUM A/c (vii) LT. A/c (viii) LT. A/c (viii) National Conference on Unani Day (viii) National Events (ix) WHO A/c (ix) WHO A/c (x) International Events		(iv) UPS A/c I						
(vii) AllUM A/c (vii) LT. A/c (viii) National Conference on Unani Day (ix) WHO A/c (x) International Events Conference A/c (x) International Events Conference A/c (xi) DST A/c (xi) DST A/c (xii) Pharmacovigilance workshop A/c (xiii) Pharmacovigilance		(v) DSOP						
(viii) I.T. A/c (viii) I.T. A/c (viii) National Conference on Unani Day (ix) WHO A/c (ix) WHO A/c (x) International Events (x) International Events (x) International Events (xi) DST A/c (xii) Pharmacovigilance (xii) Pharmacovigilance (xiii) Pharmacovigilance (xiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii		(vi) AIIUM A/c						
(viii) National Conference on Unani Day (ix) WHO A/c (ix) WHO A/c (ix) WHO A/c (ix) WHO A/c (ix) International Events <		(vii) I.T. A/c						
(ix) WHO A/c (x) International Events (x) International Events (x) International Events (x) International Events (x) DST A/c (x) DST A/c <t< td=""><th></th><td>(viii) National Conference on Unani Day</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>		(viii) National Conference on Unani Day						
(x) International Events Conference A/c <		(ix) WHO A/c						
(xi) DST A/c (xii) Pharmacovigilance (xiii) Pharmacovigilance (xiiii) Pharmacovigilance (xiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii		(x) International Events Conference A/c						
(xii) Pharmacovigilance workshop A/c		(xi) DST A/c						
		(xii) Pharmacovigilance workshop A/c						

(Dr. N. Zaheer Ahmed) Director General

(Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

Administrative Officer

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)

Sd/-

S.N.	. Name of the Scheme	NPS Employee Contribution Paid to Non Pran	ontribution Paid to Pran	Investments A/c	ents A/c	Received from LIC Disbursed	from LIC rsed
		Current Year	Previous Year	Current Year	Previous Year Current Year	Current Year	Previous Year
		(13)	3)	(14)	4)	(12)	(9
	(xiii) CRISM A/c						
	(xiv) South African A/c						
	Total S.N. 2	0	0	0	0		
<u>რ</u>	(i) NPS A/c	0	1,23,17,208.00		0	0	0
	(ii) CPF/GPF A/c			10,72,21,915.40	10,72,21,915.40 28,05,12,263.90	0	0
	(iii) GIS A/c			60,48,090.00	0	0 2,00,000.00	4,00,000.00
	(iv) Pension Fund A/c			19,16,35,448.00	19,16,35,448.00 17,13,72,907.00	0	0
	Total S.N. 3	0	1,23,17,208.00	1,23,17,208.00 30,49,05,453.35 45,18,85,170.90	45,18,85,170.90	2,00,000.00	4,00,000.00
	Grand Total S.N. 1 to 3	0	2,07,57,457.00	2,07,57,457.00 30,49,05,453.35 45,18,85,170.90 2,00,000.00 4,00,000.00	45,18,85,170.90	2,00,000.00	4,00,000.00

(Dr. Ram Pratap Meena) Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Administrative Officer (Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

(Dr. N. Zaheer Ahmed) Director General Sd/-

S.N.	. Name of the Scheme	Amount Payable	unt Payable Paid/Adjusted	Other Misc. Payments/Transfer	ments/Transfer	Refund	Refund of EMD
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(16)		(1)	(17))	(18)
<u>-</u>	Health Scheme						
	(i) Health Scheme A/c	0	54,02,503.00	1,97,50,400.00	8,90,190.00	15,89,152.000	6,64,920.00
	Health Scheme A/c						
	Total S.N.1	0	54,02,503.00	1,97,50,400.00	8,90,190.00	15,89,152.000	6,64,920.00
2.	Other Specific Accounts						
	(i) IPR						
	(ii) Herb Garden A/c						
	(iii) Pub. of Text Books A/c						
	(iv) UPS A/c I						
	(v) DSOP						
	(vi) AIIUM A/c						
	(vii) I.T. A/c						
	(viii) National Conference on Unani Day						
	(ix) WHO A/c						
	(x) International Events Conference A/c						
	(xi) DST A/c						
	(xii) Pharmacovigilance workshop A/c						
	(xiii) CRISM A/c						
	Sd/- (Shakaib Hasan) Consultant (IA)	Sd/- (Mohammad Parvez) Administrative Officer		Sd/- (Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Incharge	Meena) :hemistry)/ charge	Sd/- (Dr. N. Zaheer Ahmed) Director General	- er Ahmed) eeneral

S.N.	N. Name of the Scheme	Amount Payable	nt Payable Paid/Adjusted	Other Misc. Payments/Transfer	ments/Transfer	Refund of EMD	of EMD
		Current Year	Previous Year	Current Year	Previous Year Current Year Previous Year	Current Year	Previous Year
		(16)		(11)	()	(1	(18)
	(xiv) South African A/c						
	Total S.N. 2	0	0	0	0	0	0
છ	(i) NPS A/c	0	1,33,140.00	0	39,49,175.00		
	(ii) CPF/GPF A/c	0	10,825.00		7,45,61,400.00 7,32,17,123.00		
	(iii) GIS A/c	0	650.00	20,54,818.00	37,44,495.00		
	(iv) Pension Fund A/c	0	0	0 28,77,49,279.00 24,23,76,278.00	24,23,76,278.00		
	Total S.N. 3	0	1,44,615.00	1,44,615.00 36,43,65,497.00 32,32,87,071.00	32,32,87,071.00	0	0
	Grand Total S.N. 1 to 3	0	55,47,118.00	55,47,118.00 38,41,15,897.00 32,41,77,261.00 15,89,152.00	32,41,77,261.00	15,89,152.00	6,64,920.00

(Dr. Ram Pratap Meena) Sd/-

Research Officer (Chemistry)/ Administrative Incharge

Administrative Officer (Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

(Dr. N. Zaheer Ahmed) Director General Sd/-

S. S.	Name of the Scheme	NPS Corpus Amount Paid	Amount Paid	Unspent Balance Transferred to Ministry Fund Transfer on A/c of Closer	ansferred to Ministry	Fund Transfer on A	√c of Closer
		Current Year	Previous Year		Previous Year	Current Year Pre	Previous Year
		(19)		(20)	0)	(21)	
7.	Health Scheme					// 33 <	
	(i) Health scheme A/c	30,13,061.00		2,26,91,219.00	1,44,43,502.00		
	Health scheme A/c						
	Health scheme A/c						
	Total S.N.1	30,13,061.00		2,26,91,219.00	1,44,43,502.00		
2.	Other Specific Accounts						
	(i) IPR				2,68,997.00		0
	(ii) Herb Garden A/c						0
	(iii) Pub. of Text Books A/c						62,746.00
	(iv) UPS A/c I						52,027.00
	(v) DSOP						2,39,342.00
	(vi) AIIUM A/c				37,03,510.00		0
	(vii) I.T. A/c						0
	(viii) National Conference on			20,156.00	6,250.00		0
	(ix) WHO A/c						2,516.00
	(x) International Events Conference A/c						8,15,733.00
	(xi) DST A/c						7,64,486.20
	(xii) Pharmacovigilance workshop A/c				6,90,000.00		0

(Dr. Ram Pratap Meena)

Research Officer (Chemistry)/ Administrative Incharge

Administrative Officer (Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

(Dr. N. Zaheer Ahmed) Director General

S.N.S	Name of the Scheme	NPS Corpus /	Amount Paid	NPS Corpus Amount Paid Unspent Balance Transferred to Ministry Fund Transfer on A/c of Closer	ansferred to Ministry	Fund Transfer	on A/c of Closer
		Current Year	Previous	Current Year	Previous Year	Current Year	Current Year Previous Year
			Year				
		(19)	(6	(20)	0)	(2)	(21)
	(xiii) CRISM A/c						1,77,17,681.00
	(xiv) South African A/c						5,62,232.68
	Total S.N. 2	0	0	20,156.00	46,68,757.00		0 2,02,16,763.88
3.	(i) NPS A/c						
	(ii) CPF/GPF A/c						
	(iii) GIS A/c						
	(iv) Pension Fund A/c						
	Total S.N. 3	0	0	0	0	0	0
	Grand Total S.N. 1 to 3	30,13,061.00	0	2,27,11,375.00	1,91,12,259.00		0 2,02,16,763.88

(Dr. N. Zaheer Ahmed) Director General Sd/-

> Administrative Officer (Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

Research Officer (Chemistry)/ Administrative Incharge (Dr. Ram Pratap Meena)



Z S	I. Name of the Scheme	Fund Transfer	fer	Closing Balance	Balance	Total payments	yments
		Current Year P	Previous	Current Year	Previous Year	Current Year	Previous Year
			Year				
		(22)		(23)	3)	(24)	4)
	Health Scheme						
<u>-</u>	(i) Health scheme A/c	0	0	3,43,46,927.82	4,09,26,464.97		
	Health scheme A/c				19,82,250.00		
	Health scheme A/c						
	Total S.N.1	0	0	3,43,46,927.82		4,29,08,714.97 1,87,59,50,933.82 1,81,85,53,747.27	1,81,85,53,747.27
2	Other Specific Accounts						
	(i) IPR			2,77,985.00	11,68,000.00	13,53,079.00	22,68,997.00
	(ii) Herb Garden A/c			2,64,252.00	1,90,232.00	2,64,252.00	1,90,232.00
	(iii) Pub. of Text Books A/c						62,746.00
	(iv) UPS A/c I						52,027.00
	(v) DSOP						2,39,342.00
	(vi) AIIUM A/c						37,03,510.00
	(vii) I.T. A/c			24,15,961.00	35,94,007.00	35,94,007.00	35,95,499.00
	(viii) National Conference on Unani			5,45,529.50	13,92,933.50	16,63,449.50	69,24,424.50
	/ix) WHO A/c						2.516.00
	(x)						8 15 733 00
	(x) international Events Conference A/c						6,13,733.00
	(xi) DST A/c						7,64,486.20
	(xii) Pharmacovigilance workshop A/c						6,90,000.00
	(xiii) CRISM A/c						1,77,17,681.00
	/c	7/25		-/pS	1	7/700	J
	asan) t (IA)	(Mohammad Parvez) Administrative Officer		(Dr. Ram Pratap Meena) Research Officer (Chemistry)/ Administrative Incharge	ıtap Meena) r (Chemistry)/ e Incharge	(Dr. N. Zaheer Ahmed) Director General	er Ahmed) Seneral

S.N.	. Name of the Scheme	Fund Transfer	ansfer	Closing Balance	Salance	Total payments	yments
		Current Year	Previous Year	Current Year	Current Year Previous Year	Current Year	Previous Year
		(22)	2)	(23)	3)	(24)	4)
	(xiv) South African A/c						5,62,232.68
	Total S.N. 2	0	0	35,03,727.50	63,45,172.50	68,74,787.50	3,75,89,426.38
<u>რ</u>	3. (i) NPS A/c			78,97,056.31	76,88,547.31	78,97,056.31	2,40,88,070.31
	(ii) CPF/GPF A/c	15,000.00		2,35,16,445.29	5,02,49,455.29	20,53,38,579.60	40,39,89,667.20
	(iii) GIS A/c			39,74,819.84	50,09,435.84	1,22,77,727.84	91,54,580.84
	(iv) Pension Fund A/c	1,73,45,900.00		8,33,86,299.53	8,33,86,299.53 4,39,92,321.53	60,41,89,178.50	46,80,11,573.50
	Total S.N. 3	1,73,60,900.00	0	0 11,87,74,620.97 10,69,39,759.97	10,69,39,759.97	82,97,02,542.30	90,52,43,891.90
	Grand Total S.N. 1 to 3	1,73,60,900.00		15,66,25,276.29	15,61,93,647.44	0 15,66,25,276.29 15,61,93,647.44 2,71,25,28,263.64 2,76,13,87,065.52	2,76,13,87,065.52

(Dr. Ram Pratap Meena)

Research Officer (Chemistry)/ Administrative Incharge

Administrative Officer (Mohammad Parvez)

(Shakaib Hasan) Consultant (IA)

(Dr. N. Zaheer Ahmed) Director General Sd/-



5.3. Notes on Accounts

- 1. Annual accounts of the Council for the year 2022–2023 have been prepared on the uniform format of account for Central Autonomous Bodies (non-profit organization).
- 2. The Central Council for Research in Unani Medicine is fully financed by Government of India, Ministry of Ayush through grant-in-aid. Therefore, income tax is not applicable on the organization.
- 3. The said accounts prepared on accrual basis.
- 4. Schedules are attached wherever necessary.
- 5. Depreciation has been charged on assets on diminishing balance method.
- 6. The construction works are done by the CPWD & NPCC.
- 7. There is no valuation of Inventories since it is not a profit earning organization but a Research Organization under the Ministry of Ayush, Government of India.
- 8. A schedule of Investment prepared every year and given to audit which is duly reconciled with actual documents figures mentioning there the rate of interest, duration, amount & name of Institutions, etc.
- 9. Retirement benefits are treated as per the Government of India Rules.
- 10. Depreciation has been charged under expenditure.
- 11. Earmarked/Endowment fund has been shown separately in the Balance Sheet with necessary Schedule.
- 12. The annual accounts of the Council for the year 2022-2023 have been approved by the competent authority, i.e. Standing Finance Committee on September 06, 2023.

Sd/-Administrative Incharge CCRUM, New Delh





APPENDIX-I

INSTITUTIONAL NETWORK OF CCRUM

1	Central Council for Research in Unani Medicine 61-65, Institutional Area, Opposite D Block, Janakpuri, New Delhi – 110 058 Phone: +91-11-28521981 Fax: +91-11-28522965 E-mail: unanimedicine@gmail.com	2	National Research Institute of Unani Medicine for Skin Disorders Opp. ESI Hospital, AG Colony Road Erragadda, Hyderabad – 500 038 Telangana Phone: +91-40-23811551, 23810246 E-mail: criumhyderabad@gmail.com
3	Central Research Institute of Unani Medicine Basaha, Kursi Road, Lucknow – 226 026 Uttar Pradesh Phone: +91-522-2361720 E-mail: ddcriumlko@gmail.com	4	Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine Dr. MA Ansari Health Centre Jamia Millia Islamia, Okhla New Delhi – 110 025 E-mail: Iriumnew1986@gmail.com
5	Regional Research Institute of Unani Medicine 1, West Meda Church Street, Royapuram Chennai – 600 013, Tamil Nadu Phone: +91-44-25955519 E-mail: rriumchennai@gmail.com	6	Regional Research Institute of Unani Medicine Chandbali Bypass Road, Near Rural Police Station, Bhadrak – 756 100, Odisha Phone: +91-6784-240289 E-mail: rriumbdk_unani@yahoo.co.in
7	Regional Research Institute of Unani Medicine Guzri, Patna City, Patna – 800 008, Bihar Phone: +91-612-2631106 E-mail: rriumpatna@gmail.com	8	Regional Research Institute of Unani Medicine Shahjahan Manzil, Near AMU Riding Club, Qila Road, Aligarh – 202 001, Uttar Pradesh Phone: +91-571-2704781, 2701399 E-mail: rrium_aligarh@rediffmail.com
9	Regional Research Institute of Unani Medicine Plot No. 38–39, Sector-18, Kharghar, Navi Mumbai– 410 210, Maharashtra Phone: +91-8652871023/2523 E-mail: rrium.mumbai@gmail.com, rrium.kharghar@gmail.com	10	Regional Research Institute of Unani Medicine University of Kashmir Campus, Hazrat Bal Srinagar – 190 006, Jammu & Kashmir Phone: +91-194-2421604 E-mail: rrium.srinagar@gmail.com
11	Regional Research Institute of Unani Medicine 250A/29, GT Road (North), Liluah Howrah – 711 204, West Bengal Phone: +91-33-26550108 E-mail: kolrrium@gmail.com	12	Regional Research Institute of Unani Medicine D-11/1, Abul Fazal Enclave, Jamia Nagar New Delhi – 110 025 Phone: +91-11-26922759 E-mail: rridelhi@gmail.com
13	Regional Research Institute of Unani Medicine Veterinary Bazar, Ghungoor, Silchar, Assam 788014, (Cachar) Assam Phone: +91-3843-267522 E-mail: rrcsilchar@gmail.com	14	Drug Standardization Research Institute PLIM, Sector–23, Kamla Nehru Nagar, Ghaziabad – 201 002, Uttar Pradesh Phone: +91-120-2783029 E-mail: dsriccrum@gmail.com
15	Drug Standardization Research Unit 61-65, Institutional Area, Opposite D Block, Janakpuri, New Delhi – 110 058 Phone: +91-11-28521981 E-Mail: dsru.newdelhi@gmail.com	16	Regional Research Centre B-501/4, GTB Nagar, Opp. Dulhan Palace Kareli, Prayagraj – 211 016, Uttar Pradesh Phone: +91-532-2551223 E-mail: rrcallahabad@gmail.com



17	Clinical Research Unit Kurupatil Nina Memorial, Near Panchayat Office, Edathala (N) Alweye – 683 564, Kerala Phone: +91-484-2836006 E-mail: crukerala@gmail.com	18	Clinical Research Unit National Institute of Unani Medicine Kotigepaliya, Magadi Main Road Bengaluru – 560 091, Karnataka Phone: +91-80-25480863 E-mail: crubangalore2000@yahoo.com
19	Clinical Research Unit Dr. Abdul Haq Unani Medical College 40/23 Park Road, Kurnool – 518 001 Andhra Pradesh E-mail: cru.kurnool@gmail.com	20	Clinical Research Unit Cantonment General Hospital, Soti Ganj Begumpul, Meerut – 250 001, Uttar Pradesh Phone: +91-9012843253 E-mail: crumeerut@gmail.com
21	Clinical Research Unit Gandhi Medical College, Bhopal – 462 001, Madhya Pradesh Phone: +91-755-2540590 E-mail: cruu_incharge@yahoo.com	22	Clinical Research Unit SH Unani Tibbiya College, Ganpati Naka, Burhanpur – 450 331, Madhya Pradesh Phone: +91-7325-252250 E-mail: cruburhanpur@rediffmail.com
23	Clinical Research Unit RRIH Building, Opp. Tribal Colony, New Checkon Road, Imphal East – 795001 Manipur Phone: +91- 8811907160 E-mail: cruimphal1@gmail.com	24	Chemical Research Unit Department of Research in Unani Medicine, Near Office of Dean, Faculty of Science, Aligarh Muslim University Aligarh – 202 001, Uttar Pradesh
25	Unani Speciality Centre (Extension Centre of RRIUM, New Delhi) Deen Dayal Upadhyay Hospital Ghantaghar, Harinagar New Delhi – 110 064 E-mail: dduhospital0786@gmail.com	26	Unani Medical Centre (Extension Centre of RRIUM, New Delhi) VMMC & Safdarjung Hospital New OPD Block, Ansari Nagar East, New Delhi – 110029 Phone: +91-11-26707121 E-mail: umcsafdarjung@gmail.com
27	Unani Medical Centre (Extension Centre of RRIUM, New Delhi) Dr. Ram Manohar Lohia Hospital New Delhi – 110 001 Phone: +91-11-23404594 E-mail: unaniopdrmlh@gmail.com	28	Unani Medical Centre (Extension Centre of RRIUM, Navi Mumbai) JJ Hospital Compound, Byculla, Mumbai – 400 008, Maharashtra Phone: +91-22-23718706 E-mail: rrium.mumbai@gmail.com



Central Council for Research in Unani Medicine

Ministry of Ayush, Government of India

61–65, Institutional Area, Janakpuri, New Delhi – 110 058 Telephone: +91-11-28521981, 28525982 E-mail: unanimedicine@gmail.com Website: https://ccrum.res.in